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PROPOSITIONS
Propositions accompanying this thesis.
1. Patient heterogeneity and parameter uncertainty should both be considered in cost-
effectiveness Markov models, but separately (this thesis).
2. When only direct evidence is available, evidence from different sources is best syn-
thesized using a frequentist random effects model (this thesis).
3. When indirect evidence is also available, combining direct and indirect evidence is 
preferred over only using direct evidence (this thesis).
4. Transferability factors can be ordered by their impact on the cost-effectiveness (this 
thesis).
5. The national threshold value of a QALY has wrongly been disregarded as an impor-
tant transferability factor (this thesis).
6. Several advanced statistical methods exist to calculate country-specific cost-effec-
tiveness results based on multinational trials, but they have not been used on a wider 
scale yet, while simpler, naïve methods are still routinely employed (this thesis).
7. Mathematical formulas, even making no sense within the presented context, may 
add credibility when added to your abstract. (Eriksson K. The nonsense math effect. 
Judgment and Decision Making, 2012;7(6):746-9)
8. Although a good presentation can never save bad research, a bad presentation can 
certainly ruin good research.
9. Scientific discovery doesn’t begin with “Eureka!”, but rather with “Huh. That’s funny. 
That can’t be right.” (Paraphrased from Isaac Asimov)
10. Inequality can never be overcome by more inequality.
11. The societal impact of donating half a liter of blood every ten weeks during the past 
six years, is higher than that of this thesis.
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Chapter 1
Introduction
A simple concept; many complications
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1.1 A SIMPLE CONCEPT
At its heart, health technology assessment (HTA) is very simple. It compares two or more 
alternative courses of action, often pharmaceutical interventions, in terms of both their 
costs and health outcomes.1 One of the interventions will have better health outcomes, 
for example fewer number of exacerbations, longer survival or a better quality of life. This 
usually comes at an extra cost, often in the way of a higher price for the intervention. HTA 
makes this exchange between costs and effects explicit. 
The idea that costs are an important element to take into account, does not come 
naturally to many health care workers. Doctors, nurses, and other health care workers do 
everything they can to help patients improve their lives. The interventions these patients 
need are provided in a large part by companies developing and producing the necessary 
drugs and devices. Health care scientists and epidemiologists try to make sense of what 
constitutes health, what illness is and how disease is spread. Their focus is purely on 
the patient: what does he or she need? Choices between treatment options are usually a 
consideration between availability, possible side effects, and patient characteristics. If a 
new medication comes on the market, doctors are often eager to treat patients with this 
newest treatment option. 
With the focus on the patient in front of them, health care workers usually do not look 
beyond the operating room or treatment room. An oncologist wants to treat all patients to 
the best of his or her ability, no matter the costs of the intervention. Budgetary constraints 
are not, and should not, be part of the decision making process of a health care worker 
when dealing with an individual patient. Cost considerations should be taken into account 
at a more aggregate level in the clinical guidelines, written by their organizations. In this 
way, HTA separates health care workers from these concerns in their daily practice, which 
are in the public and political domain. 
1.2 SCARCITY
Where health care workers are trained to focus on the patient in front of them, it is the task 
of policy makers and politicians to look beyond individual concerns. Health care workers 
may want access to the newest treatment option, but the money that will be used to pay for 
the latest treatment may very well have a better use somewhere else. As the then chairman 
of the National Institute for Health and Clinical Excellence (NICE) Professor Sir Michael 
Rawlins said in an interview in 2008: ‘We have a finite amount of money for healthcare, 
and if you spend money one way you can’t spend it in another.’2 This could very well be 
within the health care sector, where the money could be put to use for another patient. It 
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could also be used for a public campaign to quit smoking or to build a new hospital wing, 
to maintain forests or to build a new museum. 
The fact that we need to make a choice between all these options, is due to the basic no-
tion of scarcity in economics. Money, like any other good, is finite and can only be spend 
once. In health care, the money is usually paid by the general public in the form of taxes 
(the UK’s National Health Service for example) or insurance premiums (The Netherlands). 
As such, “society” (that is: all of us) pays for health care and we may expect doctors to be 
careful in how they spend it. This scarcity asks for an explicit valuation of all treatment 
options and their costs. In other words: HTA. 
1.3 HEALTH TECHNOLOGY ASSESSMENT
HTA as a field is intended to provide a bridge between the world of research and the 
world of decision-making.3 HTA is the toolbox which helps to keep a societal perspective 
when making decisions about new treatments, without intervening with the day-to-day 
decision that health care workers have to make. Using the tool box of HTA, the outcomes 
are often presented as an incremental cost-effectiveness ratio (ICER) or the incremental net 
monetary benefit (INMB). The ICER is the ratio between the additional health outcomes 
of one treatment option over another (the comparator), divided by the difference in costs. 
By comparing this ICER to an (implicit or explicit) threshold, policy makers can deem 
the intervention to be cost-effective compared to the comparator when the ICER is below 
this threshold. If the ICER is above the threshold, the intervention cannot be considered 
cost-effective compared to the comparator. The height of this threshold should be a public 
choice. The INMB is the difference in health outcomes, valued in monetary terms, minus 
the monetary costs. For the valuation of health outcomes the threshold value mentioned 
above is used. If the INMB is positive, the new intervention has more value to society 
than costs, and can thus be considered cost-effective compared to the comparator. If the 
INMB is negative, the new intervention will cost more than the societal benefits, and the 
intervention cannot be considered cost-effective compared to the comparator.
Health outcome measures that are often used are the number of years that a patient lives, 
or the number of events (heart attacks, hospitalizations) a patient experiences. Often, one 
would want to also include quality in life, leading to a measure called the quality adjusted 
life year (QALY). With several interventions, the difference between these outcomes can 
then be used to say which one is “better”. Costs are commonly categorized in costs that 
are directly related to the intervention or disease, and indirect societal costs or savings.4 
Direct medical costs include for example the costs of medication. Direct non-medical 
costs include for example travel, informal care and patient time. Indirect non-medical 
costs may include productivity losses and consumption changes. Finally, indirect medical 
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costs are medical costs that may be incurred by living longer.5 Including these costs in 
life years gained make cost estimates more conservative and accurate, but are not used in 
most published CE-studies. 
HTA is an active field internationally and has seen continued growth fostered by the 
need to support management, clinical, reimbursement and other policy decisions. It has 
also been advanced by the evolution of evaluative methods in the social and applied 
sciences, including clinical epidemiology and health economics.6 Health policy deci-
sions are becoming increasingly important as the opportunity costs from making wrong 
decisions continue to grow, both in the number of in terms of wasted resources and op-
portunities for health gain forgone.7
In recent years, the field of HTA has seen rapid advances in the field of statistical tech-
niques, which allow more realistic and complex healthcare models to be simulated more 
rapidly.8 Some of these advances have helped in the calculation of parameter estimates 
and measurement of uncertainty. Techniques have also arisen to identify, quantify and 
handle differences between groups of patients, data sources and countries. This has led to 
an increased interest in these differences. This thesis focuses on some of these techniques.
1.4 THIS THESIS
At its heart, health technology assessment is very simple. However, HTA is facing many 
methodological challenges calling for more complexity in the analyses. Several of these 
challenges are addressed in this thesis, all revolving around the use of HE decision models. 
We start with an example of such a HE decision model in chapter 2, which calculates the 
long term health economic effects of the reimbursement of smoking cessation treatments.
The first methodological issue we approach is what happens when there are different 
populations for which we need to make a decision. In chapter 3, we show that heterogene-
ity, caused by differences in patient characteristics, can and should be analyzed separately 
from the measures of uncertainty used in HE models. Unfortunately, heterogeneity is often 
either ignored completely in practice, or analyzed together with parameter uncertainty, 
without taking into account the fundamental difference between the two. We show that 
this may lead to the wrong policy decision.
Next, we turn to the issue of different data sources. Often, parameters in a HE model 
come from a variety of sources, for example several trials. Each individual estimate is 
usually different from the estimate from the other sources, which may be due to either 
sampling error, or genuine differences between the trials. In order for this information to 
be useful, these estimates need to be combined into a single estimate for each parameter. 
The way to do this is called meta-analysis. In chapters 4 and 5, we compare several 
different forms of meta-analysis, using a simulation study. The methods are compared 
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with respect to their effect on the HE outcomes. When only information is used from 
a head-to-head comparison between the interventions under investigation, the methods 
used are called direct meta-analysis. Four methods of direct meta-analysis are compared 
in chapter 4. When the relative efficacy between two interventions is obtained through 
a common comparator, there is an indirect comparison. Evidence from both direct and 
indirect comparisons can also be included in a network meta-analysis.  Four methods of 
mixed treatment comparison are compared in chapter 5.
In the next three chapters we turn to the methodological issues that arise from differ-
ences between countries. The field of health economics that deals with these issues is 
called transferability. In chapter 6 we show how the outcome for a single model can be 
different, depending on the country for which the model’s parameters have been used. We 
investigate how much of the differences can be explained by different sets of parameters. 
In chapter 7, we show that the country-specific willingness-to-pay for a QALY is often 
ignored in the transferability discussion, although it does have a large influence on the 
transferability of the outcomes. Transferability issues are best dealt with as early as pos-
sible. It is possible, and in fact advantageous, to deal with differences between countries 
alongside a randomized controlled trial (RCT). In chapter 8, we compared how recent, 
large RCTs dealt with these differences in practice and showed that several advanced 
statistical techniques have been available for some time to calculate country-specific CE 
results. However, they have not been used on a wide scale yet, while simpler, naïve 
methods are still routinely employed. 
We finish with a discussion in chapter 9, of some of the outcomes from the research 
presented in this thesis, and some further issues within HTA.
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Chapter 2
If you try to stop smoking, 
should we pay for it?
The cost–utility of reimbursing smoking 
cessation support in The Netherlands
P. Vemer, M.P.M.H. Rutten-van Mölken, J. Kaper, R.T. Hoogenveen, 
C.P. van Schayck, T.L. Feenstra
Previously published in Addiction, 2010, 105, 1088–1097 
doi:10.1111/j.1360-0443.2010.02901.x
ABSTRACT
Background Smoking cessation can be encouraged by reimbursing the costs of smok-
ing cessation support (SCS). The short-term efficiency of reimbursement has been 
evaluated previously. However, a thorough estimate of the long-term cost–utility is 
lacking.
Objectives To evaluate long-term effects of reimbursement of SCS.
Methods Results from a randomized controlled trial were extrapolated to long-term 
outcomes in terms of health care costs and (quality adjusted) life years (QALY) gained, 
using the Chronic Disease Model. Our first scenario was no reimbursement. In a 
second scenario, the short-term cessation rates from the trial were extrapolated di-
rectly. Sensitivity analyses were based on the trial’s confidence intervals. In the third 
scenario the additional use of SCS as found in the trial was combined with cessation 
rates from international meta-analyses.
Results Intervention costs per QALY gained compared to the reference scenario 
were approximately € 1,200 extrapolating the trial effects directly, and € 4,200 when 
combining the trial’s use of SCS with the cessation rates from the literature. Taking all 
health care effects into account, even costs in life years gained, resulted in an esti-
mated incremental cost–utility of € 4,500 and € 7,400, respectively. In both scenarios 
costs per QALY remained below € 16,000 in sensitivity analyses using a life-time 
horizon.
Conclusions Extrapolating the higher use of SCS due to reimbursement led to more 
successful quitters and a gain in life years and QALYs. Accounting for overheads, 
administration costs and the costs of SCS, these health gains could be obtained at 
relatively low cost, even when including costs in life years gained. Hence, reimburse-
ment of SCS seems to be cost-effective from a health care perspective.
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2.1 INTRODUCTION
The World Health Organization Framework Convention on Tobacco Control is the first 
negotiated global health treaty1; most countries in the world have implemented some 
sort of smoking cessation policy. On a European level, the European Union (EU) has 
developed a policy to decrease tobacco use based on legislative policies, support for 
smoking prevention and cessation activities, mainstreaming tobacco control into other 
policies and ensuring that achievements also have an impact outside the EU region.2 These 
international efforts notwithstanding, smoking policies still remain largely a national mat-
ter.
The United Kingdom has an elaborate programme of free cessation support in special-
ized cessation clinics within the setting of the National Health Service (NHS).3,4 Other 
countries that reimburse some form of cessation support include New Zealand, Australia 
and the United States.5 However, the reimbursement is often incomplete. For instance, 
in Australia, bupropion is reimbursed, but nicotine replacement therapy (NRT) is not.5 In 
the United States, a small majority of states includes reimbursement of smoking cessation 
therapy in the Medicaid package, but Medicare does not usually cover smoking cessation 
support (SCS). Private insurances vary in their coverage.6 France and Germany do not 
reimburse SCS7, while Italy provides partial reimbursement.
Tobacco control policy in The Netherlands aims to reduce smoking prevalence to 20% 
in 2010.8 Smoking prevalence is declining in The Netherlands, but the decline has slowed 
recently and in 2007 28% of the Dutch population still smoked. Additional efforts are 
required to reach the goal. A new policy might be the broad reimbursement of SCS via 
the obligatory health care insurance. A Cochrane review from 2005 on the effects of re-
imbursement of SCS concluded that there is some evidence that complete reimbursement 
leads to higher quit rates than partial or no reimbursement, but also that more research 
was necessary.9 The Cochrane review by Reda and colleagues summarizes studies on 
financial incentives, among others full reimbursement of the costs of SCS to smokers.10 
They concluded that full financial interventions directed at smokers could increase the 
proportion quitting, quit attempts and utilization of pharmacotherapy by smokers.
In The Netherlands, SCS is reimbursed only partly at present and pharmacological SCS 
is not reimbursed at all. The health insurance board (CVZ) has advised the Dutch Ministry 
of Health to reimburse an integrated smoking cessation programme, consisting of a com-
bination of behavioural counselling and pharmacotherapy.11 Following this advice, the 
Ministry of Health intends to start reimbursement of integrated smoking cessation support 
in 2011.12
A randomized controlled trial was performed to investigate the effects of such a reim-
bursement policy in the Dutch region of Friesland13,14 in May 2002. The trial included 
smokers above the age of 18 who were representative of the Dutch population with respect 
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to age (40 in the trial and 43 in the general population) and gender (55% male, both in the 
trial and in the general Dutch population).15,16 Smokers were assigned randomly to either 
an intervention or a control group. For a period of 6 months, smokers in the intervention 
group were offered reimbursement for NRT, bupropion and behavioural counselling. They 
received a leaflet with a description of the type of SCS for which reimbursement was 
available, and information on how to receive the reimbursement. No reimbursement was 
offered to the control group. The trial was designed as a naturalistic implementation study.
The trial found that the number of participants using SCS was higher in the intervention 
group than in the control group. The difference was 6.7 percentage points (%pt), with a 
95% confidence interval (CI) of 3.8–9.5. The total number of smokers attempting to quit 
was also higher, but this difference of 2.6%pt (95% CI -2.0 to 5.0) was not significant. 
The self-reported abstinence rate after 12 months was again significantly higher in the 
intervention group than in the control group (difference = 2.7%pt, 95% CI 0.5–4.9). These 
results are in line with international studies, as reviewed recently.10
Recently, a pilot study was carried out in The Netherlands to investigate the feasibility 
of large-scale implementation of reimbursement.17 The results of that study showed that 
reimbursement improves the use of cessation support. For example, 24.8% of respondents 
used bupropion compared to 4.1% in the general population: a six-fold increase. Use 
of varenicline was nine times higher and nicotine patches 2.7 times. At the end of the 
6-month test period, one-third of the participants who were interviewed indicated that 
they had stopped smoking. The 6-month self-reported abstinence rate as found in the 
Friesland trial was substantially lower than that measured in the pilot study; this may be 
explained by the lack of randomization and selection of participants in the pilot. Partici-
pants indicated that they wanted to quit at the start of the pilot study and the abstinence 
rate was calculated as a percentage of these respondents. Therefore, the current study was 
based upon the cessation rates in the Friesland trial.
The following research question was addressed: what is the long-term cost–utility 
of reimbursing smoking cessation strategies? We aimed to answer this question by ex-
trapolating the above-mentioned trial data using a dynamic population model. The model 
calculated the effect of increased quit rates on the number of smokers, quality adjusted life 
years (QALYs) and costs, and the long-term cost–utility, accounting for relapse rates and 
delays in health effects among former smokers. Moreover, the cost–utility ratios included 
costs in life years gained (LYG) to provide a complete estimate of all health care related 
consequences of implementing reimbursement.
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2.2 METHODS
2.2.1 Three policy scenarios
We simulated the long-term outcomes for three scenarios using the Chronic Disease Model 
(CDM), with the reimbursement policy in place for half a year, as was the case in the 
original trial. Three policy scenarios were defined. The first scenario, denoted as the refer-
ence scenario, considers current practice without reimbursement of cessation support. 
The initial distribution over all smoking classes and the 1-year smoking class transition 
probabilities were estimated from survey data from the Dutch Foundation on Smoking and 
Health (STIVORO).18 This is a yearly representative national survey on smoking, including 
questions on current and past smoking status. Initiation rates of never smokers, quit rates 
of current smokers and rates of relapse for former smokers were estimated using the 2001, 
2002 and 2003 surveys.19
Scenarios 2 and 3 are different versions of what would happen if SCS were being reim-
bursed by the obligatory basic health care insurance. As was the case in the original trial, 
smokers pay for the SCS themselves and will receive the money back from their insurers. 
The scenarios were defined by changes in costs and in quit rates; that is, the number of 
people moving from a state of ‘current smoker’ to ‘former smoker’ in one 12-month cycle 
of our model. Scenario 2 will be referred to as the trial-based reimbursement scenario, 
and it remained close to the original empirical data on quit rates and costs.13,14 Because 
the CIs around the prices and effects of SCS from the original trial were relatively wide, 
we also included a third scenario. This scenario combined the use of SCS as observed in 
the trial with estimates of the effectiveness and costs of SCS from published literature.20-22 
It has higher intervention costs and lower effectiveness. This scenario will be referred to as 
the literature-based reimbursement scenario.
Year 1 of our model run, starting with 6 months of the reimbursement policy, cor-
responds to 2006. The outcomes were estimated after 20 years and for a life-time horizon. 
All input prices were in 2005 Euros, using the internationally accepted harmonized 
index of consumer prices—all items.23 All outcomes have been discounted back to 2005. 
Costs were discounted at 4% and effects were discounted at 1.5%, according to Dutch 
guidelines for pharmacoeconomic evaluations.24 We adopted a health care perspective. 
Sensitivity analyses were carried out to analyse the effect of different discount rates, the 
length of the period that the reimbursement policy will be in place and the uncertainty 
around the costs and effects of reimbursement.
2.2.2 Intervention effects
Two main effects are to be expected from reimbursement of SCS: more quit attempts 
and a higher use of cessation aids. As a result we expect more successful quitters. Yearly 
quit rates in the ‘reference scenario’ were defined by gender and 5-year age classes and 
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ranged from 4.4% for men aged 15–19 years to 11% for women older than 85 years.25 
For the ‘trial-based reimbursement scenario’, the higher quit rate was based directly on 
the original trial data (table 2.1). Six months after the end of the reimbursement period, at 
the 12-month assessment, 2.8% of the control group and 5.5% of the intervention group 
reported being abstinent for at least 6 months. This difference was statistically significant. 
In the trial-based reimbursement scenario, we calculated the additional number of suc-
cessful quitters by adding the absolute difference in quit rates, +2.7%pt, to the quit rates 
of the reference scenario. The 95% CI around this difference was used in the sensitivity 
analyses.
To calculate a quit rate, in the ‘literature-based reimbursement scenario’ the increased 
use of SCS that was observed in the trial was multiplied with efficacy estimates for these 
interventions based on meta-analyses from published Cochrane reviews (table 2.2). 
For instance, of 634 smokers in the control group, five (0.8%) used NRT only, while 
of the 632 smokers in the intervention group 15 (2.4%) used NRT only. The additional 
use of NRT is therefore 2.4 - 0.8% = 1.6%. The abstinence rate after 12 months from 
using NRT is 13.5%20, which means that the extra use of NRT will cause, on average, 
13.5 x 1.6% = 0.2% additional successful quitters. The total expected increase in success-
ful quitters over all interventions is 1.1%, which is added to the quit rates of the reference 
scenario. Alternative treatments such as homeopathy or acupuncture were not included in 
the reimbursement scheme, and were used less frequently in the trial intervention group 
than in the control group. Because there is no evidence-based effect of these treatments, 
we used the efficacy of ‘intensive counselling’ for ‘intensive counselling plus alternative 
SCS’ and the effect of ‘placebo’ for ‘alternative SCS’. Using the 95% CIs of the published 
abstinence rates and of the estimated additional numbers of users, we calculated a 95% 
CI for the effect in the literature-based reimbursement scenario, which was used in the 
sensitivity analyses.
Table 2.1: Costs per smoker and quit rates used in the trial-based reimbursement scenario. [13,14].a
Control 
group
Intervention
group
Difference (95% CI)
Costs of SCS € 3.87 € 14.06 € 10.19
Overhead costs
Application for reimbursement € 1.20 € 1.20
Identifying smokers and informing them about the 
reimbursement policy 
€ 7.32 € 7.32
Total costs per smoker in the trial-based 
reimbursement scenario 
€ 3.87 € 22.58 € 18.71 (8.82–33.90)
Quit rates
12-month assessment, prolonged abstinence, 
self-reported 
2.8% 5.5% 2.7%pt (0.5–4.9%pt)
a CI: confidence interval; SCS: smoking cessation support; %pt: percentage point.
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2.2.3 Intervention costs 
For the trial-based reimbursement scenario, costs per smoker and the corresponding 
CI were calculated bottom-up based on the resource use observed during the trial (see 
table 2.1). We included the costs of counseling and use of pharmacotherapy. Overhead 
costs consisted of the costs of identifying the smokers, sending all eligible smokers a letter 
and leaflet describing the SCS for which reimbursement were available and the way in 
which they could apply for reimbursement, plus administration costs of reimbursement. 
The costs of SCS that were used in the literature-based reimbursement scenario are given 
in table 2.2. These costs were estimated bottom-up based on recommended resource use 
and unit costs.20,25 Costs per quit attempt were multiplied by the additional use of the SCS 
to calculate the additional cost per smoker. Returning to the earlier NRT example, 1.6% 
additional users multiplied with the costs of a quit attempt using NRT (€ 186) results in a 
cost of € 2.98 per smoker. The same overhead costs as in the trial-based reimbursement 
Table 2.2: Use of smoking cessation support (SCS) in the Friesland trial and the predicted increase in successful 
quitters and costs in the literature-based reimbursement scenario.a
Additional 
use (% 
smokers) 
[13,14]
Abstinence 
rates 
[13,14,20–22,39]
Price per 
user [20,39]
Cost per 
smoker 
(95% CI)
% Increase in 
the number 
of successful 
quitters 
(95% CI)
NRT 1.6% 13.5% € 186 € 2.98 0.2%
NRT + IC 0.9% 22.0% € 394 € 3.55 0.2%
NRT + bupropion + IC 0.2% 18.4% € 573 € 1.15 0.0%
Bupropion 1.1% 13.3% € 180 € 1.98 0.2%
Bupropion + IC 2.1% 18.4% € 377 € 7.92 0.4%
IC 1.0% 13.9% € 198 € 1.98 0.1%
IC + alternative SCS -0.2% 13.9% € 253 -€ 0.50 -0.0%
Alternative SCS -0.2% 9.3% € 55 -€ 0.11 -0.0%
Overhead costs € 18.94
Application for reimbursement € 1.20
Identifying smokers and informing them about the 
reimbursement policy 
€ 7.32
Additional total costs per smoker in the 
literature-based reimbursement scenario 
€ 27.46 
(9.11–61.45)
Increase in quit rate per smoker in the 
literature-based reimbursement scenario 
1.1%pt
(0.6%–1.5%pt)
a CI: confidence interval; SCS: smoking cessation support; NRT: nicotine replacement therapy; IC: intensive 
counselling; %pt: percentage point.
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scenario were included. A CI was based upon the uncertainty surrounding additional use 
of SCS and minimum and maximum estimates for resource use.20,25
2.2.4 The CDM
To estimate the long-term effects of smoking cessation, the RIVM (National Institute for 
Public Health and the Environment) CDM was used. This model has been described 
extensively by Hoogenveen and colleagues.26 The CDM is a Markov-type state-transition 
model that describes the effects of epidemiological risk factors on morbidity and mortality 
from 28 chronic diseases in the Dutch population, and several risk factors, including 
smoking. It is a population-based, dynamic model that accounts for changes over time in 
the demographics of the population and the prevalence of risk factors. It includes realistic 
time-lags between the moment of smoking cessation and effects on the incidence of 
smoking-related disease and takes into account the fact that successful quitters can relapse 
into smoking. The CDM has been used in relation to smoking for future projections of risk 
factor and disease prevalence numbers15,27,28, cost–effectiveness analyses29 and estimates 
of healthy life expectancy.30 The CDM relates smoking to increased incidence rates of 14 
smoking related chronic diseases, including coronary heart disease, chronic obstructive 
pulmonary diseases (COPD) and several types of cancer. The incidence rates of smoking-
related diseases are increased in current smokers as well as in former smokers, with the 
relative risks of former smokers declining as a function of time since cessation.19 More 
details on the model and model inputs are presented in16,19,30 which are freely available on 
the internet and in Appendix A2.
2.3 RESULTS
2.3.1 Effects on smoking prevalence
In year 1 of our projections (2006), the percentage of smokers in The Netherlands was ap-
proximately 28.2%, which amounts to 3.8 million smokers.31 This percentage diminishes 
slowly over time. Due to the reimbursement policy, the number of smokers decreases 
faster. At the end of the first year, the number of smokers in the trial-based reimburse-
ment scenario is 0.7%pt lower than in the reference scenario and after 20 years (2025) is 
0.18%pt. In the literature-based reimbursement scenario the percentage of smokers was 
0.3%pt lower than in the reference scenario after 1 year and 0.08%pt lower after 20 years. 
Differences in the reference scenario diminish over time, as reimbursement was assumed 
to finish after half a year.
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2.3.2 QALYs gained
Figure 2.1 shows the difference in QALYs per year in the different scenarios compared to 
the reference scenario. The trial-based reimbursement scenario raised the number of QALYs 
with a maximum of 24,00 per year in 2036. At this time-point, the largest proportion of the 
smokers who quit during the intervention were reaching an age where they would have 
developed one of the smoking-related diseases included in the CDM. The smokers who 
lived at the time of the reimbursement policy die consecutively and the health benefits of 
the intervention were mainly gone by the year 2095. In the literature-based reimburse-
ment scenario, health benefits were lower than in the trial-based reimbursement scenario. 
The number of QALYs gained reached a peak in 2036 at 1,000 QALYs per year.
2.3.3 Effects on health care costs
The effects on health care costs are shown in figure 2.2 for the trial-based scenario. The 
annual costs of smoking-related diseases were lower in the intervention scenarios than 
in the reference scenario during the first decades. The difference between the trial-based 
reimbursement scenario and the reference scenario reached a peak in 2029, with annual 
smoking-related costs being € 12.0 million lower in the trial-based reimbursement scenar-
Figure 2.1: Difference in QALYs per year in the trial-based and literature-based reimbursement scenarios 
compared to the reference scenario.a
a QALY: Quality adjusted life year
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io; savings decreased thereafter. From 2059 onwards the annual smoking-related health 
care costs were higher in the trial-based reimbursement scenario than in the reference 
scenario. This can be explained by a greater number of people in the cohort still alive in 
the trial-based reimbursement scenario. The same pattern was seen for the literature-based 
reimbursement scenario, with maximum cost savings of € 4.9 million in 2029.
In the extra life years gained by successful quitters, additional costs are generated 
for diseases unrelated to smoking, such as dementia or hip fractures in old age.29 This 
increases the costs of all scenarios (figure 2.2). In the trial-based reimbursement scenario, 
annual total health care costs, including these unrelated health care costs, were lower in 
the first years than in the reference scenario, up to a maximum of -€ 3.4 million in 2018. 
From 2026 onwards, the total health care costs in the trial-based reimbursement scenario 
were higher than in the reference scenario, with a maximum cost-difference of € 32.6 
million in 2051. The literature-based reimbursement scenario showed a similar pattern, 
with cost savings up to -€ 1.4 million in 2018 and higher costs from 2026 onwards, with 
a maximum of € 13.3 million in 2051.
Figure 2.2: Difference in smoking-related, unrelated and total health care costs per year in the trial-based 
scenario compared to the reference scenario
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2.3.4 Cost–utility
Two different incremental cost–utility ratios (ICUR) were computed (table 2.3). The first 
ratio is the intervention costs per QALY gained; the second ratio relates total costs from a 
health care perspective to QALYs gained.
2.3.5 Sensitivity analysis
In our main analysis we discounted costs at 4% and outcomes at 1.5%.24 When using a 
discount rate of 0% for both costs and outcomes, the life-time ICUR was € 13,300 per 
QALY for the trial-based reimbursement scenario and € 15,100 per QALY for the literature-
based reimbursement scenario, relating total costs to QALYs gained. The respective ICURs 
after 20 years of the two reimbursement scenarios were € 2,200 and € 13,900 per QALY. 
Discounting both costs and outcomes at 4% decreases the net present value of the number 
of QALYs compared to the base analyses. Because the effects of reimbursement are found 
mainly far in the future, the LYG and QALYs gained are reduced considerably when us-
ing this higher discount rate, leading to less favourable ICURs. The life-time ICUR was 
€ 9,100 per QALY for the trial-based reimbursement scenario and € 15,100 per QALY for 
the literature based reimbursement scenario. The respective ICURs after 20 years were 
€ 5,500 and € 25,700 per QALY.
From a policy viewpoint, it is more realistic to assume that the policy will be in place 
for a longer period than the trial’s implementation period of 6 months. Therefore, we have 
Table 2.3: Difference in costs, LYs gained, QALYs gained and ICUR after 20 years and 100 years, as com-
pared to the reference scenario.a,b
Trial-based reimbursement 
scenario
Literature-based 
reimbursement scenario
Time horizon 20 100 20 100
Costs (x € 1 million)
   Smoking-related health care costs -62.2 -130.7 -25.3 -53.3
   Unrelated health care costs 37.9 305.4 15.4 124.4
   Intervention costs 68.1 68.1 93.5 93.5
Total costs 43.9 242.9 83.6 164.6
Life years (LY) gained (x 1,000) 9.2 67.7 3.7 27.6
   ICUR: intervention costs per LYG 7,450 1,010 25,080 3,390
   ICUR: total costs per LYG 4,790 3,590 22,420 5,970
QALYs gained (x 1,000) 11.2 54.6 4.6 22.2
   ICUR: intervention costs per QALY gained 6,100 1,250 20,530 4,200
   ICUR: total costs per QALY gained 3,930 4,450 18,360 7,400
a LY: life year; QALY: Quality adjusted LY; ICUR: Incremental cost-utility ratio
b Costs discounted at 4%, LYs and QALYs discounted at 1.5%.
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also calculated the outcomes for a scenario where the intervention is in place for 4 years, 
assuming the quit rates to remain constant over this period. Four years were considered an 
appropriate period because it is the time span between elections for the Dutch parliament. 
With the intervention in place for a 4-year period, the difference in total costs between 
the reference scenario and our trial-based scenario was € 823 million. The total number of 
QALYs gained was 204,000. Dividing both, the resulting ICUR of € 4,040 per QALY was 
slightly better than in the main analysis. In our literature-based scenario the difference in 
total costs amounted to € 540 million, with 84,000 QALYs gained, resulting in an ICUR 
of € 6,400 per QALY, which was also slightly better than in the main analysis. At the 
end of the reimbursement period, the number of smokers in the trial-based reimburse-
ment scenario was 1.7%pt lower than in the reference scenario. In the literature-based 
reimbursement scenario the number of smokers was 0.7%pt lower than in the reference 
scenario, using a 4-year reimbursement period.
Based on the confidence ranges presented in tables 2.1 and 2.2, the effect of uncertainty 
on intervention costs was analysed. Using a life-time horizon, the ICUR in the trial based 
scenario varied between € 3,800 and € 5,500 per QALY and the ICUR in the literature-
based reimbursement trial varied between € 4,600 and € 12,600 per QALY. Uncertainty 
about the effectiveness of the intervention was also analysed based on the 95% CIs (see 
Figure 2.3: CE-plane that shows the sensitivity of the trial-based and literature-based reimbursement scenarios 
for changes in costs and effectivity.a
a CE: Cost-effectiveness; QALY: Quality adjusted life year.
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tables 2.1 and 2.2). The ICUR of the trial-based reimbursement scenario varied between 
€ 3,900 (maximum effectiveness) and € 9,900 (minimum effectiveness) per QALY using 
a life-time horizon. The ICUR of the literature-based reimbursement scenario varied be-
tween € 6,300 and € 10,900 per QALY using a life-time horizon.
Figure 2.3 shows the cost–utility plane (CU-plane) with the results of the sensitivity 
analyses of intervention costs and effectivity. The lines show by how much the minimum 
and maximum estimates of total effects on health care costs and QALYs differed. Uncer-
tainty in effectiveness affected the estimates of both costs and QALYs, and therefore these 
lines were not horizontal.
2.4 DISCUSSION
This study showed that full reimbursement of the costs of smoking cessation support to 
smokers is a cost-effective way to contribute to a reduction in the percentage of smokers. 
Reimbursement for a period of half a year led to a decrease in the percentage of smok-
ers between 0.3%pt and 0.7%pt, compared to no reimbursement. Having the policy in 
place for 4 years would lower the percentage of smokers at the end of the reimbursement 
period between 0.7%pt and 1.7%pt. This is a contribution towards the goal of the Dutch 
government of reducing the percentage of smokers to 20%. The findings support the ad-
vice by the health insurance board CVZ to the Dutch Ministry of Health to reimburse an 
integrated smoking-cessation programme.11 However, reimbursement alone will probably 
not suffice, even if in reality this will be in place for a longer period of time, given that 
the smoking rate in the first year of our model (2006) was still 28%. In 2008 the Dutch 
smoking rate was 27%.31 The Ministry of Health intends to begin reimbursement by 2011.
The number of life years that can be gained with a reimbursement scheme that is avail-
able for half a year was 68,000 in our trial-based scenario and 28,000 in our literature-
based reimbursement scenario. When life years are adjusted for health-related quality 
of life, total gains were 55,000 and 22,000 QALYs, respectively. Because of extra health 
care costs in these life years gained, total costs of reimbursement exceed the total cost of 
no reimbursement after an initial period of savings in health care costs.32 Relating costs 
to health gains, the costs per QALY gained for a life-time horizon were found to be about 
€ 4,500 in our trial-based estimate and € 7,400 in our literature-based estimate. These 
low ratios reflect the large health gains thatmay be obtained from smoking cessation. Our 
results were robust to uncertainty in intervention costs and in effectiveness showing that, 
like most smoking cessation policies, reimbursement was a cost-effective intervention.10,33
Other evaluations of reimbursement or free supply of cessation support exist5,34-36, but 
none of them was based directly on a randomized controlled trial allowing free choice of 
support methods and showing the actual increase in the use of cessation support. Also, 
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none of these evaluations included overhead costs related to reimbursement. Our study 
showed that these additional costs are well balanced by the health gains obtained from 
more successful quit attempts.
The analyses included costs in life years gained. Compared to estimates that account 
only for savings in costs of care for smoking-related diseases (e.g.22,37), our current estimates 
are more conservative and complete. Excluding the costs in the life years gained, as is 
performed frequently in other studies, and focusing upon intervention costs minus savings 
in costs of smoking-related diseases, the intervention was cost saving in the trial-based 
reimbursement scenario and had an ICUR of less than € 2,000 in the literature-based 
reimbursement scenario (data not shown).
Sensitivity analyses showed that the time horizon and discount factors used had a con-
siderable influence on the outcomes. The health effects of cessation need some time to 
become apparent, implying that for a time horizon of 20 years, the incremental cost–util-
ity ratios (ICURs) were less favourable than for the main estimates, which used a life-time 
horizon so that all health effects were included.
The reimbursement period in our study was only 6 months, following the actual trial. Of 
course, when a reimbursement policy is implemented, it will usually remain available for 
a longer time-period. Because the trial had only 6 months of reimbursement, we do not 
have empirical data on what will happen when the policy remains in place. International 
trials all had a follow-up time of less than 12 months.10 The smokers most eager to quit 
may have tried to quit first, resulting in a decline in the number of quit attempts over time. 
Smokers and medical professionals may also become more familiar with the policy, which 
might lead to an increase in quit attempts over time. With no reliable data available, in our 
sensitivity analysis on the length of reimbursement period we have assumed no change in 
quit rates compared to the first 6 months.
A longer implementation period had only a small effect on cost-effectiveness ratios, 
even though the total number of QALYs gained and the difference in total costs were much 
larger. This is because both costs and health effects increased proportionally. The small 
changes observed were due to a difference in discounting between costs and outcomes, 
which is the current Dutch standard for cost-effectiveness analyses.
The clinical trial by Kaper et al. focused upon short term costs and effects. It found 
that if society was willing to pay € 1,000 (€ 10,000) for an additional 12-month quitter, 
the probability that reimbursement for SCS would be cost-effective was 50% (95%). The 
study also included a quick extrapolation to long-term effects, based on American data. 
They estimated an effect of 10.6 QALYs gained in the control group, amounting to 62.000 
QALYs for all smokers in The Netherlands. This is close to, but higher than, our estimate 
of the trial-based reimbursement scenario. The intervention costs per QALY gained as 
estimated by Kaper et al. were € 1,802, using discount rates of 4% for both costs and 
outcomes, which was lower than our estimates of the cost–utility of the two scenarios. 
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They concluded that if society was willing to pay € 18,000 per QALY, an accepted Dutch 
cut-off point for preventive interventions38, the probability that reimbursement for SCS 
was cost-effective was 95%. Our current estimates, based on a much more sophisticated 
model, confirmed the cost–utility of reimbursement.
A recently performed pilot study investigated the feasibility of large-scale implemen-
tation of reimbursement in The Netherlands.17 It estimated the costs of implementing 
reimbursement for a 6-month period in the whole of The Netherlands. The estimate varied 
between € 14.0 million and € 22.7 million, based upon the pilot study costs per participant 
and the number of Dutch smokers who indicated that they wanted to quit smoking within 
6 or 12 months. This is substantially lower than our calculation of the intervention costs. 
Part of this difference is explained because the pilot study ignored the overhead costs of 
reimbursement.
In the trial-based scenario we used the self-reported quit rates after 12 months. The 
biochemically validated abstinence rates after 12 months were also significantly higher 
in the intervention group compared to the control group. We based our scenario on self-
reported quit rates, as the parameter estimates on smoking in the CDM were also based 
on questionnaires. Risk differences based on the biochemically validated cessation rates 
were very similar, with a somewhat narrower CI.
The main limitation of this study is that we used the results of a single trial. The number 
of quit attempts per type of SCS was relatively limited, as was the geographical coverage. 
In order to assess the degree of certainty around the outcomes we performed sensitivity 
analyses using the CIs around costs and quit rates, and simulated an alternative scenario 
based on systematic reviews and meta-analyses for costs and effectiveness of smoking ces-
sation. Because of the small regional differences regarding smoking in The Netherlands, 
we feel that the outcomes of this study are applicable to the whole of the Netherlands. 
Even though the outcomes of the original trial were in line with those of other similar stud-
ies10, the results may, however, not be applicable to countries with different health care 
systems or at different stages of the smoking epidemic. For instance, the important role of 
general practitioners (GPs) in the Dutch health care system was reflected by the success 
of smoking cessation support delivered by primary care. This may be less applicable to 
countries with a less prominent role for GPs. Also, a country with much higher smoking 
prevalence might gain a larger reaction from the intervention than in our study. Similarly, 
a country with much lower prevalence might notice a smaller impact on quit rates.
However, the advantage of using a trial is that effects on quit rates could be estimated 
with a comparable control group over a 12-month follow-up time. Such an experimental 
setting is usually unavailable for evaluation of policy measures.
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2.5 CONCLUSION
Reimbursement of smoking cessation support via the obligatory health care insurance in 
the Netherlands will result in fewer smokers and more QALYs. Reimbursement seems a 
cost-effective way to contribute to a reduction in the percentage of smokers.
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A2 APPENDIX
A2.1 The Chronic Disease Model
To estimate the long term effects of smoking cessation, the RIVM Chronic Disease Model 
(CDM) was used. This model has been extensively described by Hoogenveen and col-
leagues.1 The CDM is a state-transition Markov-type model that was designed to describe 
the effects of epidemiological risk factors on morbidity and mortality from several chronic 
diseases in the Dutch population. It includes 28 chronic diseases and several risk factors 
amongst which smoking, Body Mass Index, and physical inactivity. In modeling diseases 
explicitly, the structure of the model is similar to the Prevent model2 and the Quit Ben-
efits model.3,4 An important difference with the Prevent model is that different risk factor 
classes are modeled. In comparison with the Quit Benefits Model the CDM includes more 
diseases and a finer structure of age categories, allows for co-morbidity and has the abil-
ity to track health effects over a longer period. The CDM has been used in relation to 
smoking for future projections of risk factor and disease prevalence numbers prevalence 
numbers5-7, cost effectiveness analyses8 and estimates of healthy life expectancy.9
The model describes the life course of cohorts in terms of transitions between risk factor 
classes and transitions between disease states over time. Risk factors and diseases are 
linked through relative risks of disease incidence.10 The parameters used in the model are 
the 1-year probabilities of each transition between model states. The main model outcome 
variables are numbers of incident and prevalent cases and numbers of deaths, specified 
by disease, age and gender.
Demographic data such as all cause mortality rates and initial population numbers were 
available from Statistics Netherlands.11 To estimate incidence, prevalence and mortality 
rates in the general population, three types of data sources were used: general practitioner 
registrations for non-cancer diseases, national cancer registries, and cohort studies for 
diabetes.12,13 To compute health effects in terms of quality-adjusted life years (QALYs), the 
CDM used quality of life weights derived from the Dutch Burden of Disease Study9,14,15, 
to adjust life years lived with a disease, with 1 reflecting full health and 0 a quality of life 
equal to death. Health care costs per patient per year are based on the Dutch Costs of 
Illness study.8,16
The CDM relates smoking to increased incidence rates of 13 smoking-related chronic 
diseases, i.e. coronary heart disease (acute myocardial infarction (AMI) and other coronary 
heart disease), congestive heart failure, stroke, chronic obstructive pulmonary diseases 
(COPD), diabetes, and cancer of the lung, stomach, larynx, oral cavity, esophagus, pan-
creas, bladder and kidney. The incidence rates of smoking-related diseases are increased 
in current smokers as well as in former smokers, with the relative risks of former smokers 
declining from the risk of a smoker immediately after stopping smoking to that of a never 
smoker as a function of time since cessation.17 Smoking specific all cause mortality rates 
39
2
were used in the model in combination with the disease specific excess mortality rates. 
More details on model inputs are presented by Van Baal et al.9
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ABSTRACT
In cost-effectiveness (CE) Markov models, heterogeneity in the patient population 
is not automatically taken into account. We aimed to compare methods of dealing 
with heterogeneity on estimates of CE, using a case study in COPD. We first present 
a probabilistic sensitivity analysis (PSA) in which we sampled only from distribu-
tions representing parameter uncertainty. This ignores any heterogeneity. Next, we 
explored heterogeneity by presenting results for subgroups. The next method samples 
parameter uncertainty simultaneously with heterogeneity in a Single Loop PSA. 
Finally, we distinguish parameter uncertainty from heterogeneity in a Double Loop 
PSA, by performing a nested simulation within each PSA iteration. Point estimates 
and uncertainty differed substantially between methods. The incremental CE ratio 
(ICER) ranged from € 4,900 to € 13,800. The Single Loop PSA led to a substantially 
different shape of the CE-plane and an overestimation of the uncertainty compared 
with the other three methods. The CE-plane for the Double Loop PSA showed sub-
stantially less uncertainty and a stronger negative correlation between the difference 
in costs and the difference in effects than the other methods. This comes at the cost 
of higher calculation times. Not accounting for heterogeneity, Subgroup Analysis and 
the Double Loop PSA, can all be viable options, depending on the decision makers’ 
information need. The Single Loop PSA should not be used in CE research. It disre-
gards the fundamental differences between heterogeneity and sampling uncertainty 
and overestimates uncertainty as a result.
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3.1 INTRODUCTION
Heterogeneity in cost-effectiveness (CE) models refers to true differences in outcomes be-
tween patients, which can be explained by differences in patient characteristics. Examples 
can be disease severity, age, presence of different biomarkers and many more.1 To date, 
only limited attention is paid to patient heterogeneity and pharmacoeconomic guidelines 
provide hardly any methodological guidance on the subject.2 CE models that follow 
individual patients, such as discrete event simulation or micro-simulation, automatically 
account for patient heterogeneity, as each individual patient can be modelled with its 
unique characteristics. However, in the case of Markov models, which follow a cohort of 
patients over time, heterogeneity is not automatically taken into account.
Patients in Markov models are often assumed to be homogeneous, with parameter 
estimates obtained from aggregated data. The probabilistic sensitivity analysis (PSA) is 
performed by drawing from distributions which represent the uncertainty about the popu-
lation average of parameters, like transition probabilities or utilities. If the model contains 
any variables representing patient characteristics, such as the starting age of the cohort, 
the models use a single point estimate. The CE outcomes for this “average patient” are then 
assumed to represent the entire patient population.
However, with non-linearity being the rule rather than the exception in Markov model-
ling3, the incremental costs and effects for the average patient are not equal to the average 
over all patients.4,5 This makes it incorrect to assume that these outcomes are applicable 
for heterogeneous populations. In order to obtain a correct CE estimate over the hetero-
geneous population as a whole, heterogeneity should be taken into account explicitly. 
Heterogeneity has been handled in Markov models in three different ways. The first is 
to calculate outcomes for several different combinations of patient characteristics in sub-
group analyses.4 The comparison of subgroups allows for the exploration of the effect that 
differences between patients have on CE outcomes. For example, Bolin et al. calculated 
CE for smoking-cessation interventions for men and women separately.6 These subgroups 
may provide useful insights. However, policy and reimbursement decisions are commonly 
made for an entire patient population, not subgroups. It is, for example, inconceivable 
that a policy maker concerned with the reimbursement of smoking cessation treatment 
will make a different decision for male and female smokers. Such a distinction is usually 
made only between disease severity classes, but this is only a part of the total existing 
heterogeneity. In addition, it is often difficult to determine in practice whether a difference 
between subgroups is genuine or simply reflects noise in the data.3 Furthermore, even if 
subgroups are a viable option in decision making, an average patient will have to be used 
to represent these subgroups. Here too, as above, the CE outcomes may not be representa-
tive for all patients in the subgroup. 
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A second approach is to perform a PSA, which draws from all available distributions at 
the same time: probability distributions that reflect parameter uncertainty and frequency 
distributions of patient characteristics. The expected outcomes of this analysis reflects 
parameter uncertainty and patient heterogeneity in a heterogeneous population5, but 
ignores the fundamental difference between the two.1 This PSA does not correctly provide 
the distribution of the expected outcome reflecting parameter uncertainty, for a heteroge-
neous population. 
In order to correctly separate parameter uncertainty and heterogeneity, the analysis re-
quires a nested Monte Carlo simulation.5 We called this method the Double Loop PSA and 
draw a number of individual patients within each PSA iteration. In this way we investigate 
sampling uncertainty, while still accounting for patient heterogeneity. The results of this 
analysis reflects parameter uncertainty in a heterogeneous population and will therefore 
lead to the required outcome.5 In essence, this “Double Loop PSA” uses the existing 
Expected Value of Partial Perfect Information (EVPPI) methodology with a different goal.7
In this paper, we discuss the value of each of the methods for decision makers. We 
illustrate the differences between the approaches by applying them to a Markov model, 
used to assess the CE of a new treatment option for patients with Severe and Very Severe 
Chronic Obstructive Pulmonary Disease (COPD). 
3.2 METHODS
3.2.1 Case Study
To illustrate the different ways of handling heterogeneity, we chose to use a case study in 
COPD. COPD is characterized by airflow limitation that is preventable and treatable but 
not fully reversible,8 often accompanied by periods of increasing symptoms, called exac-
erbations. Patients are often treated with a long-acting β2-agonist (LABA]. A relatively new 
treatment option is roflumilast (Daxas®, Takeda Pharmaceuticals International GmbH). In 
our case study, we compared patients who used roflumilast in combination with LABA 
(ROFLU + LABA) with patients who used LABA alone.
This study was performed using a published Markov model, which was used to sup-
port reimbursement decision making on roflumilast in for example the United Kingdom 
(UK)9-11, Switzerland12, and Germany13 The model was built in TreeAge Pro 2009 (TreeAge 
Software, Inc., Williamstown MA, USA) and adapted to the Netherlands. Where possible, 
the parameter estimates and frequency distribution of patient characteristics were obtained 
from the subgroup of patients in two one-year clinical trials of roflumilast (ROFLU) versus 
placebo, that had concomitant treatment with a long-acting β2-agonist (LABA subgroup).14 
The benefits of adding ROFLU to LABA were modelled by a reduction in exacerbations 
that require medical intervention, and by an initial improvement in lung function. The re-
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duction of exacerbations was expressed as a risk ratio of 0.800 (95% confidence interval: 
0,700-0,914).14 Benefits of ROFLU were further modelled as a temporality improvement 
in FEV1 of 46 ml (28-64). This improvement was assumed to last for five years, after which 
the lung function in the LABA + ROFLU treatment arm was assumed to be the same as that 
in the LABA alone treatment arm. 
The Markov model had a cycle length of 1 month and comprised three health states, 
each with different rates of exacerbations: Severe COPD, Very Severe COPD and Death 
(figure 3.1). COPD severity was based on the amount of air which can be forcibly exhaled 
from the lungs in the first second of forced exhalation, expressed as a percentage of the 
predicted normal value for a given patient’s height, gender and age, the FEV1%pred.8 
Severe COPD was defined as 30% ≤ FEV1%pred < 50% and Very Severe COPD as 
FEV1%pred < 30%. Each cycle, patients could either stay in their current state, progress 
from Severe to Very Severe COPD or die. Transitions to less severe states were impossible. 
All patients started in the Severe COPD stage. During each cycle, patients could have a 
COPD exacerbation, which was either community-treated or required a hospital admis-
sion. 
The background mortality is taken from Dutch life tables15, which was adjusted with 
standardised mortality ratios (SMR) to reflect the expected increased mortality in the 
COPD population.16 These SMR were obtained from comparing the mortality in the gen-
eral population with the mortality among COPD patients in the Dutch population-based 
COPD policy model.17,18 The case fatality rate (CFR) for hospital admissions was 7.7%.19
Costs (price level 2009) and utilities were assigned to the two COPD severity states. 
Costs and utility decrements were assigned to the exacerbations. Half cycle correction 
Figure 3.1: Markov model structure.a
a COPD = Chronic obstructive pulmonary disorder; EXA = exacerbation
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was applied. A time horizon of 20 years was used. In accordance with Dutch guidelines, 
costs were discounted at 4% and health outcomes were discounted at 1.5%.20 The CE 
analysis was performed from a societal perspective20, which included all direct health care 
costs, the cost of productivity loss due to absence from work and the direct non-health 
care costs, in this case the travel and parking costs borne by patients and their families 
when visiting a health care provider. 
3.2.2 Patient heterogeneity and sampling uncertainty
The model parameters that represent patient heterogeneity were gender, height, age at the 
start of treatment and the starting value for FEV1%pred (table 3.1). Parameter estimates 
and distributional assumptions were based on the trial data of the LABA subgroup, utiliz-
ing only patients who started with Severe COPD.14 The proportion of males / females in the 
cohort was taken to be equal to the Dutch COPD patient population and was not sampled 
from a distribution.21 
Gender was not considered part of the patient heterogeneity discussed here, as the 
model is calculated separately for male and female patients and the results are combined 
into a single CE outcome. As such heterogeneity due to gender is accounted for. Patient 
height was used, together with gender and age, to calculate the absolute FEV1, based 
on the cohort’s FEV1%pred.22 This is necessary, since the yearly lung function decline is 
modelled in absolute terms (52 ml).23 Age at the start of treatment is measured in years, 
and influences the productivity costs, background mortality and the calculation of the 
absolute FEV1. The starting value of FEV1%pred impacts the progression of the cohort to 
Table 3.1: Parameter estimates and distributional assumptions for patient heterogeneity
Starting Length in centimeters
Agea FEV1%predb Female patients Male patients
Disregard Heterogeneity 64 39.2% 161.7 171.3
Subgroup analyses
 Age 64, FEV1%pred 39% Same as “Disregard Heterogeneity”
 Age 55, FEV1%pred 39% 55 39.2% 161.7 171.3
 Age 73, FEV1%pred 39% 73 39.2% 161.7 171.3
 FEV1%pred 31%, Age 64 64 31.0% 161.7 171.3
 FEV1%pred 50%, Age 64 64 50.0% 161.7 171.3
Single Loop PSA N(64, 9.1) Trial data N(161.7, 7.0) N(171.3, 7.4)
Double Loop PSA Same as “Single Loop PSA”
a Based on average and standard error in the LABA subgroup.14
b  Based on average in the long-acting β2-agonist (LABA) subgroup14 and the inner boundaries for the Severe 
COPD stage. 
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a more severe stage. This in turn influences the probability to experience an exacerbation, 
and the resulting costs and mortality.
The model parameters for which we defined sampling uncertainty are mortality (uni-
form distributions), the probability that an exacerbation is treated in a hospital and utilities 
(beta distributions) and lung function decline, COPD exacerbation rates, utility reduction 
due to an exacerbation and cost parameters (all gamma distributions). An overview of all 
parameters can be found in the online appendix, including more detailed information on 
distributional assumptions.
3.2.3 Strategies to account for heterogeneity
First, we disregarded heterogeneity (“Disregard Heterogeneity”) and performed a standard 
PSA with 2,000 random draws from the probability distribution of the model param-
eters. For the three patient characteristics investigated, height, age at start and starting 
FEV1%pred, we used the mean values of the cohort as a point estimate (table 3.1). 
Next, we performed five subgroup analyses. The subgroups were cohorts defined by 
age, height and FEV1%pred and can be found in table 3.1. Since the effect of height on 
the outcomes is small, it is not used to define subgroups. For each of five subgroups of 
patients, we ran a PSA of 2,000 iterations. Younger patients live longer and will have more 
time to experience benefits, for example a higher number of future exacerbations which 
can be prevented. They will also experience the benefit of prevented productivity losses, 
until the Dutch pension age of 65. Because the exacerbation rate is higher in patients with 
Very Severe COPD than in patients with Severe COPD, patients with Very Severe COPD 
benefit more from the exacerbation-reducing effect of LABA + ROFL. It takes patients with 
a relatively high FEV1%pred more cycles to reach this stage, and thus experience these 
benefits, than the average group. In addition, LABA + ROFLU temporarily improves lung 
function in the intervention group, which means that patients in the intervention group 
stay on average about a year longer in the Severe COPD state than the patients in the 
control group. 
The next approach was to perform a PSA with 2000 iterations, where we sampled from 
both the probability distributions representing sampling uncertainty and the frequency 
distributions representing heterogeneity at the same time (“Single Loop PSA”). Table 3.1 
shows the distributional assumptions for the patient characteristics.
Finally, we performed a PSA, using a two-level sampling algorithm (“Double Loop 
PSA”). We used two nested levels of Monte Carlo sampling. First we drew values from 
probability distributions to reflect parameter uncertainty (outer loop). This set of values 
was kept constant when we drew values from frequency distributions (inner loop) to 
reflect heterogeneity in patients’ height, age and FEV1%pred at start. Each of these draws 
within the inner loop can be interpreted as a patient with certain characteristics; the 
average over all patients in an inner loop as a “trial”. We repeated the outer loop 2,000 
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times. Within each outer loop, we repeated the inner loop 30 times. In this way, we could 
account for both the patient heterogeneity and sampling uncertainty separately, yet at the 
same time. The result of this analysis is the average cost-effectiveness over all trials, for 
2,000 draws from the distribution of the model parameters. It gives the distribution of the 
expected outcome in the heterogeneous population, reflecting the parameter uncertainty. 
To investigate the impact of the size of the inner and outer loop, we also performed a 
Double Loop PSA with an outer loop size of 300 and an inner loop size of 2,000.
3.2.4 Comparison of methods
We first compared the strategies with respect to the point estimates and 95% confidence 
intervals (CIs) of the outcomes. The point estimates and CIs of the difference in costs and 
quality adjusted life years (QALYs) were calculated as the average and the 2.5th and the 
97.5th percentile from the PSA iterations. The point estimate for the incremental CE ratio 
(ICER) was calculated as the ratio of the two point estimates. Next, we visually compared 
the CE planes and described the differences. We then summarized the uncertainty from 
the CE planes in CE acceptability curves (CEAC). Finally, we discussed differences in 
calculation time, which was expected to differ greatly.
3.3 RESULTS
3.3.1 Point estimates of CE outcomes
Table 3.2 shows the point estimates of the results of the CE analysis for LABA + ROFLU 
versus LABA. It is clear that the CE results differ between methods. Disregard Heteroge-
neity produces an ICER of € 10,700. Subgroup analyses show considerable differences 
between subgroups with lower ICERs in patients with more severe COPD and in younger 
patients. The ICERs range from € 4,900 in the subgroup with FEV1%pred 31% and age 64, 
to € 13,800 in the subgroup with FEV1%pred 50% and age 64. Both the Single Loop PSA 
and Double Loop PSA yield an ICER of € 7,800 per QALY. 
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3.3.2 Confidence intervals
Table 3.2 also shows that the width of the 95% confidence intervals (CIs) differs consider-
ably. The most uncertainty was found around both the difference in costs and QALYs 
for the subgroup with age 55 and FEV1%pred 39%, and the least uncertainty for the 
subgroup with age 73 and FEV1%pred 39%. There is considerably less uncertainty around 
the estimates in the Double Loop PSA, than in the Single Loop PSA.
3.3.3 Cost-effectiveness planes
The CE-planes in figure 3.2 show that disregarding heterogeneity (graph 2A) led to a 
roughly cone shaped scatter plot, with a focal point towards the top left, and spreading 
outwards towards the bottom right. The relationship between the difference in costs and 
the difference in QALYs is negative, meaning that when LABA + ROFLU is relatively more 
effective (more exacerbations prevented, slower disease progression), the extra costs of 
roflumilast are also compensated more by lower other health care costs.
When performing subgroup analyses (graph 2B), all subgroups also roughly show a 
cone shape. They differ in terms of size and position in the CE plane. The subgroup with 
age 73 and FEV1%pred 39% lies closest to the origin shows the least uncertainty. In 
this subgroup, no productivity costs can be gained by using a new medication. Due to 
a shorter life expectancy the difference in QALYs that can be gained from preventing 
exacerbations and postponing death is also lower.
The subgroup with age 55 and FEV1%pred 39% has the highest uncertainty and is the 
only one including net cost savings, which are due to productivity gains in these younger 
patients. The reduced progression to Very Severe COPD leads to considerable QALY gains. 
The subgroup with FEV1%pred 50% and age 64 lies closer to the y-axis of the graph, with 
a greater proportion of simulations showing a small difference in QALYs. It also further to 
Table 3.2: CE results (average, 95% CI) of a long-acting β2-agonist (LABA) in combination with roflumilast 
versus LABA alone, using four different methods. 
Δ Costs (in €) Δ QALYs ICER
Disregard Heterogeneity 3,080 (1,760;3,940) 0.286 (0.147;0.438) € 10,700
Subgroup analysesa
 Age 64, FEV1%pred 39% 3,080 (1,760;3,940) 0.286 (0.147;0.438) € 10,700
 Age 55, FEV1%pred 39% 2,200 (-760;4,050) 0.394 (0.132;0.713) €     5,600
 Age 73, FEV1%pred 39% 2,100 (1,210;2,730) 0.165 (0.091;0.249) € 12,700
 FEV1%pred 31%, Age 64 2,110 (440;3,210) 0.427 (0.251;0.619) €     4,900
 FEV1%pred 50%, Age 64 3,370 (2,200;4,220) 0.245 (0.110;0.394) € 13,800
Single Loop PSA 2,350 (270;3,930) 0.299 (0.071;0.613) €     7,800
Double Loop PSA 2,330 (1,220;3,360) 0.300 (0.154;0.464) €    7,800
a Results for the subgroup “Age 64, FEV1%pred 39%” are by definition the same as for “Disregard 
Heterogeneity”.
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the top of the graph, with a greater proportion of simulations pointing to a high cost in-
crease. In this group it takes relatively long for the cohort to reach the Very Severe disease 
stage, where real differences in costs and QALYs between LABA+ROFLU and LABA occur. 
Consequently the difference in health care costs and health outcomes between the two 
interventions are more heavily affected by discounting. The subgroup with FEV1%pred 
31% and age 64 lies lower and more to the right, while the cohort defined by the average 
age and staring FEV1% predicted lies in the middle. 
The Single Loop PSA (graph 2C), resulted in a differently shaped CE plane compared 
with the other methods, and is also much larger in size. It has a rough arch shape, which 
is explained when looking at the subgroup analyses. In essence, the Single Loop PSA is a 
collection of 1,000 subgroups, each with their own patient characteristics and therefore 
different point estimates. The left side of the arch consists mostly of people with Severe 
COPD and an age higher than 65, with patients with a lower starting FEV1% closer to the 
origin and patients with a relatively higher starting FEV1% higher in the graph. The gains 
from reducing exacerbations are less than in Very Severe COPD and no productivity costs 
can be gained by using ROFLU. The average age rises going left in the graph towards the 
origin, diminishing the extra costs and gains for LABA + ROFLU, since patients die earlier. 
Moving towards the right in the graph, we find patients with a lower age on average and 
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Figure 3.2: CE-plane of a long-acting β2-agonist (LABA) in combination with roflumilast versus LABA alone, 
comparing incremental costs to incremental QALYs, using four different methods.a 
a A: Disregard Heterogeneity, 2,000 iterations; B: Subgroup analyses (approximations of 95% confidence 
regions shown for readability), 2,000 iterations for each subgroup; C: Single Loop PSA, 2,000 iterations; D: 
Double Loop PSA, outer loop 2,000, inner loop 30 iterations.
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a lower starting FEV1%. Younger patients result in more productivity gains due to ROFLU 
and patients with a worse lung function lead to a larger difference in health care costs 
between the two arms due to discounting. This may offset the extra medication costs for 
ROFLU.
Performing a Double Loop PSA (graph 2D) produced a cone shape, which is more 
compact than with Disregard Heterogeneity (2A). The CE plane from the Double Loop 
PSA was situated slightly lower in the graph (less difference in costs) and showed a more 
clear negative relationship between the difference in costs and the difference in effects. 
3.3.4 Double loop PSA: impact of loop size
To test whether a cohort size of 30 was appropriate, we have also performed a PSA with 
an outer loop size of 300 and an inner loop size of 2,000. The resulting point-estimate 
and shape of the CE-plane is shown in figure 3.3, with the original Double Loop PSA 
reproduced in figure 3.3A and the new cohort size in figure 3.3B. The shape and position 
of the two CE-planes are similar. The ICER with a lower cohort size is € 7,500, which is 
very close to the ICER of the original Double Loop PSA of € 7,800. 
3.3.5 Policy decisions
The difference in the amount of uncertainty shown in the CE planes is summarized in 
the CEACs in figure 3.4 which show the percentage of PSA draws, where LABA + ROFLU 
can be considered cost-effective, for different threshold values of a QALY. The Double 
Loop PSA is much more certain at the three thresholds shown in table 3.3 than when 
disregarding heterogeneity or performing a Single Loop PSA. This is a result of relatively 
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Figure 3.3: CE-plane of a long-acting β2-agonist (LABA) in combination with roflumilast versus LABA alone, 
comparing incremental costs to incremental QALYs, using the Double Loop PSA, with different inner and 
outer loop sizes.a
a A: Outer loop 2,000, inner loop 30 iterations; B: Outer loop 300, inner loop 2,000 iterations.
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low variation in incremental costs and effects compared to the Single Loop PSA and a 
lower point estimate of the ICER compared to Disregard Heterogeneity. If a policy maker 
would be interested in subgroup analyses it is clear the ROFLU has the highest probability 
to be considered cost-effective in the subgroup of very severe patients with a low FEV1% 
pred. and in patients with a longer life expectancy.
Disregard Heterogeneity (2,000 iterations) 
 
Subgroup analyses (2,000 iterations for each subgroup) 
 
Single Loop PSA (2,000 iterations) 
 
Double Loop PSA (outer loop 2,000, inner loop 30 iterations) 
 
 
0%
20%
40%
60%
80%
100%
%
 o
f s
im
ul
at
io
ns
 w
it
h 
fa
vo
ra
bl
e 
IC
ER
Willingness to pay for a QALY
0%
20%
40%
60%
80%
100%
%
 o
f 
si
m
ul
at
io
ns
 w
it
h 
fa
vo
ra
bl
e 
IC
ER
Willingness to pay for a QALY
Age 64, FEV1% pred 39%
Age 55; FEV1% pred 39%
Age 73; FEV1% pred 39%
FEV1% pred 31%; Age 64
FEV1% pred 50%; Age 64
0%
20%
40%
60%
80%
100%
%
 o
f s
im
ul
at
io
ns
 w
it
h 
fa
vo
ra
bl
e 
IC
ER
Willingness to pay for a QALY
0%
20%
40%
60%
80%
100%
%
 o
f 
si
m
ul
at
io
ns
 w
it
h 
fa
vo
ra
bl
e 
IC
ER
Willingness to pay for an avoided exacerbation
Figure 3.4: CEAC of a long-acting β2-agonist (LABA) in combination with roflumilast versus LABA alone, com-
paring incremental costs to incremental QALYs, using four different methods. 
Table 3.3: Percentage of PSA draws where a long-acting β2-agonist (LABA) in combination with roflumilast is 
deemed cost-effective versus LABA alone, at different threshold values for a QALY, using four different meth-
ods. 
€ 10,000 / QALY € 20,000 / QALY € 40,000 / QALY
Disregard Heterogeneity 41% 92% 100%
Subgroup Analysesa
 Age 64, FEV1%pred 39% 41% 92% 100%
 Age 55, FEV1%pred 39% 73% 97% 100%
 Age 73, FEV1%pred 39% 26% 87% 100%
 FEV1%pred 31%, Age 64 94% 100% 100%
 FEV1%pred 50%, Age 64 20% 80% 98%
Single loop PSA 56% 91% 99%
Double loop PSA 70% 97% 100%
a Results for the subgroup “Age 64, FEV1%pred 39%” are the same as for “Disregard Heterogeneity”.
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3.3.6 Calculation time
There were also differences in calculation times between the different methods. All calcu-
lations were done on the same dedicated computer. Both Disregard Heterogeneity and the 
Single Loop PSA took approximately 20 minutes to calculate, as did each of the subgroups 
in the subgroup analyses. With a total of five subgroups, the total analysis time is above 
1.5 hours, plus the extra time in processing and interpretation. The Double Loop PSA had 
a much longer calculation time, close to 9 hours. The run-time of the Double Loop PSA 
with an outer loop of 300 and an inner loop of 2,000, was approximately 5 days. 
3.4 DISCUSSION
Medical decision models are intended to inform physicians and policy makers, to aid in 
their choices in providing efficient health care. Since patients are by nature heterogeneous, 
these models should take this heterogeneity into account. In the case of Markov models, 
this is not straightforward. In this study, we have shown that there are several ways of deal-
ing with heterogeneity and that the outcomes, and thus the policy decision may change 
when heterogeneity is handled differently. In practice, heterogeneity is often ignored. An 
average value of the patient population will then be used for any variables representing 
patient characteristics in the model. In addition to ignoring available evidence, the results 
are difficult to interpret since the “average patient” does not exist. It is also argued that 
ignoring patient heterogeneity will be costly in both monetary terms and health gains.24,25 
An alternative is to define several subgroups of patients and to calculate the outcomes 
for each of these. This has been proposed as the best method for dealing with heterogene-
ity4, although no comparison with the Double Loop PSA was made. Subgroup analyses 
did lead to insight in the differences between the different types of patients, but not all 
outcomes were useful for decision makers. If a decision maker wants to use the subgroup 
analyses for decision regarding specific subgroups, equity concerns are always an issue.2,26 
Patient heterogeneity in clinical characteristics, such as starting FEV1% in our example, 
may be acceptable for sub-group specific recommendations. Other input parameters, such 
as gender, race or in this case age, are not.2 
Heterogeneity has sometimes been handled by combining it with parameter uncertainty 
in a PSA.27-29 Using the Single Loop PSA, one is able to consider many different types of 
patients, without a significant increase in calculation time. However, because of a larger 
number of parameters being sampled, the amount of uncertainty increases and the shape 
of the CE-plane also changes compared to disregarding heterogeneity. The outcomes from 
the Single Loop PSA reflect both parameter uncertainty and patient heterogeneity, but 
it ignores the fundamental difference between the two. The expected outcome for the 
Single Loop PSA is correct for the population and equals the expected outcome for the 
56
3
Double Loop PSA.5 However, the distribution of the expected outcome, that reflects the 
uncertainty in which many decision makers are interested, is not correct. In order to 
correctly separate parameter uncertainty and heterogeneity, the analysis requires a nested 
Monte Carlo simulation.5 
In the Double Loop PSA we drew a number of individual patients for each of the PSA 
draws and calculate the average CE outcomes. This method accounts sufficiently for 
heterogeneity, is easily interpretable and can be performed using existing software. It was 
not our main goal to minimize uncertainty around our CE outcomes, but the Double Loop 
PSA did lead to the smaller CIs. They are a correct reflection of the parameter uncertainty 
around the expected outcome, for this heterogeneous populations. This reduction oc-
curred because each dot in the Double Loop PSA is an average of 30 patients. For each 
patient, the relationship between the difference in costs and the difference in effects is 
more of less the same, as we could see in the subgroup analyses, which all generally 
have a downward sloping cone shape. The Double Loop PSA is a combination of 2,000 
of these subgroups, which leads to a more defined relationship between the difference in 
costs and effects. In the Double Loop PSA, extreme values of heterogeneity parameters 
can be drawn, but are averaged out in the inner loop, while in the Single Loop PSA, these 
extremes are shown.
Calculation time may be a burden, even with the relatively small cohort size of 30. 
On the other hand, a calculation time of 9 hours (one overnight calculation) is not a 
huge obstacle, in our opinion. Another drawback is that this method cannot be used to 
directly inform subgroup-specific policy decisions. When a policy maker wants or needs 
to consider subgroups, for example defined by disease severity classes, one solution may 
be to perform a Double Loop PSA within each subgroup. This however, will increase the 
computational burden.
We have chosen for a small sample of 30, because larger sample sizes rapidly increases 
the computation time. This so-called “M by N problem”, where the calculation time 
increases due the number of inner calculations, is a major obstacle to performing PSAs 
in for example patient level models.3,30,31 We tested to see whether our cohort size of 
30 was appropriate for our needs, by also performing a Double Loop PSA with an outer 
loop size of 300 and an inner loop size of 2,000. The run-time of this model was ap-
proximately 5 days, which made it impractical in daily use. The resulting point-estimate 
and shape of the CE-plane were similar to Double Loop PSA with a smaller cohort size. 
We therefore concluded that 30 would be a good middle ground between accuracy and 
runtime. However, we acknowledge that a larger number of patients in the inner loop 
might improve results. Fortunately, since computational speed increases rapidly, it is likely 
that using faster, more modern computers would decrease the necessary time. Since the 
model was build, a newer version of TreeAge has also been released, which might also 
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increase computational speed. This means that a higher number of patients in the inner 
loop is becoming possible.
In the current model, the COPD health states were defined by lung function and the 
probability to get a COPD exacerbation was estimated for each state.8 The model was 
constructed before the revision of the GOLD strategy document in 2011, in which a clas-
sification of COPD based on three characteristics, symptoms, lung function and exacerba-
tion history, was proposed. The latter increases the number of variables used to describe 
the heterogeneity of a patient population and -when the possible combinations of these 
3 characteristics are taken- the number of subgroups. This reinforces the need to separate 
heterogeneity from parameter uncertainty. However, applying the latest classification is 
unlikely to have a big impact our point estimate of the ICER in the double loop PSA, 
because the sample as a whole does not change, only the way it is classified.
The uncertainty around the standardized mortality ratio and the case fatality ratio was 
modelled with a uniform distribution. It could be argued that a more natural choice might 
be a lognormal or a beta distribution, respectively. Since the model was built to support 
the reimbursement dossier in several countries, it was decided not to make any changes 
to the provided distributions, to preserve consistency with these dossiers. It was expected 
that these changes would not have impacted our study results.
3.5 CONCLUSION
To conclude, we think that three of the methods discussed can be useful in CE research, 
each in different circumstances. When little or no heterogeneity is expected, or when it 
is not expected to influence the CE results, disregarding heterogeneity may be correct. In 
our case study, heterogeneity did have an impact. Subgroup analyses may inform policy 
decisions on each subgroup, as long as they are well defined and the characteristics of the 
cohort that define a subgroup truly represent the patients within that subgroup. Despite 
the necessary calculation time, the Double Loop PSA is a viable alternative which leads 
to better results and better policy decisions, when accounting for heterogeneity in a Mar-
kov model. The Single Loop PSA can only be used to calculate the point estimate of the 
expected outcome. It disregards the fundamental differences between heterogeneity and 
sampling uncertainty and overestimates uncertainty as a result.
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A3 APPENDIX
A3.1 Input data used in the model
Information on epidemiological data as used in the model, and efficacy of roflumilast, can 
be found in table A3.1. 
A3.2 Utilities
EQ-5D utility weights for stable COPD, which can be found in table A3.2, were derived 
from the LABA-subgroup analysis.14 Utility decrements from experiencing either a 
community-treated or a hospital-treated exacerbation were obtained from a Dutch study 
in which one-year COPD health profiles were valued by the general population using 
the time trade-off method.32 The entire utility decrement is applied at the time of the 
exacerbation.
A3.3 Direct health care costs
Monthly costs of roflumilast were calculated using a daily price for the Netherlands 
provided by the manufacturer of € 1.38. The monthly costs of LABA was calculated 
as the weighted average of the monthly costs of long-acting β2-agonists and inhaled 
corticosteroids in separate devices and in fixed combinations, as published in the 
Pharmacotherapeutic Compass.33 In both calculations, IMS panel data on the number of 
prescriptions of the various medications among COPD patients in the Netherlands were 
used as weights.34, VAT of 6% and a Dutch mark-up on the price per prescription of € 7.28 
to cover pharmacy-expenses (receptregelvergoeding) was included in the calculation of 
all medication costs. It was assumed that each patient received four prescriptions per year.
Direct health care costs of maintenance treatment and COPD exacerbations were 
calculated using data from Oostenbrink et al. who reported the costs of maintenance 
treatment by GOLD stage and the costs of non-severe and severe COPD exacerbations.35 
These costs were updated to the price level of 2009 using consumer price indices.15 In 
addition, the length of hospital stay for a severe COPD exacerbation was adjusted from 
11 days as reported by Oostenbrink et al. to 9.5 days as obtained from the most recent 
LMR data, calculated as the weighted average of the length of stay for ICD-9 codes 490, 
491, 492, 494 and 496.36 Furthermore, the costs of maintenance treatment as reported by 
Oostenbrink et al were adjusted by excluding the costs of theophylline and corticoste-
roids, because both medications were not allowed during the trials.14
A3.4 Direct non-health care costs
Direct non-health care costs are made up of travel costs to and from health care providers. 
Severe and Very Severe COPD patients were assumed not to visit a GP for their regular 
control visits, but rather a pulmonary specialist in a hospital. For stable severe COPD, 
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we have used two outpatient visits per year to the pulmonary specialist, and four for very 
severe COPD. A community-treated exacerbations required 0.34 visits to the pulmonary 
specialist and 0.66 visits to the GP.35 Hospital-treated exacerbations required 1 inpatient 
admission, 0.82 visits to the pulmonary specialist and 0.70 visits to the GP.35 The average 
distance to the hospital in the Netherlands is 7 km and 1.1 km to the GP.37 Unit costs per 
kilometer of travel by car, public transportation and taxis, as well as starting tariffs for the 
taxi, were based on by standard tariffs.38 It was assumed that one third of the travel for 
control visits by patients with Severe COPD was done by car, one third by public transport 
and one third by taxi. For Very Severe COPD and all exacerbations, the mix was half 
car, half taxi. Family of patients who experienced a hospital-treated exacerbations, were 
assumed to visit the patient every other day, which amounted to 5.5 visits.35 Family was 
assumed to travel half of these visits by car and half by public transportation.
A3.5 Productivity costs
In the model it is assumed that 40% of the COPD patients younger than 55 years had paid 
employment. This is reduced to 20% at age 55 and to 0% at age 65. Given the age and 
gender distribution of the patients in the model this would lead to an overall percentage 
of COPD patients with paid employment of 14.1%.39 This percentage was close to the 
percentage observed in the INTERCOM trial (14%), a Dutch randomized trial on the ef-
fects of an interdisciplinary community-based COPD program for patients with impaired 
exercise capacity.40 
In the model productivity days were lost because of death or absenteeism during an 
exacerbation, among patient with paid employment. Death is caused by both back-
ground mortality and the case fatality of a hospital-treated exacerbation. Absenteeism 
was assumed to be either 7 days for a community-treated exacerbation and 21 days for 
a hospital-treated exacerbation.41 In accordance to Dutch guidelines, productivity costs 
were calculated using the friction cost method.20 This method accounts for the fact that 
almost all employees are replaceable in the work force.42 The length of the period it takes 
for a person to be replaced (i.e. the friction period) is dependent on the time it takes to fill 
job openings. This was estimated to be 156 days in the Netherlands.38 The productivity loss 
per day was calculated using the average productivity loss per hour for a male employee 
of € 31 and € 25.33 for a female employee.43 Using the gender distribution from the LABA 
subgroup, the weighted average productivity loss is € 29.55 per hour.14,38 We assumed a 
full work day of 8 hours. 
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Table A3.1: Parameter estimates and distributional assumptions for treatment arms.a
Variable Point estimate Distribution Source
FEV1 decline per year in the COPD 
population in litres
0.052 Gamma(mean 0.052, se 0.001) 23
FEV1 improvement due to ROFLU in litres
LABA + ROFLU versus LABA 0.046 Normal(mean 0.046, s.e.0.009) 14
Estimated duration of FEV1 
improvement in years
5 - Assumption
Rate of COPD exacerbations per year
Severe COPD (LABA) 1.606 Gamma(mean 1.606, se 0.113) 14
Very Severe COPD (LABA) 1.910 Gamma(mean 1.910, se 0.235) 14
Relative risk for all COPD exacerbations due to ROFLU
LABA + ROFLU versus LABA 0.8 Lognormal(mean -0.223, s.e. 
0.068)
14
Standardised mortality ratio (SMR)
Severe COPD 2.779 Uniform(2.4-3.2) 17,18, 
Assumption 
uniform 85% - 
115% of mean
Very Severe state COPD 3.572 Uniform(3.0-4.1) 17,18,44, 
Assumption 
uniform 85% - 
115% of mean
Proportion of exacerbations that are hospitalized
Severe COPD 0.142 Beta(mean 0.142, se 0.011) 14
Very Severe COPD 0.226 Beta(mean 0.226, se 0.017) 14
Case fatality rate for hospital 
admissions
7.7% Uniform(0.054-0.100) 45, Assumption 
uniform 80% - 
120% of mean.
a ROFLU = roflumilast, LABA = long acting β2-agonist, se = standard error.
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Table A3.2: Parameter estimates and distributional assumptions for utilities for stable COPD and utility decre-
ments for a COPD exacerbation.a
Variable Point estimate Distribution Source
Utility for stable COPD
Severe COPD 0.751 Beta(mean 0.751, se 0.007) 14
Very Severe COPD state 0.657 Beta(mean 0.657, se 0.011) 14
Annual utility reduction in case of 1 exacerbation per year
Community-treated exacerbation 0.01 Gamma(mean 0.010, se 0.007) 32
Hospital-treated exacerbation 0.042 Gamma(mean 0.042, se 0.009) 32
a se = standard error
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Table A3.3: Parameter estimates and distributional assumptions for direct healthcare and non-healthcare costs.a
Variable Point estimate Distribution Source
Drug costs
Monthly cost of LABA € 29.49 - 39,40
Monthly cost of roflumilast € 47.07 - Takeda
Cost of one month COPD maintenance treatment
Severe COPD € 33.78 Gamma(mean 33.78, se 3.1) 35
Very Severe COPD € 107.41 Gamma(mean 107.41, se 13.3) 35
Cost of COPD exacerbations
Community-treated COPD 
exacerbations
€ 83.07 Gamma(mean 83.07, se 6.8) 35
Hospital-treated COPD 
exacerbations
€ 2,997.07 Gamma(mean 2,997.07, se 802.1) 35
Length of stay in days for a 
hospital-treated exacerbationb
9.5 - 36
Travel costs
Per month for a patient with severe 
COPD.
€ 2.23 Gamma(mean 2.23, se 0.3) 37,43, 
assumption se 
15% of mean.
Per month for a patient with very 
Severe COPD.
€ 6.22 Gamma(mean 6.22, se 0.9) 37,43, 
assumption se 
15% of mean.
For a patient experiencing a 
community-treated exacerbation 
€ 7.90 Gamma(mean 7.90, se 1.2) 37,43, 
assumption se 
15% of mean.
For a patient experiencing a 
hospital-treated exacerbation
€ 35.71 Gamma(mean 35.71, se 5.4) 37,43, 
assumption se 
15% of mean.
For the family of a patient 
experiencing a hospital-treated 
exacerbation
€ 25.50 Gamma(mean 25.50, se 3.8) 37,43, 
assumption se 
15% of mean.
a ROFLU = roflumilast, LABA = long-acting β2-agonist, se = standard error
b Not a separate variable in the model, only used to calculate other cost variables
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ABSTRACT
Background Decision-analytic cost-effectiveness (CE) models combine many different 
parameters like transition probabilities, event probabilities, utilities and costs, which 
are often obtained after meta-analysis. The method of meta-analysis may affect the 
CE estimate.
Aim Our aim was to perform a simulation study that compares the performance of 
different methods of meta-analysis, especially with respect to model-based health 
economic (HE) outcomes.
Methods A reference patient population of 50,000 was simulated from which sets 
of samples were drawn. Each sample drawn represented a clinical trial comparing 
two fictitious interventions. In several scenarios, the heterogeneity between these 
trials was varied, by drawing one or more of the trials from predefined subpopula-
tions. Parameter estimates from these trials were combined using frequentist fixed 
(FFE) and random effects (FRE), and Bayesian fixed (BFE) and random effects (BRE) 
meta-analysis. The pooled parameter estimates were entered into a probabilistic cost-
effectiveness Markov model. The four methods of meta-analysis resulted in different 
parameter estimates and HE outcomes, which were compared with the true values in 
the reference population. Performance statistics were: (1) the percentage of repetitions 
that the confidence interval of the probabilistic sensitivity analysis covers the true 
value (coverage), (2) the difference between the estimated and true value (bias), (3) 
the mean absolute value of the bias (MAD) and (4) the percentage of repetitions that 
result in a statistically significant difference between the two interventions (statistical 
power). As the differences between methods could be due to chance, we repeated 
every step of the analysis 1,000 times to study whether differences were systematic.
Results FFE, FRE and BFE lead to different parameter estimates, but, when entered 
into the model, they do not lead to large differences in the point estimates of the 
HE outcomes, even in scenarios where we built in heterogeneity. Random effects 
methods do not necessarily reduce bias when heterogeneity is added to the trials, and 
may even increase bias in certain situations. BRE tends to overestimate uncertainty 
reflected in the CE acceptability curve.
Conclusion FFE, FRE and BFE lead to comparable HE outcomes. BRE tends to overes-
timate uncertainty. Based on this study, we recommend FRE as the preferred method 
of meta-analysis. 
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4.1 INTRODUCTION
In 2006, the Netherlands implemented a policy of conditional, temporary reimbursement 
of potentially innovative, but expensive hospital drugs.1 Additional hospital funding is 
provided on the condition that outcomes research is performed to show further evidence 
of the value of the new drugs. The final reimbursement decision is made based on all 
evidence available, after 4 years. A systematic approach to aid decision making is called 
comprehensive decision modelling, in which available evidence is structured in a proba-
bilistic decision-analytic model.2, 3 Meta-analysis is one step in this process, and is used to 
combine all available evidence in model parameters. A wide range of model parameters 
need to be estimated, from transition probabilities to costs and utility values.4
Many different methods of meta-analysis exist, and many authors have compared them 
(e.g. [5–8]). They have shown that the choice of method can considerably affect parameter 
estimates. These comparisons concentrated on the impact of the method of meta-analysis 
on the estimate of a single treatment effect, for example a risk ratio (RR). However, in the 
probabilistic models used in economic evaluations we need to estimate many different 
parameters, including the baseline value of each model parameter in the comparator 
group. Altogether, the method of meta-analysis to obtain these parameters may consider-
ably affect the final cost-effectiveness (CE) estimates.
Our group has previously investigated the effect of four different methods of meta-
analysis on model-based CE estimates.9 Although we found considerable differences, 
there was no way of knowing which of the methods was best, because we had no ‘truth’ 
to which we could compare our results. That is, we only had data from different samples 
of the total patient population, not of the population itself. To overcome this problem 
we performed a simulation study, in which we created a reference population, which 
reflected the value that should be obtained by the different methods. We then proceeded 
by drawing sets of samples from this population, mimicking sets of clinical trials, and 
combined these trial estimates. Each method of meta-analysis generated a separate set of 
pooled parameters. We filled a health economic (HE) model with these different sets of 
parameters and investigated whether there were systematic differences between the meta-
analysis methods by comparing the outcomes of the sets of samples with the outcomes of 
the reference population. We were especially interested in the impact on the differences 
in costs and quality-adjusted life years (QALYs), the incremental CE ratio and the CE 
acceptability curve.
The available methods of meta-analysis can be divided into two groups, namely direct 
and indirect methods. Direct methods of meta-analysis combine evidence from trials that 
compare the two interventions of interest directly. In the absence of head-to-head studies, 
or with the availability of both direct and indirect evidence, indirect methods of meta-
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analysis come into play. Methods of indirect meta-analysis are compared in chapter 5. We 
therefore focus here on direct meta-analysis methods.
4.2 METHODS
4.2.1 Simulation study
The simulation comprised several steps, shown in fi gure 4.1. In step 1 (Create reference 
population), we simulated a reference patient population (n = 50,000), including indi-
vidual patient-level disease progression using one of two fi ctitious treatments. The mean 
values of the parameters and HE outcomes, as calculated from the entire population, 
are reference values to which we compared the estimates of the meta-analyses. In other 
words, they represented the ‘truth’ and are referred to as reference parameters and refer-
ence outcomes. Parameters included transition probabilities, probabilities to experience 
an event, maintenance costs, utilities and costs and utility-decrements due to an event. HE 
outcomes included the total number of QALYs, life years (LY) and events, intervention and 
maintenance costs, and the incremental CE ratio (ICER). 
In step 2 (Trial selection), we sampled trials from the reference population, comparing 
the two treatments. For each of the trials we calculated the parameters that are needed 
as input for the HE model, called trial parameters. In step 3 (Meta-analysis), we pooled 
Figure 4.1: Design of the simulation study.
a HE: health-economic, CE: cost-effectiveness
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the trial parameters using several methods of meta-analysis. These methods are explained 
in detail in paragraph 4.2.4. The combined estimates are called model parameters. For 
each model parameter, both mean and appropriate dispersion measures were calculated. 
We used a disease progression model in step 4 (CE modeling), filled first with a set of 
model parameters obtained by the first method of meta-analysis. A probabilistic sensitivity 
analysis (PSA; 1,100 iterations) was run and the HE outcomes, called model outcomes, 
were collected. This process was repeated with model parameters obtained from each of 
the methods of meta-analysis.
Differences in model outcomes could be due to chance, i.e. the particular set of trials 
that was drawn. In order to study whether there was a systematic difference between the 
methods of meta-analysis, we repeated steps 2 to 4 in step 5 (Repeat), further referred to 
as 1,000 repetitions.
4.2.2. Disease and model structure
The modeled disease was a progressive, chronic disease (figure 4.2), with events during 
which symptoms worsen considerably. The disease was simulated using a Markov model 
with four stages: moderate, severe and very severe disease, and death. 
For each patient in the reference population, we simulated their disease progression. We 
did this by first defining the reference disease progression (RDP), which can be thought of 
as the disease progression of an untreated, base-case patient. It consists of a set of distribu-
tions for each reference parameter (table 4.1). Next, these distributions were modified 
 
Figure 4.2: Markov model of the chronic disease.
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based on individual patient characteristics—gender, age, developed/developing country, 
body-mass index (BMI) and smoking status and interventions. These characteristics made 
it possible for us to add heterogeneity to trials in relevant scenarios, by sampling from sub-
populations. In this manner we have simulated a heterogeneous population of individual 
patients.
How patient characteristics and interventions influenced the RDP is stated in appendix 
A4. In short, male patients have a higher probability to move to a worse disease stage 
than female patients. Older patients have a higher probability to move to a worse disease 
stage than younger patients; they have higher costs and a wider spread in quality-of-life 
weights. Patients from developing countries have lower maintenance costs than patients 
from developed countries. Patients with a higher BMI have a higher probability to move to 
a worse disease stage than patients with lower BMI; they also have a higher probability of 
an event, higher maintenance costs and lower quality of life. Patients who smoke have a 
higher probability to move to a worse disease stage and a higher probability of an event, 
than patients who do not smoke.
Interventions influence the RDP in the same manner as patient characteristics do. For 
each patient in the reference population, we simulated their disease progression twice: 
once receiving Usual Care and once receiving the New Intervention. Usual Care is a drug 
that decreases the probability of disease progression compared with the RDP, at € 60 per 
monthly cycle. New Intervention, the focus of the HE analysis, decreases the probability 
of disease progression, more so than Usual Care, plus it increases the probability of mov-
ing to a better disease stage and decreases the probability of an event. The costs were set 
at € 350 per monthly cycle. In the HE model, probabilities for the New Intervention are 
modeled as a RR, with the estimated probabilities for the Usual Care as a baseline.
Changes to reference parameters were additive across patient characteristics and inter-
ventions. For example, a female patient aged 35–64 years who used the New Intervention 
Table 4.1: Characteristics of the simulated patient population.
Size simulated cohort 50,000
Starting disease stage 5/8 in moderate, 2/8 in severe and 1/8 in very severe
Gender 50% male, 50% female
Age in years 18 – 34; 35 – 64; 65+
Determined by a random draw from a uniform distribution from 18 
to 75
Developed/developing country. 50% from developed countries, 50% developing countries
Body Mass Index (BMI) <25 (average or low); 25-30 (high); >30 (obese),
Determined by a random draw from a normal distribution with mean 
23 and standard deviation of 4.
Smoking status 30% smokers, 70% non-smokers
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had a monthly probability to die in the very severe disease stage of 10 % (the probability 
within the RDP) – 2 % (modification for gender) + 4 % (modification for age) - 3 % 
(modification for New Intervention) = 9%.
Table 4.2 shows the reference outcomes when applying the two interventions to the 
entire patient population. They represent the ‘truth’ with which the outcomes of the meta-
analyses were compared.
The structure of the HE model mirrors the disease progression in the reference popula-
tion; in other words, there was no structural uncertainty. The time horizon of the HE model 
was 1 year and the cycle length 1 month. We assumed that data in the trials were collected 
each month during 1 year. We have not applied discounting. Simulation and modelling 
were performed using SAS 9.2 and WinBUGS 1.4.3.
4.2.3. Scenarios
The number and size of the trials sampled in step 2: Trial selection was varied in scenarios, 
as well as the amount of heterogeneity between trials. Heterogeneity in the meta-analysis 
literature is any kind of variability between different studies.10 Trial heterogeneity is dif-
ferent from patient heterogeneity, which is the difference between patients that can be 
adequately explained by patient characteristics. Table 4.3 shows the different scenarios 
that were investigated. The last column of table 4.3 described the impact of the non-
randomly drawn trials on the trial parameters. We will focus mainly on the three scenarios 
Table 4.2: Reference outcomes, per patient per 12 cycles/months – Mean (Standard deviation).a
Variables Usual Care New Intervention Difference
QALYs 0.485 (0.232) 0.540 (0.231) 0.054
LYs 0.740 (0.328) 0.786 (0.313) 0.046
Intervention costs € 533 (€ 236.24) € 3,300 (€ 1,310) € 2,770
Maintenance costs € 3,260 (€ 2,080) € 3,070 (€ 1,810) - € 180
Event costs € 2,330 (€ 2,610) € 1,260 (€ 1,780) - € 1,070
Total costs € 6,120 (€ 4,340) € 7,630 (€ 3,830) € 1,520
Number of cycles in:
 Moderate disease 5.171 (3.750) 6.209 (3.965) 1.038
 Severe disease 2.477 (2.512) 2.313 (2.507) -0.164
 Very severe disease 1.238 (1.850) 0.911 (1.554) -0.327
 Death 3.114 (3.937) 2.567 (3.751) -0.547
Number of events 1.160 (1.259) 0.630 (0.856) -0.530
Proportion surviving 49.9% 58.3% 8.4%pt
ICER, total costs per QALY € 28,020
a LY: Life year; QALY: Quality adjusted LY; ICER = Incremental cost-effectiveness ratio; %pt: percentage 
points 
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in shaded rows, namely 1, 4 and 7. The other scenarios will be discussed in the discussion 
section of this paper.
4.2.4. Methods of meta-analysis
In our study, we compared four widely used methods of meta-analysis: frequentist fixed 
effects (FFE), frequentist random effects (FRE), Bayesian fixed effects (BFE) and Bayesian 
random effects (BRE). The FFE and FRE were based on the Inverse Variance method, which 
can be used for meta-analysis of both continuous and dichotomous data.11 The pooled 
effect estimate for the FFE is calculated as a weighted average of the individual study 
estimates, using the inverse of the squared standard error (s.e.) of the effect estimates as 
weights. Thus, studies with a smaller s.e., typically larger studies, are given more weight 
than studies with a larger s.e.. For the FRE, we used the DerSimonian-Laird method.11 It 
was developed for situations where there is heterogeneity between study results, caused 
for example by differences in patient population or study design. It incorporates an esti-
mate of the between-study heterogeneity into the weights. It is assumed that all studies 
are samples drawn from a pool of all possible studies, i.e. the population.10 The goal is to 
Table 4.3: Overview of different scenarios in the simulation study.a
Scenario Number 
of trials
Number of patients 
per treatment arm
Added heterogeneity with effect on disease progression
1 5 All trials 500 -
2 5 Trial 1 en 2: 500, 
trial 3: 100, trial 4: 
250, trial 5: 1,000
-
3 10 All trials 250 -
4 5 All trials 500 Trial 5 has relatively old patients, more smokers and 
more obese patients, which leads to more rapid disease 
deterioration, higher probability of events, higher maintenance 
costs, lower quality of life.
5 5 All trials 500 Trial 2 has relatively young patients, which leads to slower 
disease deterioration
Trial 4 has only patients from developing countries, which 
leads to lower maintenance costs
Trial 5: the same as in scenario 4
6 5 Trials have different 
sample sizes, the 
same as in scenario 
2
The same as in scenario 5
7 5 Trials have different 
sample sizes, the 
same as in scenario 
2
Trials 2, 4 and 5 has relatively old patients, more smokers 
and more obese patients, which leads to more rapid disease 
deterioration, higher probability of events, higher maintenance 
costs, lower quality of life.
a Scenarios in shaded rows are discussed in main text. The other four scenarios are discussed in the discus-
sion.
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estimate the mean of this population. The true parameter value may be study-specific and 
can vary across studies.
Both the FFE and FRE assume that the weights are known. With little or no heterogeneity 
among the studies, the FFE and FRE will give identical results.10 With heterogeneity pres-
ent, confidence intervals will be wider for the FRE and claims of statistical significance 
will be more conservative. The point estimate of the parameter might also be different. 
We report the I2-statistic as a measure of heterogeneity12, which can be interpreted as 
the proportion of the total variation in the pooled estimates that is due to heterogeneity 
between studies. When the amount of between-trial heterogeneity increases compared 
with the within-trial variance, then the I2 also increases. Higgins et al. provide a rough 
guide to the interpretation of I2.8 Above 30% “may represent moderate heterogeneity”; 
above 50% “may represent substantial heterogeneity”.
The BFE method requires the data from the different trials, the definition of a prior for 
the parameter to be synthesized and a likelihood linking both.9,13 We used a binomial 
likelihood function to model the total number of transitions, with a flat beta prior; and a 
normal likelihood function for all other parameters, with a flat normal prior centered on 
0 and a precision of 1.0E-6. When specifying the BRE method, prior distributions need 
also be defined for the between-trial heterogeneity.9,13,14 We used the inverse of a squared 
uniform distribution from 0 to 10. Other likelihoods and priors were as in the BFE. Before 
simulation started, we tested several priors and could find no meaningful differences.
Conceptually, confidence intervals in frequentist statistics and credibility intervals in 
Bayesian statistics have very different interpretations (see for example15,16). However, for 
convenience and legibility, we abbreviate both as CI. For each pooled parameter estimate, 
we report the mean and the 95% CI.
We performed meta-analysis on all baseline values (transition probabilities, utilities, etc) 
using data on the New Intervention. In addition, we performed meta-analysis on all effect 
measures (RR), using data on the difference between the New Intervention and Usual 
Care. Interested readers may request code on both the simulation study and the methods 
of meta-analysis from the corresponding author.
4.2.5. Comparing performance
When judging the performance of the methods of meta-analysis, we assumed that a re-
searcher doing a meta-analysis aims to estimate the CE of the New Intervention compared 
with Usual Care in the entire patient population, not a specific subgroup. We further 
assumed that a researcher is unaware of the fact that heterogeneity, when present, was 
caused by sampling from subgroups (i.e. they do not know we deliberately built in hetero-
geneity). To the researcher, the heterogeneity might either be caused by random sampling 
or unobserved differences between the trials in terms of patient characteristics, setting or 
other elements that could affect the parameter estimates. These assumptions are made 
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because, if these differences in design are known to the researcher, either the trials would 
not be synthesized at all, or a way has to be found to control for these differences. Hence, 
these assumptions made it possible to judge the performance of the different methods of 
meta-analysis by comparing model parameters and outcomes with the reference values.
The statistical performance of the different methods was judged by calculating the 
coverage, bias, mean absolute deviation (MAD) and statistical power. Coverage is the 
percentage of all repetitions that the simulated CI covered the ‘truth’. Since the coverage 
is based on 95% CIs, we expect that, if all trials are drawn randomly, the coverage should 
on average be close to 95%.5 The observed coverage was compared to this benchmark. As-
suming that we have an unbiased point estimate, if the coverage is below 95%, the model 
does not take into account all uncertainty. If the coverage is above 95%, it has accounted 
for too much uncertainty. In this study, if the coverage was smaller than 90%, we say the 
method underestimated uncertainty; if the coverage was higher than 98% the method 
overestimated uncertainty. Bias is expressed as the difference between the point estimate 
in the simulated data set and the true population value, averaged over all repetitions. 
The MAD is the average, over all repetitions, of the absolute value of the bias. The MAD 
indicates how far the estimated value was from the ‘truth’, regardless of whether it was 
too high or too low. For HE outcomes, we also calculated statistical power, expressed as 
the percentage of all repetitions where the simulated result yields a statistically significant 
difference between treatments.
4.3 RESULTS
4.3.1. Model parameters for one set of trials
Figure 4.3 compares the methods for scenarios 1, 4 and 7, using only the first repeti-
tion. From bottom to top, we compare the different meta-analysis models for the seven 
scenarios. Each dot represents the point estimate for the model parameter, in this case the 
transition probability from severe to very severe disease, and the bars the estimated CIs. 
At the bottom of the graph the ‘true’ reference parameter value, as found in the popula-
tion, is pictured, with which each of the estimates needs to be compared. The results are 
illustrative for the other parameters. When five equally sized, large trials are randomly 
drawn from the same population (scenario 1), all methods lead to similar point estimates 
of the model parameters, but the BRE model has a much wider CI and a higher coverage. 
The difference in point-estimate between FFE and BFE is due to the different distributional 
assumptions: BFE assumes a binomial model, whereas FFE (implicitly) assumes a normal 
distribution.
In scenario 4 we added heterogeneity by drawing one of the trials from a less healthy 
population. The point estimates from the random effects (RE) models are further from the 
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reference parameter. RE models assign a relatively greater weight to trials which outcomes 
differ from the rest. Due to the wider CIs, RE models are more likely to include the refer-
ence parameter value, but tend to overestimate uncertainty.
Varying trial sizes, with three trials from the same subgroup (scenario 7) leads to results 
comparable to scenario 4, where only one of the trials was drawn from this subgroup.
4.3.2. Model parameters for 1,000 repetitions
To investigate whether the results from the previous paragraph are due to chance, or if 
there are systematic differences, table 4.4 presents a summary of the performance indica-
tors over 1,000 repetitions. It reports the number of model parameters out of 33 for which 
the performance indicators are below or above certain threshold values. First we look at 
the I2, averaged over 1,000 repetitions. For many parameters and scenarios, the mean of 
the I2 statistic does not exceed 30%, indicating no heterogeneity, even in scenarios where 
heterogeneity is built in. Some parameters show substantial heterogeneity, even if all trials 
are randomly drawn from the same population. The number of parameters with a mean 
I2 below 30% decreases when the amount of heterogeneity increases and the number of 
parameters with a mean I2 above 50% increases slightly. 
Reference 
parameter, 
"Truth"
Scenario 1:
5 random trials, 
500 pts
Scenario 4:
5 trials, 500 pts, 
1 heterog trial 
(health)
Scenario 7:
5 trials, differing 
trial sizes,
3 heterog trials
7% 9% 11% 13% 15%
Bayesian
Random
Effects
Bayesian
Fixed
Effects
Frequentist
Random
Effects
Frequentist
Fixed
Effects
'Truth'
Figure 4.3: Meta-analysis on the transition from the severe to very severe disease stage, for three of the seven 
scenarios, for the Usual Care arm, for one repetition.a
a pts = number of patients per trial, equal in each arm. heterog = added heterogeneity by sampling from 
subpopulations
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When equally sized trials are randomly drawn from the same underlying population 
(scenario 1), the number of parameters with mean coverage below 90% or above 98% is 
comparable for FFE, FRE and BFE. BRE, on the other hand, shows no underestimation of 
uncertainty in any of the parameters, and an overestimation in 26 of the 33 parameters. 
FFE and BFE have a tendency to underestimate uncertainty when heterogeneity is added 
(scenarios 4 and 7), as is illustrated by the increasing number of parameters with a cover-
age lower than 90%. It should be noted that an increase in bias and MAD also contributes 
to a lower coverage. In scenario 7, even the FRE model underestimates uncertainty for 
several parameters and the number of parameters where the uncertainty is overestimated 
decreases. BRE never underestimates uncertainty, and overestimates uncertainty for nearly 
Table 4.4: Summary of the result of meta-analysis on all parameters of the health-economic model. Means 
over 1,000 repetitions.
Total number of parameters for which: Scenario 1 Scenario 4 Scenario 7
Total number of parameters 33 33 33
Parameters influenced by added heterogeneity 0 24 24
Mean I2 < 30%: heterogeneity might not be important 27 27 22
Mean I2 > 50%: substantial heterogeneity 4 6 6
Mean coverage < 90% (underestimation of uncertainty)
 Frequentist fixed effects method (FFE) 6 9 23
 Frequentist random effects method (FRE) 6 0 21
 Bayesian fixed effects method (BFE) 6 9 23
 Bayesian random effects method (BRE) 0 0 0
Mean coverage > 98% (overestimation of uncertainty)
 FFE 11 7 3
 FRE 12 13 4
 BFE 12 10 4
 BRE 26 32 24
Mean bias > 2%
 FFE 0 12 19
 FRE 0 13 19
 BFE 0 12 20
 BRE 0 13 21
Mean MADa > 5%
 FFE 0 3 16
 FRE 0 5 16
 BFE 3 6 17
 BRE 5 9 17
a MAD: Mean Absolute Deviation
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all of the parameters in all scenarios. In fact, the coverage is 100% in a large number of 
cases (not shown).
There are only small differences between methods in bias, with more bias in the 
scenarios with more added heterogeneity. There are, however, differences between the 
methods with respect to the MAD. The number of parameters where the MAD is larger 
than 5% is smaller for the FFE and FRE, than for the BFE and BRE methods, regardless of 
heterogeneity. The BRE method generally yields point-estimates that are further away from 
the true population value than the other methods. Using RE models in scenarios with 
heterogeneity does not necessarily reduce bias. They may even increase bias, especially 
when the trials that differ from the others all differ in the same direction (scenario 7).
Table 4.5: Health economic outcomes for three of the seven scenarios. Both intervention arms and the differ-
ence. Means and range from the 2.5th and 97.5th percentiles over 1,000 repetitions.a
Scenario Scenario 1 Scenario 4 Scenario 7
Five randomly drawn, equally 
sized trials
Five equally sized trials; one 
trial drawn from a less health 
population
Five equally sized trials; 
three trials drawn from a less 
health population
Intervention 
arm
New Int Usual Diff New Int Usual Diff New Int Usual Diff
Number of QALYs
Truth 0.540 0.485 0.054 0.540 0.485 0.054 0.540 0.485 0.054
FFE 0.542 0.488 0.054 0.533 0.480 0.053 0.515 0.464 0.051
FRE 0.541 0.487 0.054 0.532 0.479 0.053 0.514 0.463 0.051
BFE 0.541 0.486 0.054 0.531 0.478 0.053 0.513 0.461 0.052
BRE 0.540 0.487 0.054 0.531 0.478 0.052 0.513 0.462 0.051
Number of LYs
Truth 0.786 0.740 0.046 0.786 0.740 0.046 0.786 0.740 0.046
FFE 0.789 0.744 0.045 0.781 0.738 0.044 0.767 0.723 0.043
FRE 0.788 0.744 0.045 0.780 0.736 0.044 0.766 0.723 0.044
BFE 0.787 0.742 0.045 0.779 0.735 0.044 0.764 0.720 0.044
BRE 0.787 0.743 0.045 0.779 0.735 0.043 0.764 0.721 0.042
Total costs
Truth € 7,633 € 6,116 € 1,517 € 7,633 € 6,116 € 1,517 € 7,633 € 6,116 € 1,517
FFE € 7,657 € 6,140 € 1,517 € 7,652 € 6,158 € 1,494 € 7,643 € 6,167 € 1,476
FRE € 7,653 € 6,137 € 1,515 € 7,644 € 6,152 € 1,492 € 7,639 € 6,164 € 1,475
BFE € 7,639 € 6,126 € 1,513 € 7,627 € 6,136 € 1,490 € 7,615 € 6,139 € 1,476
BRE € 7,650 € 6,129 € 1,522 € 7,635 € 6,145 € 1,490 € 7,627 € 6,157 € 1,470
a FFE: Frequentist fixed effects method; FRE: Frequentist random effects method; BFE: Bayesian fixed ef-
fects method; BRE: Bayesian random effects method; New Int: New Intervention; Usual: Usual Care; Diff: 
Difference between two intervention arms 
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4.3.3. Health-economic outcomes for 1,000 repetitions
Differences in model parameters may also lead to differences in HE outcomes. In table 4.5, 
we show the mean HE outcomes over 1,000 repetitions, for both interventions and the 
difference between them. In scenario 1, all HE outcomes are very close to the true popula-
tion value. In scenario 7, we can see that the point-estimates are further from the truth 
than is the case in the other two scenarios, for all methods of meta-analysis. On average, 
the number of QALYs estimated in each of the treatment arms is around 5% below the 
true population value, and so is the difference in QALYs. In scenario 7, the fixed effects 
(FE) CIs (not shown) are comparable to those in scenario 1, but the RE CIs are much wider, 
especially for the BRE method. 
Table 4.6 shows the coverage, bias and MAD, for the difference between the two inter-
vention groups. In general we see that the coverage is larger in the RE methods, due to 
wider CIs which take heterogeneity into account. In addition, the Bayesian methods have 
higher coverage than the frequentist methods. Bias is generally low when no heterogene-
ity is included (scenario 1) and increases when it is (scenarios 4 and 7). The largest bias 
and MAD is found in the BRE method, for all outcomes in all scenarios. For the other three 
methods, bias and MAD are comparable. Despite the higher bias and MAD, the coverage 
of the BRE is still larger.
For the number of QALYs, events and total costs, statistical power (appendix A4) is 100% 
for all scenarios of FFE, FRE and BFE. It is slightly lower for the LYs for FFE, FRE and BFE, 
with a minimum of 96.7%. For the BRE method, the statistical power for LYs ranges from 
17.5% (scenario 6) to 100% (scenario 3). It is generally lower when there are more trials 
drawn from a subgroup of patients and when there is a difference in sample size between 
the trials.
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Figure 4.4 shows the CE acceptability curves (CEAC) for scenario 7. The four graphs 
represent the four methods of meta-analysis. In each graph, we show the CEAC for ten 
repetitions, the median, 2.5th and 97.5th percentile over 1,000 repetitions. It is clear that 
even in this scenario with a lot of heterogeneity, the graphs are very similar for FFE, FRE 
and BFE. At a ceiling ratio of € 30,000 per QALY, which is very close to the true population 
ICER of € 28,020 (dashed vertical line), the median probability of New Intervention being 
cost effective is between 60–70%, for these three methods. At a ceiling ratio of € 21,000, 
the median probability for all three methods is below 20% and the 97.5th percentile is 
below 30%. At € 39,000, the median probability is above 95% and the 2.5th percentile is 
above 65%, again for all three methods. Therefore, no great difference in policy decision 
would arise from using these three different methods of meta-analysis.
However, using BRE, the outcome would be different. Even at a ceiling ratio of € 
48,000, the 97.5th percentile is below 60%, and the median probability is below 90%. 
Using BRE, a policy maker would be much less certain of the cost-effectiveness of the new 
intervention.
Table 4.6: Health economic outcomes for three of the seven scenarios. Means of coverage, bias and mean 
absolute deviance (MAD) of the difference between two interventions, over 1,000 repetitions.a
Scenario Scenario 1 Scenario 4 Scenario 7
Five randomly drawn, equally 
sized trials
Five equally sized trials; one 
trial drawn from a less health 
population
Five equally sized trials; three 
trials drawn from a less health 
population
Coverage Bias MAD Coverage Bias MAD Coverage Bias MAD
Number of 
QALYs
 FFE 98.1% -0.2% 8.3% 97.4% -2.4% 8.5% 96.0% -5.1% 9.5%
 FRE 98.8% -0.1% 8.3% 99.5% -2.2% 8.5% 99.3% -5.0% 9.7%
 BFE 98.3% 0.2% 8.7% 98.6% -2.1% 8.8% 97.9% -5.0% 9.4%
 BRE 100.0% -1.0% 9.6% 100.0% -3.3% 10.7% 100.0% -6.6% 13.4%
Number of 
LYs
 FFE 98.2% -1.6% 13.9% 97.1% -3.8% 14.2% 97.5% -4.6% 15.0%
 FRE 99.3% -1.4% 14.0% 99.1% -3.4% 14.3% 98.9% -4.4% 15.5%
 BFE 98.6% -0.9% 14.5% 98.4% -3.1% 14.8% 99.2% -4.1% 15.0%
 BRE 100.0% -2.3% 16.1% 100.0% -4.9% 17.5% 100.0% -6.9% 20.8%
Total costs
 FFE 98.5% 0.0% 5.1% 98.2% -1.5% 5.5% 97.1% -2.7% 5.9%
 FRE 99.3% -0.1% 5.2% 99.5% -1.7% 5.6% 99.4% -2.8% 6.1%
 BFE 98.5% -0.3% 5.3% 98.5% -1.8% 5.7% 98.4% -3.2% 6.1%
 BRE 100.0% 0.3% 6.4% 100.0% -1.8% 6.8% 100.0% -3.1% 8.1%
a FFE: Frequentist fixed effects method; FRE: Frequentist random effects method; BFE: Bayesian fixed effects 
method; BRE: Bayesian random effects method; MAD: Mean Absolute Deviation 
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4.4 DISCUSSION
In this study, we compared four methods of meta-analysis. Using a simulation study we 
could compare the HE outcomes to a gold standard and judge their statistical perfor-
mance. In order to do this, we made a few crucial assumptions. First, we assumed that the 
researcher wants to estimate the parameter values of the entire population, not a subpopu-
lation. This allows us to compare the results to the outcomes for the entire population. We 
also assumed the researcher was unaware of the fact that any heterogeneity was caused 
by sampling from subgroups. A researcher might not have combined the trials at all, had 
they been aware of the differences, by seeing the patient characteristics or trial protocols. 
A researcher might also have tried to compensate using regression methods, which were 
not the focus of the paper, nor would they be feasible with only five to ten trials.
With almost no heterogeneity, we found that the results of the FFE, FRE and BFE meth-
ods were comparable. With heterogeneity added to the trials, we saw differences on a 
parameter level, but these did not translate into important differences in HE outcomes. 
That could be because the HE model combines all parameter estimates and their uncer-
tainties into one estimate of QALYs and total costs. All these uncertainties together may 
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Figure 4.4: CEACs for the four models in the heterogeneous scenario 7. Graphs depicts median, 2.5th and 
97.5th percentile CEACs over 1,000 repetitions, as well as the CEACs for the first 10 repetitions; horizontal line 
is the ‘true’ population ICER.a
a CEAC: Cost-effectiveness acceptability curve; ICER: incremental cost-effectiveness ratio
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hide the (subtle) differences we have seen between the methods. In addition, we did not 
take structural uncertainty into account, which may exceed any parameter uncertainty.
Using any of these three methods would not lead to differences in policy decisions. 
Using BRE would, as it has a tendency to overestimate uncertainty and yield a larger prob-
ability that a new treatment is rejected or that more research is asked for where it might 
not be necessary. Partly, this is due to the number of trials included in the meta-analysis. 
Generally speaking, sophisticated methods, such as RE, require more data than simple 
methods, because of the increased number of parameters. This is particularly important 
for BRE, as it estimates between-study heterogeneity and also takes the uncertainty around 
this estimate into account. This can be estimated more precisely from ten trials than from 
five. In scenario 3, where we have the same amount of patients in ten trials instead of 
five, we have seen that the CI around the BRE is still larger than those of the other three 
methods, but the difference is much smaller. We also saw that the coverage for the BRE is 
much closer to 95% and that uncertainty is overestimated in fewer parameters.
We speculate that with more than ten trials the differences might be even less pro-
nounced and the BRE method will yield almost the same results as the other three methods, 
although the amount of uncertainty will always exceed that of the other methods. We did 
not test this assumption as this situation is unlikely within the scope of the expensive drug 
programme. In addition, time and budget constraints did not permit the calculation time 
needed for a simulation of this many trials, especially in a number of different scenarios.
Based on this, we recommend not using the BRE when only few sources of evidence 
are available. Unfortunately, this is more the rule than the exception, especially in the 
expensive drugs programme which was the reason to initiate this study. With only a few 
differences between the other three methods, we would personally favor FRE, as it auto-
matically reduces to FFE in the absence of heterogeneity, is easy to implement and is more 
easily understood by physicians and policy makers who will be using the results.
By calculating outcomes for a number of scenarios, we have covered many of the differ-
ent situations that are likely to arise in meta-analysis. We have drawn a few larger trials, 
but more smaller trials, and trials with differences in trial sizes. We have drawn trials 
randomly from the same population, one trial from a subgroup of patients, several trials 
from different subgroups and several trials from the same subgroup. Because of this, we 
feel that the results of our study are generalizable to other studies that use meta-analysis 
to obtain pooled estimates of parameters to fill a HE model.
We have made sure that the difference between the two interventions is large. When 
two interventions are much closer to each other, it unlikely this will change our conclu-
sions regarding the methods of meta-analysis. The same is true for a longer time horizon, 
or including discounting.
Despite our feelings that the results are generalizable to other situations, there are sev-
eral limitations to our study. The first limitation is that we have assumed that all data comes 
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from the same set of trials. In practice, the data for transition probabilities will likely come 
from different sources than, for example, the RR for those transition probabilities or the 
utilities. The exact source of the evidence will not have an impact on the performance of 
the methods of meta-analysis. Therefore, we decided not to explore this extra complexity 
in this paper.
Another limitation is the choice of prior for the Bayesian models. The use and choice of 
priors is an important subject when discussing the Bayesian methodology. Any Bayesian 
calculation can be affected by the type of priors used. In the case of meta-analysis, a 
small number of studies is extra vulnerable to the type of prior.8, 17 As we did not assume 
the researcher to have prior information, we also used so called vague, or flat priors. 
Even though they are supposed to be ‘uninformative’, they may influence the outcomes, 
especially the posterior scale parameters.17 We tested several different specifications of 
the priors but did not find any differences in outcomes, likely from the relative simplicity 
of the models used. However, researchers using the BFE or BRE should keep these restric-
tions in mind and different priors may lead to different results.
Our results are not generalizable to network meta-analysis and should only be used in 
the case of a pair-wise comparison of two interventions. In the case that more than two 
comparators are available, other methods of meta-analysis are available, which make use 
of all the available evidence (see 18–21 and chapter 5).
We have seen that both the RE methods and the appropriate measure for heterogene-
ity, I2, have a tendency to detect heterogeneity, when trials have differences in number 
of patients, even with a large number of total patients, randomly drawn from the same 
underlying population. This is a very common occurrence in meta-analysis and may lead 
to too conservative CIs as none of the methods can make the distinction between sampling 
error and heterogeneity. Trials can therefore be considered heterogeneous, not only when 
one or more trials are drawn from a (different) subgroup of patients, but also when all 
trials are randomly drawn from the same population, but with differences in trial sizes. 
At the same time, with heterogeneity built in, many of the parameters show no important 
degree of heterogeneity. From this we can see that the I2 might be an imperfect measure 
for heterogeneity, at least with a relatively low number of trials.
In our simulation study, we have made sure that the reference parameters are not close 
to their natural limits; for example, probabilities or costs close to 0. In cases when the 
reference parameters are closer to these limits, we expect that the Bayesian methods will 
have model parameters that are closer to the true population value than the frequentist 
methods. First of all, frequentist methods usually need a correction term (continuity cor-
rection) if one of the trial parameters is 0, because it will not be possible to calculate 
the necessary standard errors otherwise. Bayesian methods do not. In addition, Bayesian 
methods may use a bounded likelihood function, while frequentist methods always im-
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plicitly use a normal distribution. This might be a valid reason to prefer Bayesian methods 
over frequentist methods.
The transition probabilities and probabilities to experience an event in the New Inter-
vention arm were calculated using the model parameter in the Usual Care arm, and the 
corresponding RR. Results using the risk difference were similar and therefore not shown.
In many HE models, many input parameters need to be estimated. When more than one 
input parameter is estimated from the same set of sources, we recommend heterogeneity 
is not checked for each parameter separately, but rather for the set of trials. If statistics 
indicate trials are homogeneous for one parameter, but heterogeneous for another, it is 
recommended that all parameters are calculated using the same type of model. The model 
type selection should be based on trial heterogeneity rather than parameter heterogeneity.
4.5 CONCLUSION
In conclusion, the FFE, FRE and BFE meta-analysis methods led to comparable HE out-
comes, even in scenarios where we built in heterogeneity. The differences that we see 
between the methods point towards a broader CI (which is translated in a higher cover-
age), a higher MAD and a lower statistical power for Bayesian methods compared with 
frequentist methods, and for RE methods compared with FE methods. RE methods do not 
necessarily reduce bias when heterogeneity is added to the trials, and may even increase 
bias in certain situations. BRE tends to overestimate uncertainty reflected in the shape of 
the CEAC. Based on this study, we recommend the FRE method as the preferred method 
of meta-analysis.
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A4 APPENDIX
Table A4.1: Monthly transition probabilities in the Reference Disease Progression and changes in probabilities 
due to patient characteristics or interventions.
From:/To: Moderate Severe Very severe Death
Reference disease progression (RDP)
1 – Moderate 80% 10% 6% 4%
2 – Severe 20% 65% 10% 5%
3 – Very Severe 10% 20% 60% 10%
4 – Death 0% 0% 0% 100%
Changes due to gender. RDP = male, changes applicable to female patients.
1 – Moderate +1% +1% -1% -1%
2 – Severe +1% +1% -1% -1%
3 – Very Severe +1% +1% -2%
Changes due to age class. RDP = 18-34, changes applicable to patients aged 35-64, double these changes 
applicable to patients aged 65+.
1 – Moderate -4% +2% +0% +2%
2 – Severe -4% +2% +2%
3 – Very Severe -4% +4%
No changes due to developed/developing country.
Changes due to BMI. RDP = low/average BMI, changes applicable to patients with high BMI, double these 
changes applicable to patients with double BMI.
1 – Moderate -1% +1% +0% +0%
2 – Severe -1% +1% +0%
3 – Very Severe -1% +1%
Changes due to smoking status. RDP = non-smokers, changes applicable smokers.
1 – Moderate -3% +1% +1% +1%
2 – Severe -3% +1% +2%
3 – Very Severe -3% +3%
Changes due to use of Usual Care.
1 – Moderate +5% -2% -2% -1%
2 – Severe +2% -1% -1%
3 – Very Severe +2% -2%
Changes due to use of New Intervention.
1 – Moderate +10% -5% -3% -2%
2 – Severe +3% +3% -4% -2%
3 – Very Severe +5% -2% -3%
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Table A4.2: Probability of an event per cycle for each disease stage in the Reference Disease Progression and 
changes in probabilities due to patient characteristics or interventions.
Disease stage Moderate Severe Very severe Death
Reference disease progression (RDP) 5% 10% 40% 0%
No changes due to gender.
No changes due to age class.
No changes due to developed/developing 
country.
Changes due to BMI. RDP = low/average BMI, 
changes applicable to patients with high BMI, 
double these changes applicable to patients 
with double BMI. +1% +2% +4%
Changes due to smoking status. RDP = non-
smokers, changes applicable smokers. +2% +5% +10%
No changes due to use of Usual Care.
Changes due to use of New Intervention. -2% -10% -20%
Table A4.3: Monthly costs per stage using a Gamma distribution in the Reference Disease Progression and 
changes in distributional parameters due to patient characteristics or interventions.
Disease stage Moderate Severe Very severe Death
Reference disease progression (RDP)
Alpha 4 5 10
Beta 50 80 100
No changes due to gender.
Changes due to age class. RDP = 18-34, changes applicable to patients aged 35-64, double these changes 
applicable to patients aged 65+.
Alpha
Beta +5 +5 +5
Changes due to developed/developing country. RDP = developed country, changes applicable to patients 
from developing country.
Alpha
Beta -10 -10 -10
Changes due to BMI. RDP = low/average BMI, changes applicable to patients with high BMI, double these 
changes applicable to patients with double BMI.
Alpha
Beta +2 +2 +2
No changes due to smoking status.
No changes due to use of Usual Care.
No changes due to use of New Intervention.
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Table A4.4: Quality of life weights using a Beta distribution in the Reference Disease Progression and changes 
in distributional parameters due to patient characteristics or interventions.
Disease stage Moderate Severe Very severe Death
Reference disease progression (RDP)
Alpha 64 35 20
Beta 16 15 20
No changes due to gender.
Changes due to age class. RDP = 18-34, changes applicable to patients aged 35-64, double these changes 
applicable to patients aged 65+.
Alpha +5 +5 +5
Beta +5 +5 +5
No changes due to developed/developing country.
Changes due to BMI. RDP = low/average BMI, changes applicable to patients with high BMI, double these 
changes applicable to patients with double BMI.
Alpha
Beta +5 +5 +5
No changes due to smoking status.
No changes due to use of Usual Care.
No changes due to use of New Intervention.
Table A4.5: Costs due to an event using a Gamma distribution in the Reference Disease Progression. No 
changes due to patient characteristics or interventions.
Disease stage Moderate Severe Very severe Death
Reference disease progression (RDP)
Alpha 10 10 10 0
Beta 200 200 200 0
Table A4.6: Quality of life decrement due to an event using a Beta distribution in the Reference Disease 
Progression No changes due to patient characteristics or interventions.
Disease stage 1 2 3 4
Reference disease progression (RDP)
Alpha 6 6 6 0
Beta 4 4 4 0
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Table A4.7: Summary of the result of meta-analysis on all parameters of the health-economic model for four of 
the seven scenarios. Means over 1,000 repetitions.
Total number of parameters for which: Scenario 2 Scenario 3 Scenario 4 Scenario 6
Total number of parameters 33 33 33 33
Parameters influenced by added heterogeneity 0 0 24 24
Mean I2 < 30%: heterogeneity might not be important 27 27 27 22
Mean I2 > 50%: substantial heterogeneity 4 6 6 6
Mean coverage < 90% (underestimation of 
uncertainty)
 Frequentist fixed effects method (FFE) 6 6 9 17
 Frequentist random effects method (FRE) 4 2 0 3
 Bayesian fixed effects method (BFE) 6 6 9 17
 Bayesian random effects method (BRE) 0 0 0 0
Mean coverage > 98% (overestimation of uncertainty)
 FFE 13 12 7 4
 FRE 13 13 13 10
 BFE 12 13 10 4
 BRE 31 14 32 32
Mean bias > 2%
 FFE 0 3 12 17
 FRE 0 0 13 16
 BFE 0 0 12 18
 BRE 3 0 13 17
Mean MADa > 5%
 FFE 2 1 3 11
 FRE 3 0 5 9
 BFE 3 3 6 13
 BRE 9 3 9 12
a MAD: Mean absolute deviation
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Table A4.8: Health economic outcomes for two of the seven scenarios. Both intervention arms and the differ-
ence. Means and range from the 2.5th and 97.5th percentiles over 1,000 repetitions.a
Scenario Scenario 2 Scenario 3
Intervention arm New Int Usual Diff New Int Usual Diff
Number of QALYs
Truth 0.540 0.485 0.054 0.540 0.485 0.054
FFE 0.542 0.488 0.054 0.543 0.489 0.053
FRE 0.541 0.488 0.054 0.542 0.489 0.053
BFE 0.541 0.486 0.054 0.540 0.487 0.054
BRE 0.540 0.487 0.053 0.540 0.486 0.054
Number of LYs
Truth 0.786 0.740 0.046 0.786 0.740 0.046
FFE 0.789 0.745 0.044 0.790 0.747 0.044
FRE 0.788 0.744 0.044 0.790 0.746 0.044
BFE 0.787 0.742 0.045 0.787 0.743 0.044
BRE 0.786 0.743 0.043 0.787 0.742 0.045
Total costs
Truth € 7,633 € 6,116 € 1,517 € 7,633 € 6,116 € 1,517
FFE € 7,652 € 6,142 € 1,510 € 7,667 € 6,151 € 1,516
FRE € 7,649 € 6,141 € 1,508 € 7,661 € 6,146 € 1,515
BFE € 7,636 € 6,125 € 1,511 € 7,629 € 6,117 € 1,512
BRE € 7,641 € 6,129 € 1,512 € 7,629 € 6,114 € 1,515
a LY: Life year; QALY: Quality Adjusted LY; FFE: Frequentist fixed effects method; FRE: Frequentist random 
effects method; BFE: Bayesian fixed effects method; BRE: Bayesian random effects method, New Int = New 
Intervention, Usual = Usual Care, Diff = Difference between two intervention arms
95
4 
Table A4.9: Health economic outcomes for two of the seven scenarios. Both intervention arms and the differ-
ence. Means and range from the 2.5th and 97.5th percentiles over 1,000 repetitions.a
Scenario Scenario 5 Scenario 6
Intervention arm New Int Usual Diff New Int Usual Diff
Number of QALYs
Truth 0.540 0.485 0.054 0.540 0.485 0.054
FFE 0.534 0.481 0.053 0.524 0.472 0.052
FRE 0.532 0.480 0.053 0.529 0.477 0.052
BFE 0.532 0.479 0.053 0.521 0.469 0.052
BRE 0.531 0.479 0.052 0.528 0.477 0.051
Number of LYs
Truth 0.786 0.740 0.046 0.786 0.740 0.046
FFE 0.782 0.739 0.044 0.774 0.731 0.043
FRE 0.781 0.737 0.044 0.777 0.733 0.043
BFE 0.780 0.736 0.044 0.771 0.727 0.044
BRE 0.780 0.736 0.043 0.776 0.733 0.042
Total costs
Truth € 7,633 € 6,116 € 1,517 € 7,633 € 6,116 € 1,517
FFE € 7,604 € 6,103 € 1,501 € 7,624 € 6,142 € 1,482
FRE € 7,604 € 6,105 € 1,499 € 7,597 € 6,111 € 1,486
BFE € 7,578 € 6,081 € 1,497 € 7,592 € 6,110 € 1,481
BRE € 7,596 € 6,099 € 1,497 € 7,622 € 6,099 € 1,523
a LY: Life year; QALY: Quality Adjusted LY; FFE: Frequentist fixed effects method; FRE: Frequentist random 
effects method; BFE: Bayesian fixed effects method; BRE: Bayesian random effects method, New Int = New 
Intervention, Usual = Usual Care, Diff = Difference between two intervention arms
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Table A4.10: Health economic outcomes for two of the seven scenarios. Means of coverage, bias and mean 
absolute deviance (MAD) of the difference between two interventions, over 1,000 repetitions.a
Scenario Scenario 2 Scenario 3
Intervention arm Coverage Bias MAD Coverage Bias MAD
Number of QALYs
 FFE 97.6% -0.9% 8.5% 97.9% -1.5% 8.1%
 FRE 98.7% -1.1% 8.8% 98.5% -1.3% 8.1%
 BFE 98.9% 0.2% 8.6% 99.1% -0.8% 8.5%
 BRE 100.0% -2.5% 11.4% 99.9% -0.8% 8.8%
Number of LYs
 FFE 98.2% -2.9% 14.5% 97.6% -4.0% 13.8%
 FRE 98.6% -3.3% 15.0% 98.3% -3.5% 13.8%
 BFE 99.1% -1.0% 14.6% 99.0% -2.5% 14.2%
 BRE 100.0% -5.1% 19.0% 99.8% -2.3% 14.8%
Total costs
 FFE 98.3% -0.5% 5.7% 98.9% -0.1% 5.4%
 FRE 99.0% -0.6% 5.9% 99.5% -0.2% 5.4%
 BFE 99.0% -0.4% 5.8% 99.5% -0.4% 5.5%
 BRE 100.0% -0.3% 7.8% 99.9% -0.2% 5.9%
a LY: Life year; QALY: Quality Adjusted LY; FFE: Frequentist fixed effects method; FRE: Frequentist random 
effects method; BFE: Bayesian fixed effects method; BRE: Bayesian random effects method
Table A4.11: Health economic outcomes for two of the seven scenarios. Means of coverage, bias and mean 
absolute deviance (MAD) of the difference between two interventions, over 1,000 repetitions.a
Scenario Scenario 5 Scenario 6
Intervention arm Coverage Bias MAD Coverage Bias MAD
Number of QALYs
 FFE 97.6% -3.0% 8.5% 96.7% -4.5% 9.1%
 FRE 99.2% -2.8% 8.5% 99.7% -3.9% 9.2%
 BFE 98.5% -2.6% 9.0% 98.0% -3.5% 9.1%
 BRE 100.0% -3.6% 11.2% 100.0% -5.8% 13.8%
Number of LYs
 FFE 97.6% -4.5% 14.1% 96.8% -5.4% 15.1%
 FRE 98.9% -4.0% 14.2% 99.3% -5.4% 15.5%
 BFE 98.2% -3.7% 15.0% 98.7% -3.4% 15.1%
 BRE 100.0% -5.1% 17.7% 100.0% -7.4% 21.2%
Total costs
 FFE 98.1% -1.1% 5.4% 97.6% -2.3% 6.2%
 FRE 99.7% -1.2% 5.5% 99.5% -2.1% 6.2%
 BFE 98.7% -1.4% 5.7% 98.6% -2.4% 6.4%
 BRE 100.0% -1.3% 6.8% 100.0% 0.4% 10.5%
a LY: Life year; QALY: Quality Adjusted LY; FFE: Frequentist fixed effects method; FRE: Frequentist random 
effects method; BFE: Bayesian fixed effects method; BRE: Bayesian random effects method
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Table A4.12: Statistical power for the health economic outcomes in all scenarios. Means over 1,000 repetitions.a
 Scen 1 Scen 2 Scen 3 Scen 4 Scen 5 Scen 6 Scen 7
Difference in number of QALY
 FFE 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
 FRE 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
 BFE 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
 BRE 98.8% 93.3% 100.0% 96.7% 96.9% 83.9% 81.9%
Difference in number of LY
 FFE 100.0% 99.7% 100.0% 99.9% 99.9% 99.9% 99.4%
 FRE 99.7% 98.7% 99.9% 99.3% 99.1% 96.9% 96.7%
 BFE 99.8% 99.8% 99.8% 99.6% 99.4% 99.7% 99.8%
 BRE 65.9% 37.4% 98.0% 49.7% 47.8% 17.5% 19.9%
Difference in total costs
 FFE 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
 FRE 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
 BFE 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
 BRE 98.4% 97.8% 100.0% 99.2% 99.4% 97.1% 97.9%
Total costs per QALY
 FFE 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
 FRE 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
 BFE 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
 BRE 99.7% 94.9% 100.0% 97.9% 97.7% 88.0% 83.7%
a LY: Life year; QALY: Quality Adjusted LY; FFE: Frequentist fixed effects method; FRE: Frequentist random 
effects method; BFE: Bayesian fixed effects method; BRE: Bayesian random effects method
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ABSTRACT
Background Decision-analytic cost-effectiveness (CE) models combine many param-
eters, often obtained after meta-analysis
Aim We compared different methods of mixed-treatment analysis (MTC), especially 
with respect to health-economic (HE) outcomes like (quality adjusted) life years and 
costs.
Methods Trials were drawn from a simulated reference population, comparing two of 
four fictitious interventions. The goal was to estimate the CE between two of these. 
The amount of heterogeneity between trials was varied in scenarios. Parameter esti-
mates were combined using direct comparison, MTC methods proposed by Song and 
Puhan, and Bayesian generalized linear fixed effects (GLMFE) and random effects 
models (GLMRE). Parameters were entered into a Markov model. Parameters and HE 
outcomes were compared with the reference population using coverage, statistical 
power, bias and mean absolute deviation (MAD) as performance indicators. Each 
analytical step was repeated 1,000 times.
Results The direct comparison was outperformed by the MTC methods on all indica-
tors, Song’s method yielded low bias and MAD, but uncertainty was overestimated. 
Puhan’s method had low bias and MAD and did not overestimate uncertainty. GLMFE 
generally had the lowest bias and MAD, regardless of the amount of heterogene-
ity, but uncertainty was overestimated. GLMRE showed large bias and MAD and 
overestimated uncertainty. Song’s and Puhan’s methods lead to the least amount of 
uncertainty, reflected in the shape of the CE acceptability curve. GLMFE showed 
slightly more uncertainty
Conclusion Combining direct and indirect evidence is superior to using only direct 
evidence. Puhan’s method and GLMFE are preferred.
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5.1 INTRODUCTION
In 2006, The Netherlands implemented conditional reimbursement of potentially inno-
vative, but expensive hospital drugs, on the condition that further real-life evidence is 
collected.1 After four years, a new reimbursement decision is made, based on all evidence 
available. Unfortunately, new drugs are often compared to placebo or standard care and 
the interventions of interest vary by country or over time. Trials incorporating all compet-
ing interventions are impractical at best, impossible at worst.2 Much of the evidence will 
therefore come from indirect comparisons. 
The simplest form is the indirect treatment comparison, where the relative efficacy be-
tween two interventions is obtained through a common comparator.3 With three or more 
interventions, there may be several direct and indirect comparisons, analyzed simultane-
ously using mixed treatment comparisons (MTC). 
To aid reimbursement decision making, a probabilistic decision-analytic cost-effective-
ness (CE) model is often used, using parameters that are calculated from evidence com-
bined using meta-analysis. The choice of meta-analysis method can considerably affect 
final CE estimates.4 Most studies comparing meta-analysis methods focused on a single 
treatment effect (e.g.5-8). However, in modeling studies a wide range of model parameters 
need to be estimated.9 In this study we aimed to compare the performance of standard 
methods of MTC when applied to different types of model parameters, especially with 
respect to their impact on health-economic (HE) outcomes. A similar comparison of direct 
meta-analysis methods is reported separately.10
5.2 METHODS
5.2.1 Simulation study
The simulation comprised several steps (figure 5.1). In step 1: Create reference population, 
we simulated a superpopulation11 containing 50,000 patients. The disease progression 
was simulated four times for each patient, once for each of four fictitious interventions. 
The mean values of parameters and HE outcomes within the superpopulation represent 
the ‘truth’ with which parameter estimates and HE outcomes were compared, referred 
to as reference parameters and reference outcomes. Parameters included transition and 
event probabilities, maintenance and event costs, utilities and utility-decrements due to 
an event. HE outcomes included (quality adjusted) life years (QALY/LY), intervention and 
maintenance costs, number of events, incremental CE ratio (ICER) and CE acceptability 
curves (CEAC). 
In step 2: Trial selection, we sampled trials comparing two treatments from the reference 
population. For each of the trials we calculated trial parameters. In step 3: Meta-analysis 
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we calculated model parameters, by pooling trial parameters using several methods of 
meta-analysis (paragraph 5.3.4). We used a CE model in step 4: CE modeling, which was 
fi lled with a set of model parameters obtained by each of the methods of meta-analysis. 
Probabilistic sensitivity analysis (PSA; 1,100 iterations) yielded model outcomes.
To study systematic differences between the methods of meta-analysis, we repeated 
steps 2 to 4 in step 5: Repeat in 1,000 repetitions. 
5.2.2. Disease and model structure
We modeled a progressive, chronic disease with events, during which symptoms tempo-
rarily worsen, simulated using a four-stage Markov model (fi gure 5.2). 
To simulate disease progression, we fi rst defi ned the Reference Disease Progression 
(RDP), which can be thought of as the disease progression of an untreated, base-case 
patient. The RDP was modifi ed based on individual patient characteristics and interven-
tions, to simulate a heterogeneous population of individual patients. Table 5.1 shows 
characteristics of the reference population. By sampling from sub-populations, it was 
possible to add heterogeneity to trials in relevant scenarios 
How patient characteristics and interventions infl uenced the RDP is stated in tables in 
the appendix A5.1-A5.6. 
Focusing on the interventions, “No Intervention” has no effects on the RDP. “Old Inter-
vention” decreases the probability of an event and has a positive effect on mortality, with a 
Figure 5.1: Design of the simulation study.
a HE: health-economic, CE: cost-effectiveness
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one-off cost of €250 at the beginning of treatment. “Usual Care” decreases the probability 
of disease progression at €60 per month. “New Intervention” costs €350 per month and 
decreases the probability of disease progression, increases the probability of moving to a 
better disease stage and decreases the probability of an event. The intervention effects are 
dependent on the disease stage of the patient.
Changes to parameters were additive across patient characteristics and interventions. 
For example, for a female patient aged 35-64 who gets New Intervention, the probability 
to move from the severe disease stage to death was 
10% (RDP) - 2% (modification for gender) + 4% (age) - 3% (intervention) = 9%.
 
Figure 5.2: Design of the chronic disease model.
Table 5.1: Characteristics of the simulated patient population.
Size simulated cohort 50,000
Starting disease stage 5/8 in moderate, 2/8 in severe and 1/8 in very severe
Gender 50% male, 50% female
Age in years 18 – 34; 35 – 64; 65+
Determined by a random draw from a uniform distribution from 18 
to 75
Developed/developing country. 50% from developed countries, 50% developing countries
Body Mass Index (BMI) <25 (average or low); 25-30 (high); >30 (obese),
Determined by a random draw from a normal distribution with mean 
23 and standard deviation of 4.
Smoking status 30% smokers, 70% non-smokers
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The comparison of interest is that between New Intervention and Usual Care. Table 5.2 
shows the reference outcomes when applying these interventions to the complete patient 
population. 
The structure of the HE model mirrors the disease progression. We assumed that trial 
data was collected each month during one year. Likewise, the time horizon of the HE 
model was 1 year, with monthly cycles. We did not apply discounting. Simulation and 
modeling was performed using SAS 9.2 and WinBUGS 1.4.3.
5.2.3. Scenarios
The amount of heterogeneity in the trials sampled in step 2: Trial selection was varied in 
eight scenarios. Heterogeneity in the meta-analysis literature is any kind of variability be-
tween different studies.12 All scenarios contained data from nine trials, with 500 patients 
in each of the two treatment arms. The comparisons made in each of the trials can be 
found in figure 5.3. It is clear from this graph that the nine trials provide evidence for all 
available contrasts. A similar structure can be found in Hasselblad13 and Lu and Ades.14
The heterogeneity in all eight scenarios is described in table 5.3. In scenario 8 we used 
heterogeneity definitions at extreme values. This scenario included as a stress test for the 
methods, with very high amounts of heterogeneity between trials. In practice, trials that 
display this amount of heterogeneity would (should) not be combined.
Table 5.2: Reference outcomes, per patient per 12 cycles/months – Mean (Standard deviation).a
Variables Usual Care New Intervention Difference
QALYs 0.485 (0.232) 0.540 (0.231) 0.054
LYs 0.740 (0.328) 0.786 (0.313) 0.046
Intervention costs € 533 (€ 236.24) € 3,300 (€ 1,310) € 2,770
Maintenance costs € 3,260 (€ 2,080) € 3,070 (€ 1,810) - € 180
Event costs € 2,330 (€ 2,610) € 1,260 (€ 1,780) - € 1,070
Total costs € 6,120 (€ 4,340) € 7,630 (€ 3,830) € 1,520
Number of cycles in:
 Moderate disease 5.171 (3.750) 6.209 (3.965) 1.038
 Severe disease 2.477 (2.512) 2.313 (2.507) -0.164
 Very severe disease 1.238 (1.850) 0.911 (1.554) -0.327
 Death 3.114 (3.937) 2.567 (3.751) -0.547
Number of events 1.160 (1.259) 0.630 (0.856) -0.530
Proportion surviving 49.9% 58.3% 8.4%pt
ICER, total costs per QALY € 28,020
a LY: Life year; QALY: Quality adjusted LY; ICER = Incremental cost-effectiveness ratio; %pt: percentage 
points 
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Usual Care 
No 
Intervention 
New 
Intervention 
Old 
Intervention 
{1} {4} 
{2,3} 
{6,7} 
{5} {8,9} 
Figure 5.3: Evidence network for simulation studya
a The figures in curly brackets are the trial numbers making the corresponding comparisons, as described in 
the text. Trials 1, 6 and 8 are trials that may be drawn from a subpopulation in selected scenarios.
Table 5.3: Overview of different scenarios in the simulation study.
Scenario Added heterogeneity with effect on disease progression
1 9 randomly drawn trials, with 500 patients in each of the treatment arms.
2 8 randomly drawn trials
Non-random trial 1 (Old Intervention versus No Intervention), with worse average health.a
3 8 randomly drawn trials
Non-random trial 6 (New Intervention versus No Intervention), with worse average health.a
4 8 randomly drawn trials
Non-random trial 8 (New Intervention versus Usual Care directly), with worse average health.a
5 7 randomly drawn trials
Non-random trial 1 (Old Intervention versus No Intervention), with worse average health.a
Non-random trial 6 (New Intervention versus No Intervention), with lower average age.b
6 6 randomly drawn trials
Non-random trial 1 (Old Intervention versus No Intervention), with worse average health.a
Non-random trial 6 (New Intervention versus No Intervention), with lower average age.b
Non-random trial 8 (New Intervention versus Usual Care directly), with higher average age.c
7 6 randomly drawn trials
Non-random trials 1 (Old Intervention versus No Intervention), 6 (New Intervention versus No 
Intervention) and 8 (New Intervention versus Usual Care), with worse average health.a
8 6 randomly drawn trials
Non-random trials 1 (Old Intervention versus No Intervention), 6 (New Intervention versus No 
Intervention) and 8 (New Intervention versus Usual Care), with worse average health.a
Extreme scenario
a Trial contains, on average, patients with a higher age, more smokers and more obesity; patients have there-
fore on average a more rapid disease deterioration, higher event probability, higher maintenance costs, lower 
quality of life.
b Trial contains, on average, patients with a lower age; patients have therefore on average a slower disease 
deterioration.
c Trial contains, on average, patients with a higher age; patients have therefore on average a more rapid 
disease deterioration.
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5.2.4. Methods of meta-analysis
In MTC, only measures of relative differences between treatments can be compared. De-
spite being used in many applications of MTC, the odds ratio (OR) is not commonly used 
in HE modeling. We have chosen to use the natural logarithm of the relative risk (ln(RR)) 
as relative measure of treatment benefit for the transition and event probabilities. For all 
non-relative variables in the model  costs, quality of life weights and baseline values for 
the comparator , we used estimates from standard direct methods.10,15 
As a baseline method, we combined all available direct evidence (DIRECT) on an ln(RR)-
scale using the DerSimonian-Laird random effects method (DL).15 The pooled estimate is 
calculated as a weighted average of individual study estimates, using the inverse of the 
within-study and between-study variance (heterogeneity) as weights. This is a relevant 
comparison, since it has been debated whether or not direct and indirect evidence can 
and should be combined, or even if indirect methods should be used at all. Since there 
is no reason not to use direct evidence when it is available, results on indirect treatment 
comparison methods were not reported separately in this paper.
The first MTC method is proposed by Song et al. (SONG).(17) They calculated a direct 
estimate using the DL method described above. Next, all possible indirect estimates are 
calculated. (18) The estimate of indirect association on a ln(RR)-scale between A and C, 
from the paired comparisons of A versus B and C versus B, is calculated as 
ln(RRAC)=ln(RRAB)−ln(RRCB) (1)
The variance of ln(RR)AC can be obtained from
Var[ln(RRAC)]=Var[ln(RRAB)]+Var[ln(RRCB)] (2)
The SONG estimate of the association between A and C is calculated by performing a 
DL meta-analysis using all direct and indirect estimates.15
Puhan et al. performed a logistic regression (PUHAN).18,19 A data set is first created 
based on summary tables from each included study. The number of data entries is equal to 
the number patients in each respective cell, with dummy variables for treatment as inde-
pendent variables and the presence of an event as dependent variable. Since PUHAN uses 
logistic regression, ln(OR) is the only relative measure possible. We estimated ln(RR) using 
the ln(OR) estimate that come from the model, and the treatment effect of the comparator.
The most widely used method of meta-analysis is the Bayesian generalized linear model 
(GLM), either in a fixed effect (GLMFE) or random effect (GLMRE) variant.20 The GLM 
is applicable for both direct meta-analysis and MTC. It allows the definition of many 
different possible link functions, depending on the nature of the data. GLMFE requires the 
trial data, the definition of a prior for the parameter of interest and a likelihood function 
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linking both. Defining rik as the number of events, out of the total number of patients in 
each arm nik, for arm k of trial i, we assumed that the data generation process follows a 
binomial likelihood:
rik~Binomial(pik,nik) (3)
where pik represents the probability of an event in arm k of trial i. We modeled the 
probabilities of success pik on the logit-scale, the most commonly used link function for a 
binomial likelihood20:
logit(pik)=μi+δi,1k*I(k≠1) (4)
where I(k≠1) takes the value 0 when intervention k is equal to comparator 1, and 1 oth-
erwise. The µi are trial-specific log-odds in the comparator arm, and δi,1k are trial-specific 
log-odds for the treatment group compared to control. For the GLMRE, we assumed
 
δi,1k~N(di,1k,σ2) (5)
where σ2 represents the between-trial heterogeneity. For the GLMFE, (4) reduces to 
logit(pik)=μi+di,1k*I(k≠1) (6)
which is equivalent to setting σ2 in (5) to zero, thus assuming homogeneity of the 
underlying treatment effects. Using ln(RR) is possible, but may run into computational 
problems.21 We therefore estimated ln(RR) using the ln(OR) estimate and the treatment 
effect of the comparator.
We used a flat beta prior Beta(0.5,0.5) for all baseline transitions, and a flat normal 
prior N(0,1E12) for all other baseline parameters. We used a flat normal prior centered 
on N(0,1E8) for all treatment effects of the comparator. For GLMRE we used the inverse 
of a squared uniform distribution U(0.001,10) for the between-trial heterogeneity. The 
minimum value of this prior was not 0, to avoid numerical problems. 
Conceptually, confidence intervals in frequentist statistics and credibility intervals in 
Bayesian statistics have very different interpretations (e.g.22,23). However, for convenience 
and legibility, we abbreviate both as CI. For each pooled parameter estimate, we report the 
mean and the 95% CI. Interested readers may request code on both the simulation study 
and the methods of meta-analysis from the corresponding author.
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5.2.5. Comparing performance
We assumed that a researcher doing a meta-analysis aims to estimate the CE of the New 
Intervention compared to Usual Care in the entire patient population, not a specific 
subgroup. Evidence on other interventions is solely used to provide extra evidence for 
this comparison. We further assumed that the researcher is unaware of the fact that het-
erogeneity, when present, was caused by sampling from subgroups. To the researcher, 
heterogeneity is either caused by random sampling or unobserved trial differences. These 
assumptions are made, because if these differences in design are known, either the trials 
would not be synthesized at all, or a way has to be found to control for these differences. 
These assumptions made it possible to judge the performance of the different methods of 
meta-analyses by comparing model parameters and HE outcomes with the reference val-
ues. Because the same patients were included to calculate HE outcomes for each method 
of meta-analysis, any difference between the methods can be attributed to the methods 
themselves (moderately dependent samples).11
Statistical performance is measured using coverage, statistical power, bias and mean 
absolute deviation (MAD). Coverage is the percentage of all repetitions, that the simulated 
CI covered the ‘truth’. Since the coverage is based on 95% CIs, we would expect that, 
if all trials are drawn randomly, the coverage should on average be close to 95%.5,11,24 
Over-coverage, where the CI are so wide that coverage rates are above 95 per cent, sug-
gests that the results are too conservative, thus leading to a loss of statistical power. In 
contrast, under-coverage, where the coverage rates are lower than 95 per cent, indicates 
over-confidence in the estimates. More simulations will incorrectly detect a significant 
result, leading to higher than expected type I errors.11 We said a method underestimated 
uncertainty if the coverage was smaller than 90%; and overestimated if the coverage was 
higher than 98%. 
Statistical power is the percentage of all repetitions where the simulated result yields 
a statistically significant difference between the two treatments. Bias is the difference 
between the point estimate in the simulated data set and the true population value, aver-
aged over all repetitions. MAD is the average, over all repetitions, of the absolute value of 
the bias. The MAD indicates how far the estimated value was from the ‘truth’, regardless 
of whether it was too high or too low.
5.3 RESULTS
5.3.1. Model parameters for one set of trials
Figure 5.4 compares the methods on one example parameter for each of the scenarios, 
using only the first repetition. From bottom to top, we compare the different meta-analysis 
models for the eight scenarios. Each dot represents the point estimate for the parameter, 
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in this case the transition probability from severe to very severe disease, and the bars the 
estimated CIs. The ‘true’ population value is displayed at the bottom. As can be seen, 
when all trials were drawn randomly (scenario 1), GLMRE had the broadest CI, followed 
by DIRECT, GLMFE and SONG. PUHAN had the smallest CI. All methods had the true pa-
rameter value in its CI and the point estimates were all very similar. In the other scenarios, 
each with a different amount of heterogeneity, we see a similar pattern as in scenario 1, 
except that in scenario 7 SONG had a relatively larger CI. The point estimate of SONG 
and PUHAN, and of GLMFE and GLMRE are very similar.
Based on similar patterns for other parameters (not shown), we can conclude that 
DIRECT and GLMRE yielded the widest CI. GLMFE had a point estimate that is generally 
closer to the true parameter value than DIRECT, with a smaller CI. The smallest CI was 
found for SONG and PUHAN. In all scenarios, for all methods, the true parameter value 
lay within the CI of the estimated parameters. 
5.3.2. Model parameters for 1,000 repetitions
The results from the previous paragraph might be due to chance. To see if there were sys-
tematic differences, we now discuss parameter estimates averaged over 1,000 repetitions. 
Reference, "Truth"
Scenario 1: 9 random 
trials with 500 patients 
in each arm
Scenario 2: Tr 1 (Old vs 
No Int) worse ave. 
health
Scenario 3: Tr 6 (New 
vs No Int) worse ave. 
health
Scenario 4: Tr 8 (New 
Int vs Usual Care) 
worse ave. Health
Scenario 5: Tr 1 worse 
ave. health, tr 6 lower 
ave. age
Scenario 6: Tr 1 worse 
ave. health, tr 6 lower 
ave. age, tr 8 higher 
ave. age
Scenario 7: Tr 1, 6 and 
8 worse ave. health
Scenario 8: Tr 1, 6 and 
8 worse ave. health 
(extreme scenario)
-1.0 -0.5 0.0 0.5
Bayesian GLM
Random Effects
Bayesian GLM
Fixed Effects
Puhan
Song
Direct comparison
'Truth'
Figure 5.4: Meta-analysis on the logarithm of the risk ratio of the transition from the severe to very severe dis-
ease stage, for the New Intervention arm compared to the Usual Care arm, for one repetition.a
a All scenarios have nine trials, each with 500 patients in both treatment arms
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Table 5.4 shows the number of parameters that correspond to several threshold values 
of coverage, bias and MAD. No parameter had an average coverage below 90%, which 
we defined as underestimation of uncertainty, except in the extreme scenario 8. In this 
scenario GLMFE and GLMRE had the least amount of parameters for which uncertainty 
is underestimated. The least overestimation of uncertainty could generally be found with 
DIRECT and PUHAN, regardless of the amount of heterogeneity.
GLMRE had a large number of parameters with an average bias larger than 1% or even 
2%. All methods had a large number of parameters with a large bias in scenario 4, where 
extra heterogeneity was added to trial 8, which directly compares the Usual Care with the 
New Intervention. In scenarios 6 to 8, where three out of nine trials have patients drawn 
from a subpopulation, all methods showed bias in several parameters. The lowest amount 
of bias was found in SONG and PUHAN, with a similar number of parameters in each 
category of bias.
For all methods, the estimated parameter value was quite far from the true population 
value. The minimum MAD, averaged over 1,000 estimates of the same parameters (not 
in graphs/tables), ranged from 2.6% for PUHAN to 4.2% for GLMRE. In other words, 
none of the methods estimated parameters with an average MAD lower than 2.6%. The 
maximum MAD, averaged over 1,000 estimates of the parameters, was 27.6% for GLMRE 
in the extreme scenario 8. This means that one of the parameters, in this case ln(RR) of 
the number of events in the severe disease stage, differed from the reference value by 
more than 27%, averaged over 1,000 repetitions. The discrepancy will therefore be much 
larger for individual repetitions. SONG and PUHAN generally had the lowest number of 
parameters in each of the categories of MAD.
Generally, SONG, GLMFE and GLMRE overestimated uncertainty for most parameters. 
PUHAN overestimated uncertainty for fewer parameters. Neither of these methods under-
estimated uncertainty, except in the extreme scenario. The bias and MAD was generally 
lowest for SONG and PUHAN, followed by GLMFE.
5.3.3. Health-economic outcomes for 1,000 repetitions
In table 5.5, we show the coverage, statistical power, bias and MAD for four scenarios. 
Information on other scenarios can be found in the appendix A5. It shows the range in 
values over the four types of HE outcomes, the difference in QALYs, LYs, number of events 
and total costs. PUHAN had a coverage closest to the benchmark of 95%. Only in case of 
heterogeneity (i.e. scenarios 7 and 8) did PUHAN overestimate uncertainty. Both GLMFE 
and GLMRE had a coverage above 99% for all methods, for all HE outcomes. No method 
underestimated uncertainty.
Regardless of heterogeneity, GLMRE had the lowest statistical power. For the difference 
in LYs, GLMRE had a statistical power below 10% in scenario 1, where all trials were 
drawn randomly, and even lower in scenarios with added heterogeneity. All methods had 
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Table 5.5: Coverage, statistical power, absolute value of the bias and mean absolute deviation (MAD) of health-
economic outcomes for four of the eight scenarios.
Direct 
comparison
Song’s 
method
Puhan’s 
method
GLM FE 
method
GLM RE 
method
Coverage, range in values over the four health-economic outcomesa
Scenario 1: Nine randomly drawn 
trials
>98% >98% 97.0%-97.3% >98% 100%
Scenario 4: Eight randomly drawn 
trials; one trial drawn from a less 
health population
97.1%-98.6% >98% 96.8%-97.9% >99% 100%
Scenario 7: Six randomly drawn 
trials; three trials drawn from a less 
healthy population
97.2%-99.1% 97.9%-99.3% 96.3%-98.2% >99% 100%
Scenario 8: Six randomly drawn 
trials; three trials drawn from a 
less healthy population (extreme 
scenario)
>98% >99% 90.0%-100% >99% 100%
Statistical power, range in values over the four health-economic outcomesa
Scenario 1: Nine randomly drawn 
trials
81.5%-100% 95.3%-100% >99% 73.4%-100% 5.8%-95.9%
Scenario 4: Eight randomly drawn 
trials; one trial drawn from a less 
healthy population
76.3%-100% 93.5%-100% >98% 56.8%-100% 4.1%-94.3%
Scenario 7: Six randomly drawn 
trials; three trials drawn from a less 
healthy population
79.3%-100% 91.9%-100% >98% 60.3%-100% 3.6%-93.5%
Scenario 8: Six randomly drawn 
trials; three trials drawn from a 
less healthy population (extreme 
scenario)
70.0%-100% 83.7%-100% 94.1%-100% 13.0%-100% 0.5%-83.2%
Bias, range in values over the four health-economic outcomesa
Scenario 1: Nine randomly drawn 
trials
0.4%-5.7% 0.2%-3.0% 0.2%-2.1% 0.3%-3.5% 0.3%-13.6%
Scenario 4: Eight randomly drawn 
trials; one trial drawn from a less 
healthy population
0.5%-11.8% 0.5%-5.5% 0.5%-5.4% 0.8%-9.3% 2.0%-6.3%
Scenario 7: Six randomly drawn 
trials; three trials drawn from a less 
healthy population
0.2%-10.1% 0.5%-9.7% 0.4%-8.1% 0.0%-7.7% 0.2%-17.8%
Scenario 8: Six randomly drawn 
trials; three trials drawn from a 
less healthy population (extreme 
scenario)
3.1%-11.9% 0.4%-11.9% 0.5%-9.8% 1.7%-10.5% 2.5%-17.5%
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a statistical power of 100% for the number of events and above 99% for total costs, in all 
scenarios. PUHAN generally had the lowest bias and MAD across all scenarios. GLMRE 
had the highest MAD for all HE outcomes in all scenarios. In the online tables A5.7 and 
A5.8, the results for the different HE outcomes are presented separately.
In figure 5.5 we show the CE acceptability curves (CEACs) for the heterogeneous scenario 
7. The five graphs represent the methods we compared. In each graph, we show the CEAC 
of ten repetitions, the median and 2.5th and 97.5th percentiles over 1,000 repetitions. 
The vertical line indicates the true population ICER. Graphs for other scenarios can be 
found in the online figures A5.1 to A5.3. In this scenario where three trials are drawn from 
a less healthy population (scenario 7), we can see that SONG and PUHAN displayed a 
steeper shape than the other methods. This indicates that they were more certain of the CE 
of the New Intervention than the other methods. At a WTP of € 30,000 per QALY, which 
is close, but slightly above the true population ICER, the median likelihood that the New 
Intervention was cost-effective was 45%-60% for all methods. At higher WTPs, GLMFE 
and GLMRE were less certain than the other methods. With less heterogeneity (scenario 
1 and 4), the CEACs express a higher certainty for all methods. Still, SONG and PUHAN 
seem to be the most certain of the CE, in these scenarios followed by GLMFE. With more 
heterogeneity (scenario 8) all methods displayed less certainty. SONG and PUHAN still 
had the most certainty around the CE. SONG had all the CEACs lying closest to each other.
Regardless of the amount of heterogeneity, SONG and PUHAN lead to the least amount 
of uncertainty. GLMFE model is slightly less certain. DIRECT and GLMRE have a lot of 
uncertainty, even at WTP values far from the true population ICER. They also display a lot 
of differences between the different repetitions.
Table 5.5: Coverage, statistical power, absolute value of the bias and mean absolute deviation (MAD) of health-
economic outcomes for four of the eight scenarios. (Continued)
Direct 
comparison
Song’s 
method
Puhan’s 
method
GLM FE 
method
GLM RE 
method
MAD, range in values over the four health-economic outcomesa
Scenario 1: Nine randomly drawn 
trials
6.0%-21.7% 5.1%-17.9% 4.9%-16.9% 6.2%-22.7% 6.9%-25.9%
Scenario 4: Eight randomly drawn 
trials; one trial drawn from a less 
healthy population
6.6%-23.5% 5.3%-18.4% 5.1%-17.4% 6.8%-25.1% 7.9%-29.9%
Scenario 7: Six randomly drawn 
trials; three trials drawn from a less 
healthy population
6.3%-22.8% 5.4%-19.2% 5.1%-18.0% 6.8%-24.1% 7.9%-28.5%
Scenario 8: Six randomly drawn 
trials; three trials drawn from a 
less healthy population (extreme 
scenario)
8.3%-22.5% 6.9%-19.9% 6.4%-18.0% 10.1%-27.6% 10.7%-31.0%
a MAD = Mean absolute deviation, the four health-economic outcomes are QALYs, LYs, number of events 
and total costs
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5.4 DISCUSSION
In this study, we compared four methods of indirect meta-analysis in a simulation study 
and judged their statistical performance by creating a gold standard. On a parameter level, 
Puhan’s method (PUHAN) showed the best performance, overestimating uncertainty for 
the fewest parameters with low bias and MAD. Song’s method (SONG) and the Bayesian 
fixed effect generalized linear model (GLMFE) also had generally low bias and MAD.
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Figure 5.5: Cost-effectiveness acceptability curves (CEACs) for the five meta-analysis methods in the hetero-
geneous scenario 7.a
a The vertical lines depicts median, 2.5th and 97.5th percentile of the likelihood that the New Intervention 
is cost-effective compared with Usual care, at various threshold values of a QALY (averaged over 1,000 repeti-
tions). The curves are the CEACs for the first 10 repetitions. The dotted vertical line is the ‘true’ population ICER.
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On HE outcomes, PUHAN showed a coverage closest to 95%, regardless of heterogene-
ity. Only with high heterogeneity did PUHAN overestimate uncertainty. Both PUHAN 
and GLMFE performed best on bias and MAD, followed by SONG. GLMFE had a very 
high coverage, which we defined as overestimating uncertainty. The same is true for the 
Bayesian random effect generalized linear model (GLMRE), which also had the lowest 
statistical power and the highest MAD for all HE outcomes.
The use of these methods would lead to differences in policy decisions. Using either 
only the direct evidence or GLMRE would lead to more rejections of new treatments 
compared to the other methods or more unnecessary research. Generally speaking, so-
phisticated methods require more data than simple methods, because of the increased 
number of parameters. It is possible that the GLMRE method, which requires the largest 
number of parameter to be estimated, may have more desirable properties when more 
trials have to be combined. Unfortunately, this situation is unlikely within the scope of the 
expensive drug program in the Netherlands. Based on this study, we would recommend 
either PUHAN or GLMFE. PUHAN is easier to implement and more easily understood by 
physicians and policy makers who will be using the results. GLMFE is the most widely 
used method, but requires advanced knowledge of statistical programming. 
In scenarios, we covered many likely situations. We have drawn all trials randomly, 
added heterogeneity on the different “legs” of the network, and changed the amount 
of heterogeneity. Compared to a few large trials, the effect of having more but smaller 
trials and trials with differences in trial sizes, on the performance of different methods 
is small.10 We therefore feel our study results are generalizable to many other situations 
where parameters for a HE model are obtained through MTC. 
However, the network is very “regular” with direct evidence for all treatment combina-
tions. This is often not the case. New interventions are usually only compared to the latest 
alternative, or to placebo. Other forms of the evidence network are routinely found in 
MTC research. It remains open to further research whether adding irregularity to such 
networks will change the results of this study.
Another limitation is the choice of prior for the Bayesian models. In the case of meta-
analysis, a small number of studies is extra vulnerable to the type of prior.8,25 As we did 
not assume the researcher to have prior information, we used vague priors. Even though 
they are supposed to be “uninformative”, they may influence outcomes, especially scale 
parameters.25 We tested several different prior specifications but did not find any differ-
ences in outcomes.
Bayesian statistics at its heart is ideally suited for meta-analysis, since the premise of 
both are the same: prior available information is updated with new data.26 However, 
Bayesian statistics is not ideally suited for a simulation study such as we have done. Bayes-
ian statistics starts with the available data, which is examined in detail. This will drive all 
subsequent modelling decisions. Additionally, Bayesian outcomes are meaningless when 
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the model itself does not converge. Checking for convergence requires visual examination 
of plots, and careful examination of other outcome measures. However, all this is impos-
sible in a simulation study, where many data sets are fitted one after the other. 
In practice, there is still a strong preference to use direct over indirect evidence. One of 
the main concerns is that indirect comparisons may be subject to greater biases than direct 
comparisons.17 They are essentially observational findings across trials, and may have 
similar biases. The Cochrane Handbook for Systematic Reviews of Interventions recom-
mends that direct and indirect evidence is considered separately and direct comparisons 
should take precedence as a basis for forming conclusions.8 In contrast, it has also been 
argued that it would be improper to exclude any evidence.27 Our study seems to support 
this second view: the direct comparison has a smaller statistical power, leading to new 
interventions not being found statistically different from older interventions. The biases 
and MAD are also higher than the MTC methods, except for the GLMRE method. 
5.5 CONCLUSION
In conclusion, when indirect evidence is available, regardless of the amount of hetero-
geneity present, combining all evidence is superior to using only the direct evidence. 
Puhan’s method and GLMFE showed similar results, with GLMFE having the tendency 
to overestimate uncertainty, but also having lower average bias and MAD. Based on 
this study, where we had to combine nine trials in a network that includes evidence for 
all treatment combinations, we would recommend PUHAN or GLMFE as the preferred 
method of indirect meta-analysis.
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Figure A5.1: Cost-effectiveness acceptability curves (CEACs) for the five meta-analysis methods in the hetero-
geneous scenario 1. Graphs depicts median, 2.5th and 97.5th percentile CEACs over 1,000 repetitions, as well 
as the CEACs for the first 10 repetitions; vertical line is the ‘true’ population ICER.
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Figure A5.2: Cost-effectiveness acceptability curves (CEACs) for the five meta-analysis methods in the hetero-
geneous scenario 4. Graphs depicts median, 2.5th and 97.5th percentile CEACs over 1,000 repetitions, as well 
as the CEACs for the first 10 repetitions; vertical line is the ‘true’ population ICER.
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Figure A5.3: Cost-effectiveness acceptability curves (CEACs) for the five meta-analysis methods in the hetero-
geneous scenario 8. Graphs depicts median, 2.5th and 97.5th percentile CEACs over 1,000 repetitions, as well 
as the CEACs for the first 10 repetitions; vertical line is the ‘true’ population ICER.
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ABSTRACT
Objectives Many different factors affect the transferability of cost-effectiveness results 
between countries. The objective is to quantify the impact of nine potential causes 
of variation in cost-effectiveness of pharmacological smoking cessation therapies 
(SCTs) between The Netherlands (reference case), Germany, Sweden, UK, Belgium, 
and France.
Methods The life-time benefits of smoking cessation were calculated using the Benefits 
of Smoking Cessation on Outcomes model, following a cohort of smokers making an 
unaided quit attempt, or using nicotine replacement therapy (NRT), bupropion, or 
varenicline. We investigated the impact of between-country differences in nine fac-
tors—demography, smoking prevalence, mortality, epidemiology and costs of smok-
ing related diseases, resource use and unit costs of SCTs, utility weights and discount 
rates—on the incremental net monetary benefit (INMB), using a willingness-to-pay 
(WTP) of € 20,000 per quality adjusted life year (QALY).
Results The INMB of 1000 quit attempts with NRT versus unaided, varies from €0.39 
million (Germany) to €1.47 million (France). The differences between the countries 
were primarily due to differences in discount rates, causing the INMB to change 
between -65% to +62%, incidence and mortality rates (epidemiology) of smoking-
related diseases (-43% to +35%) and utility weights. Impact also depended on the 
WTP for a QALY and time horizon: at a low WTP or a short time horizon, the resource 
use and unit costs of SCTs had the highest impact on INMB.
Conclusions Although all INMBs were positive, there were significant differences 
across countries. These were primarily related to choice of discount rate and epide-
miology of diseases.
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6.1 INTRODUCTION
An increasing number of regulatory agencies across the world require evidence on the 
cost-effectiveness of new pharmacotherapies. All these agencies need results that represent 
their own unique national or regional setting. Nevertheless, time and budget constraints 
limit the number of clinical trials and economic evaluations pharmaceutical companies 
can conduct in potential markets. In addition, there is increased acknowledgement of the 
limited external validity of country-specific cost-effectiveness data. In recognition of these 
difficulties, ISPOR initiated the Transferability of Economic Data Task Force. Their mission 
was to develop good research practices on the transferability of economic data in health 
technology assessment.1
The Task Force advocates the use of mathematical decision analytic models to assess 
setting-specific cost-effectiveness. These models synthesize and structure evidence from 
diverse sources, allow expanding the time horizon beyond that of a clinical trial, as well 
as adapting and transferring results from one setting to another.2,3 For these reasons, mod-
els have been developed to assess the long-term cost-effectiveness of smoking cessation 
interventions.
A recent example is the BENESCO (Benefits of Smoking Cessation on Outcomes) model4 
which was developed by Heron Evidence Development Ltd, to support the launch of var-
enicline in various countries, e.g., The Netherlands5, Sweden6, Belgium [Annemans et al., 
unpubl. ms.], Germany7, the UK8, the Czech Republic9, Korea10, Japan11, and Denmark.12 
Interesting differences in the cost-effectiveness of the various smoking cessation medica-
tions were observed13,14, which may relate to various sources of variation, for example the 
incidence and prevalence of smoking and smoking-related diseases, characteristics of the 
population of smokers, differences in absolute and relative unit costs of medications and 
health-care services and many other factors.
This study was designed to unravel the factors driving differences in cost-effectiveness 
of pharmacological smoking cessation therapies (SCTs) between six European countries. 
The countries included were The Netherlands, Belgium, Germany, Sweden, the UK, and 
France, countries for which, at the start of the study, country-specific input data of the 
model were available.
6.2 METHODS
6.2.1 The model
The projections of the effects of smoking cessation were based on the BENESCO model15, 
which is a probabilistic, updated, and improved version of the Health and Economic 
Consequences of Smoking model.16 The BENESCO model simulates the consequences 
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of smoking and the benefits of quitting in terms of smoking-related morbidity, mortality, 
and associated medical costs in a population. The model is structured as a Markov model 
(cycle length 1 year) and follows a hypothetical cohort of current smokers making a single 
attempt to quit smoking at the beginning of the simulation. The cohort is followed from 
the time of their quit attempt until all members of the cohort have died. Individuals are 
classified into one of three smoking states, i.e., smoker, recent quitter (abstinent 1 to 5 
years after successful quit attempt), or long-term quitter. Transition probabilities between 
smoking states in the first year depend on cessation rates of the interventions, while the 
probabilities after 1 year depend on relapse rates, which in turn depend on time since 
quitting. The model simulates the age, gender, and smoking status-specific incidence and 
mortality of four major diseases for which smoking is a well-established risk factor: chronic 
obstructive pulmonary disease (COPD), lung cancer, coronary heart disease (CHD), and 
stroke. Smoking state-specific incidence and mortality rates were calculated using relative 
risks.17,18 The incidence and mortality rates for recent quitters were calculated using the 
relative risks of former smokers versus nonsmokers, while the rates for long term quitters 
were assumed to be the same as those of never smokers. Because COPD and lung cancer 
are chronic progressive conditions, these diseases were given hierarchical prominence 
over the other conditions with acute recurrent events. This means that individuals with 
COPD or lung cancer remain in this state until they die and cannot move to a CHD or 
stroke state, whereas individuals with CHD or stroke can move to the COPD or lung 
cancer state. As in all Markov models, states are mutually exclusive, which means that a 
patient cannot have two diseases at the same time. The model calculates the total num-
ber of smokers and quitters that have one of the smoking-related diseases as well as the 
number of deaths (due to one of the smoking-related diseases and overall) over the time 
horizon of the simulation. Based on these numbers, the total health-care costs associated 
with the different disease states and the total number of (quality adjusted) life years is 
calculated. The model uses three age bands: 18 to 34 years, 35 to 64 years, and 65 years 
and older. Subjects alive in the model at age 99 years are all assumed to die in the next 
cycle. It is assumed that there is no smoking-related morbidity or mortality in the 18 to 34 
years age class.
6.2.2 Smoking cessation therapies
We calculate the cost-effectiveness of three frequently used pharmacological SCTs— 
nicotine replacement therapy (NRT), bupropion, and varenicline—and unaided cessation. 
NRT is the generic term for any form of smoking cessation aid which delivers a measured 
dose of nicotine to the person using it. Examples include the nicotine patch or nicotine 
gum. Bupropion is an antidepressant used to support smoking cessation.19 Varenicline 
is designed to relieve symptoms of nicotine withdrawal including cigarette craving and 
block the reinforcing effects of continued nicotine use.20 The 12-month continuous ab-
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stinence rates were based on a meta-analysis of available randomized controlled trials, 
where the SCTs were always given in combination with counselling.5 They were 5.0% for 
unaided cessation, 14.8% for NRT, 17.0% for bupropion, and 22.4% for varenicline. In 
all analyses, we assumed that 25% of smokers undertake a single quit attempt, using one 
of the smoking cessation interventions, or unaided. It is this cohort that is followed over 
lifetime.
6.2.3 Factors affecting transferability
A total of nine factors that could potentially cause differences in cost-effectiveness be-
tween countries were investigated. Each factor consists of a group of country-specific 
input parameters which are varied simultaneously. Table 6.1 gives the most important 
input parameters of each of the nine factors. The nine country-specific factors include:
F1: Demography. This includes the total number of people older than 18 years of age 
and the break-downs of the population by gender and age-classes.
F2: Smoking Prevalence. This refers to the percentage of smokers, nonsmokers, and 
former smokers in each age/gender class.
Table 6.1: Main country-specific input parameters for each factor potentially contributing to between-country 
variation in cost-effectiveness of smoking cessation interventions.a
The 
Netherlands
Belgium Germany Sweden United 
Kingdom
France
Population characteristics (age 18+, x mln)
Population size 12.7 8.2 67.1 7.3 46.6 46.8
Number of smokers 3.54 2.25 18.61 1.51 12.70 11.53
As % of adult 
population 
28% 27% 28% 21% 27% 25%
Cohort size: smokers 
making a quit attempt 
0.88 0.56 4.65 0.38 3.17 2.88
F1: Demography
Males, 18 to 34 years 14.1% 13.9% 13.6% 15.4% 14.4% 14.6%
Males, 35 to 64 years 27.3% 25.5% 26.5% 24.7% 25.4% 24.6%
Males, 65+ years 7.6% 8.9% 7.9% 9.0% 8.7% 8.6%
Females, 18 to 34 years 13.8% 13.7% 13.5% 14.9% 14.3% 14.4%
Females, 35 to 64 years 26.8% 25.3% 25.8% 24.0% 26.1% 25.3%
Females, 65+ years 10.4% 12.7% 12.6% 12.0% 11.1% 12.4%
Total 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
Source 21 22 23 24 25 26
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Table 6.1: Main country-specific input parameters for each factor potentially contributing to between-country 
variation in cost-effectiveness of smoking cessation interventions.a (Continued)
The 
Netherlands
Belgium Germany Sweden United 
Kingdom
France
Population characteristics (age 18+, x mln)
Population size 12.7 8.2 67.1 7.3 46.6 46.8
Number of smokers 3.54 2.25 18.61 1.51 12.70 11.53
As % of adult 
population 
28% 27% 28% 21% 27% 25%
Cohort size: smokers 
making a quit attempt 
0.88 0.56 4.65 0.38 3.17 2.88
F2: Smoking prevalence
Males, 18 to 34 years 32.3% 34.6% 38.7% 15.0% 32.6% 39.4%
Males, 35 to 64 years 34.1% 35.4% 36.0% 22.4% 27.7% 29.3%
Males, 65+ years 15.6% 19.2% 13.3% 15.4% 12.7% 10.2%
Females, 18 to 34 years 27.4% 26.1% 29.7% 23.0% 28.0% 31.2%
Females, 35 to 64 years 28.8% 27.8% 27.2% 26.8% 28.5% 21.8%
Females, 65+ years 12.3% 8.9% 6.4% 12.8% 26.7% 6.2%
Source 27 28 29 24 25 30,31
F3: All-cause mortality
Males, 18 to 34 years 0.06% 0.12% 0.08% 0.07% 0.09% 0.09%
Males, 35 to 64 years 0.40% 0.54% 0.58% 0.39% 0.47% 0.55%
Males, 65+ years 5.48% 4.89% 4.14% 4.88% 4.72%
Females, 18 to 34 years 0.03% 0.04% 0.03% 0.03% 0.04% 0.04%
Females, 35 to 64 years 0.28% 0.29% 0.29% 0.25% 0.30% 0.25%
Females, 65+ years 4.57% 4.48% 4.67% 2.85% 3.87% 3.65%
Source 21 22 23 24 32 26
F4: Epidemiology: annual incidence rate of COPD per 1,000 inhabitants
Males, 18 to 34 years 0.17 0.16 0 0.02 0 0.03
Males, 35 to 64 years 2.08 2.31 0.1 0.74 0.15 0.17
Males, 65+ years 9.68 12.77 3.26 15.22 3.82 1.73
Females, 18 to 34 years 0.17 0.17 0 0.02 0 0.01
Females, 35 to 64 years 2.13 2.63 0.06 0.97 0.11 0.09
Females, 65+ years 6.46 12.17 2.25 9.58 1.95 2.05
Source 33 33 29 34 35,36 37–42
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Table 6.1: Main country-specific input parameters for each factor potentially contributing to between-country 
variation in cost-effectiveness of smoking cessation interventions.a (Continued)
The 
Netherlands
Belgium Germany Sweden United 
Kingdom
France
Population characteristics (age 18+, x mln)
Population size 12.7 8.2 67.1 7.3 46.6 46.8
Number of smokers 3.54 2.25 18.61 1.51 12.70 11.53
As % of adult 
population 
28% 27% 28% 21% 27% 25%
Cohort size: smokers 
making a quit attempt 
0.88 0.56 4.65 0.38 3.17 2.88
F4: Epidemiology: annual incidence rate of lung cancer per 1,000 inhabitants
Males, 18 to 34 years 0.01 0.01 0.01 0.01 0 0.01
Males, 35 to 64 years 0.56 0.61 0.69 0.69 0.56 1
Males, 65+ years 4.24 5.15 5.38 4.95 4.84 4.25
Females, 18 to 34 years 0.01 0.01 0 0.01 0.01 0.01
Females, 35 to 64 years 0.42 0.48 0.39 0.56 0.36 0.2
Females, 65+ years 1.07 1.71 1.43 1.88 1.63 0.82
Source 43 43 29,44–47 34 25 48
F4: Epidemiology: annual incidence rate of CHD per 1,000 inhabitants, all events
Males, 18 to 34 years 0.35 0.33 0.8 0.05 0.04 0
Males, 35 to 64 years 7.6 7.95 8.36 6.97 2.32 4.27
Males, 65+ years 24.35 26.26 33.15 33.84 25.58 33.42
Females, 18 to 34 years 0.06 0.05 0.6 0.02 0.01 0
Females, 35 to 64 years 2.37 2.54 5.29 2.32 0.53 1.21
Females, 65+ years 15.29 17.44 25.76 20.84 15.48 15.45
Source 49 49 29,50 34 25,51 52
F4: Epidemiology: annual incidence rate of CHD per 1,000 inhabitants, first event only
Males, 18 to 34 years 0.33 0.32 0.46 0.04 0.04 0
Males, 35 to 64 years 5.69 5.95 4.86 4.39 1.6 3.8
Males, 65+ years 17.5 18.87 19.25 17.24 14.93 26.27
Females, 18 to 34 years 0.06 0.05 0.35 0.02 0.01 0
Females, 35 to 64 years 1.81 1.94 3.07 1.57 0.46 1.12
Females, 65+ years 11.42 13.04 14.96 12.11 11.27 13.42
Source 49 49 29,50 34 25,51,53 52
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Table 6.1: Main country-specific input parameters for each factor potentially contributing to between-country 
variation in cost-effectiveness of smoking cessation interventions.a (Continued)
The 
Netherlands
Belgium Germany Sweden United 
Kingdom
France
Population characteristics (age 18+, x mln)
Population size 12.7 8.2 67.1 7.3 46.6 46.8
Number of smokers 3.54 2.25 18.61 1.51 12.70 11.53
As % of adult 
population 
28% 27% 28% 21% 27% 25%
Cohort size: smokers 
making a quit attempt 
0.88 0.56 4.65 0.38 3.17 2.88
F4: Epidemiology: annual incidence rate of stroke per 1,000 inhabitants, all stroke events
Males, 18 to 34 years 0.03 0.03 0.12 0.06 0.08 0.14
Males, 35 to 64 years 1.31 1.39 1.89 1.69 2.29 0.79
Males, 65+ years 11.69 12.61 17.8 14.67 13.25 9.07
Females, 18 to 34 years 0.1 0.1 0.03 0.05 0.07 0.13
Females, 35 to 64 years 0.88 1 1.34 0.93 1.58 0.73
Females, 65+ years 11.43 12.71 11.95 13.23 12.28 6.19
Source 54 54 29 34 25 55
F4: Epidemiology: annual incidence rate of stroke per 1,000 inhabitants, first event only
Males, 18 to 34 years 0.03 0.03 0.06 0.05 0.06 0
Males, 35 to 64 years 1.19 1.25 0.99 1.44 1.73 0.43
Males, 65+ years 10.53 11.36 9.29 11.29 8.74 8.15
Females, 18 to 34 years 0.1 0.1 0.02 0.04 0.05 0
Females, 35 to 64 years 0.8 0.91 1.07 0.8 1.17 0.43
Females, 65+ years 10.52 11.7 9.51 10.66 8.03 5.07
Source 54 54 29 34 25 55
F5:Annual costsb per patient with a smoking-related disease
COPD 1,036 1,928 2,245 2,907 1,127 2,220
Lung Cancer
First year 13,236 13,505 33,983 10,355 5,132 17,629
After first year 13,236 13,505 33,983 5,502 5,132 17,629
CHD
First year 4,841 4,867 1,969 4,795 1,348 5,721
After first year 2,949 796 985 1,374 1,348 5,721
Stroke
First year 23,119 7,685 10,741 7,056 22,006 9,641
After first year 5,229 5,439 4,618 1,884 22,006 9,641
Source 56–59 57,60–63 29,64 65,66c 67–70 71
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Table 6.1: Main country-specific input parameters for each factor potentially contributing to between-country 
variation in cost-effectiveness of smoking cessation interventions.a (Continued)
The 
Netherlands
Belgium Germany Sweden United 
Kingdom
France
Population characteristics (age 18+, x mln)
Population size 12.7 8.2 67.1 7.3 46.6 46.8
Number of smokers 3.54 2.25 18.61 1.51 12.70 11.53
As % of adult 
population 
28% 27% 28% 21% 27% 25%
Cohort size: smokers 
making a quit attempt 
0.88 0.56 4.65 0.38 3.17 2.88
F6: Resource use: intervention costs using different resource use across countries, but equal unit costsb
Varenicline 391.79 304.79 294.59 391.79 381.59 294.59
Bupropion 327.81 244.81 226.60 335.51 160.30 230.61
NRT 323.35 213.94 207.00 298.79 234.56 231.05
Unaided cessation   0.00   0.00 0.00 0.00 0.00 0.00
Source 20,72 73,74 75 19,76,77 78
F7: Unit costs: intervention costs using different unit costs across countries, but equal resource useb
Varenicline 391.79 391.78 337.28 401.90 290.62 390.60
Bupropion 327.81 277.42 292.22 350.92 285.02 327.15
NRT 323.35 311.05 317.13 365.76 213.15 387.03
Unaided cessation 0.00 0.00 0.00 0.00 0.00 0.00
Source 79,80 73,74 75 19,76,77 81
F8: General population utility weights
Males, 18 to 34 years 0.91 0.91 0.93 0.93 0.93 0.93
Males, 35 to 64 years 0.91 0.91 0.877 0.877 0.877 0.877
Males, 65+ years 0.82 0.82 0.8 0.8 0.8 0.8
Females, 18 to 34 years 0.92 0.92 0.91 0.91 0.91 0.91
Females, 35 to 64 years 0.89 0.89 0.853 0.853 0.853 0.853
Females, 65+ years 0.76 0.76 0.77 0.77 0.77 0.77
Source 82–90
F8: Disease-specific utility weights
COPD 0.69 0.76 0.76 0.76 0.76 0.76
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F3: All-cause mortality. Mortality in the general population is expressed as the all-
cause mortality rate, which is the percentage of the total number of people in each age/
gender class that dies during a single year.
F4: Epidemiology of smoking-related diseases. The epidemiology of smoking-related 
diseases consists of three elements: the incidence rates, prevalence rates, and annual 
cause-specific mortality rates by age/gender class. We applied the disease definitions that 
were actually used in each country at the time of writing the reimbursement dossiers for 
varenicline. To identify COPD, all countries used ICD-10 codes J40–44, UK and Sweden 
also used J47. To identify lung cancer, all countries used C33–34, except Sweden that 
defined lung cancer as C34. CHD is identified in all countries as I20–25. Stroke in The 
Netherlands and Belgium is identified as I60–I69 plus G45, in Sweden as I61 and I63, in 
Germany as I60, I61, I63 and I64, and in the UK and France as I60–I64.
Table 6.1: Main country-specific input parameters for each factor potentially contributing to between-country 
variation in cost-effectiveness of smoking cessation interventions.a (Continued)
The 
Netherlands
Belgium Germany Sweden United 
Kingdom
France
Population characteristics (age 18+, x mln)
Population size 12.7 8.2 67.1 7.3 46.6 46.8
Number of smokers 3.54 2.25 18.61 1.51 12.70 11.53
As % of adult 
population 
28% 27% 28% 21% 27% 25%
Cohort size: smokers 
making a quit attempt 
0.88 0.56 4.65 0.38 3.17 2.88
Lung Cancer first year 0.61 0.61 0.61 0.61 0.61 0.61
Following years 0.5 0.5 0.5 0.5 0.5 0.5
CHD 0.71 0.76 0.76 0.76 0.76 0.76
Stroke first year 0.54 0.74 0.74 0.74 0.74 0.74
Following years 0.29 0.15 0.15 0.15 0.15 0.15
Source 83–93
F9: Discount rates
Costs 4.00% 3.00% 5.00% 3.00% 3.50% 3.00%
Outcomes 1.50% 1.50% 5.00% 3.00% 3.50% 0.00%
Source 94 95 96 97 98 99
a COPD: chronic obstructive pulmonary disease; CHD, coronary heart disease; NRT, nicotine replacement 
therapy 
b In 2006 Euros, accounting for differences in purchasing power
c Bolin K, Dozet A, unpublished data. 
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Given the causal relationship, there is a strong association between smoking prevalence 
and the epidemiology of smoking related diseases. To enter these two factors as inde-
pendent factors in the univariate analysis, we calculated the country-specific incidence, 
prevalence, and mortality of smoking-related diseases among nonsmokers, i.e., the 
country-specific baseline risk. This was done using the country-specific epidemiology and 
smoking prevalence, and the relative risks for smokers, former smokers, and nonsmokers 
used within the model. When studying the impact of the factor “epidemiology” in the 
univariate analysis, the Dutch baseline-risk was replaced by the country-specific baseline 
risk, which was then combined with the relative risks and the Dutch smoking prevalence 
to estimate the incidence (or prevalence or mortality) of smoking-related diseases among 
smokers and ex-smokers.
F5: Costs of smoking-related diseases. The model makes a distinction between the 
first-year costs and subsequent-year costs for lung cancer, CHD, and stroke, diseases for 
which high initial costs are generally followed by lower maintenance costs. As COPD 
does not have (much) higher initial costs, this distinction is not relevant for COPD.
F6: Resource use and F7: Unit costs of SCTs. The intervention costs of SCTs are 
separated into two components: the amount of resource use (i.e., medication and counsel-
ling) associated with the SCTs and the unit costs of these resources. We have investigated 
both these factors separately.
F8: Utility weights. The BENESCO model requires two categories of utility inputs: 
utility weights for the general, disease-free (developed no smoking-related disease) popu-
lation, which vary by age, and the disease-specific utility weights, which vary by type of 
smoking-related disease. The Netherlands is the only country in our sample for which 
country-specific utility weights for both categories were provided. Germany, Sweden, the 
UK, and France all have used the provided default values within the model. Belgium has 
used the general population utility weights from The Netherlands and the default disease-
specific utility values.
F9: Discount rates. All costs and outcomes are discounted using the country-specific 
values that are recommended in the national guidelines for economic evaluations. In the 
reference case, costs are discounted at 4%, outcomes at 1.5%.
We adopted a health-care perspective and included healthcare costs that are either 
covered from the health-care budgets or paid for by patients. All prices and costs were 
inflated to 2006, using the Harmonised Indices of Consumer Prices—all items.100 We also 
compensated for differences in purchasing power, using the average exchange rates on 
January 2, July 3, and December 31, 2006, and 2006 purchasing power parities.100
6.2.4 Analyses
The starting point of all between-country comparisons were the results of the BENESCO 
model populated with Dutch input data. Hence, The Netherlands was the reference case. 
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In a series of univariate analyses we replaced the group of input parameters belonging 
to the same factor by its country-specific estimates. We changed one factor at a time; all 
other factors were kept constant at the reference values. We compared the impact of each 
factor on the outcomes. In the subsequent multivariate analysis, we consecutively enter 
parameters from the highest to the lowest impact. Eventually, this results in models that 
are filled completely with country-specific parameters. In all analyses, the time horizon 
is lifetime. Sensitivity analyses were done using different time horizons and different 
threshold values of the willingness-to-pay (WTP) for a quality adjusted life year (QALY).
6.2.5 Outcomes
Outcomes were presented as incremental costs, QALYs gained, incremental cost-
effectiveness ratios (ICERs), and incremental net monetary benefits (INMBs). The ICER 
is the difference in total costs between two smoking cessation interventions, divided by 
the difference in total QALYs. The percentage change in the INMB of the reference case 
caused by each factor was our primary measure of interest. The INMB was calculated 
as the difference in QALYs between two interventions, times societies’ WTP, for a QALY 
(threshold value) minus the difference in costs. The INMB was calculated with a relatively 
low threshold value of € 20,000 per QALY. For each country,we have ranked all country-
specific input parameters according to the percentage of change in INMB compared with 
the reference case. A rank order of 1 indicates that this factor caused the INMB to change 
most; a rank order of 9 indicates that this factor had the least impact on the INMB. We 
present the outcomes according to a hierarchy of effectiveness of the interventions: NRT 
versus unaided cessation, bupropion versus NRT, and varenicline versus bupropion. The 
ranking was averaged over these three pair-wise comparisons.
6.3 RESULTS
6.3.1 Reference case
In table 6.2, the outcomes of the reference case are given. The ICER of NRT compared 
with unaided cessation was about € 1,600 per QALY. Bupropion dominated NRT, and 
varenicline dominated bupropion. Using a WTP of € 20,000 per QALY, the INMBs of all 
three comparisons were positive.
6.3.2 Univariate analysis
F1: Demography. Demography influences the age and gender distribution of the cohort 
of smokers that is followed over lifetime. If the cohort of smokers that attempts to quit 
becomes older than in the reference case, the INMB and ICER worsen, for all three pair-
wise comparisons of smoking-cessation interventions. This is primarily due to a decrease 
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Table 6.2: Lifetime outcomes of the Benefits of Smoking Cessation on Outcomes model filled with Dutch input 
data, expressed per 1000 smokers making a quit attempt.a
NRT versus 
unaided 
cessation
Bupropion 
versus NRT
Varenicline 
versus 
bupropion
Difference in total costs (€ 1000)b 126.7 -40.4 -44.7
Difference in QALYs 77.4 17.7 42.8
Incremental net monetary benefit (INMB) (€1 mln)c 1.42 0.39 0.90
Incremental cost-effectiveness ratio (ICER) 1636.7 Dominant Dominant
a Outcomes differ from 5 because all cost inputs were updated to 2006 prices, Harmonised Indices of 
Consumer Prices were used, asthma exacerbations were excluded and the price of varenicline was updated. 
NRT: nicotine replacement therapy; QALYs: quality adjusted life years; WTP: willingness-to-pay.
b Intervention costs plus total costs of smoking-related diseases.
c WTP is € 20,000.
Table 6.3: Effect of changing the reference case input values to the country-specific input values on cost-
effectiveness outcomes compared with the reference case.a
Effect on INMB and 
ICER compared with the 
reference case
F1: Demography
Older cohort Worsens
F2: Smoking prevalence
Higher smoking prevalence among elderly Worsens
F3: All-cause mortality
Lower mortality Improves
F4: Smoking-related disease epidemiology
Higher incidence Improves
Higher mortality Improves
F5: Costs of smoking-related diseases
Higher costs Improves
F6: Resources used for SCTs
Resource use of a more effective SCT increases more than the resource use of 
a less effective SCT 
Worsens
F7: Unit costs of SCTs
Unit cost of a more effective SCT increases more than the unit costs a less 
effective SCT 
Worsens
F8: Utility weights
Higher disease-specific utility weights Worsens
Lower general population utility weights Worsens
F9: Discount rates
Higher discount rates on costs Worsens
Higher discount rates on outcomes Worsens
a INMB: incremental net monetary benefit; ICER: incremental cost-effectiveness ratio; SCTs: smoking cessa-
tion therapies.
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in QALYs that is greater for the more effective intervention because the number of people 
who remain disease free and survive to old age is greater for this intervention. Table 6.3 
summarizes these effects. Replacing the age and gender distribution in the reference case 
by the country-specific age and gender distribution caused the INMB of NRT versus un-
aided cessation to change between -2.1% in Belgium and -0.4% in Sweden. The change 
in INMB of bupropion versus NRT varies from -1.7% in Belgium to -0.4% in Sweden. The 
change in INMB of varenicline versus bupropion varies from -1.8% in Belgium to -0.4% 
in Sweden (figure 6.1).
Figure 6.1: Relative change in incremental net monetary benefits of nicotine replacement therapy versus un-
aided cessation of the reference case, caused by applying each country-specific factor univariately.
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F2: Smoking prevalence. Like demography, smoking prevalence primarily influences 
the age and gender distribution of the cohort of smokers attempting to quit. When smok-
ing prevalence among the elderly gets higher, the cohort of smokers attempting to quit 
becomes older and the INMB and the ICER worsen. Compared with the reference case, 
the change in INMB for NRT versus unaided cessation that is due to a change towards 
country-specific smoking prevalence varies from -6.2% in Sweden to +7.6% in France. 
The change in INMB for bupropion versus NRT varies from -5.1% in Sweden to +6.3% 
in France. The change in INMB for varenicline versus bupropion varies from -5.4% in 
Sweden to +6.6% in France (figure 6.1).
F3: All-cause mortality. In countries where the all-cause mortality rate is lower (i.e., the 
life expectancy is higher) than in the reference case, the INMBs of the smoking cessation 
interventions are higher and the ICERs improve, primarily because of higher QALY gains. 
The increase in QALYs that result from a lower mortality rate is largest for the most effec-
tive treatment, because the number of people who stop smoking and remain disease free 
is highest for this intervention. The change in INMB for NRT versus unaided cessation 
because of a change in all-cause mortality varies from -1.9% in Belgium to +12.9% in 
Sweden. The change in INMB for bupropion versus NRT varies from -1.6% in Belgium 
to +10.6% in Sweden. The change in INMB for varenicline versus bupropion varies from 
-1.7% in Belgium to +11.3% in Sweden (figure 6.1).
F4: Epidemiology of smoking-related diseases. In countries where the incidence of 
all smoking-related diseases is higher than in the reference case, the INMBs and ICERs 
improve, because preventing more diseases results in higher QALY gains and greater cost 
savings. The same holds for countries where the mortality due to smoking-related diseases 
is higher. Change in prevalence has only a limited effect on the INMB. The change in 
INMB for NRT versus unaided cessation because of a change in epidemiology varies from 
-43.2% in France to +34.5% in Sweden. The change in INMB for bupropion versus NRT 
varies from -35.6% in France to +28.5% in Sweden. The change in INMB for varenicline 
versus bupropion varies from -37.7% in France to +30.1% in Sweden (Figure 6.1).
F5: Costs of smoking-related diseases. In countries where the health-care costs of 
smoking-related diseases are higher than in the reference case, the INMBs are higher 
and the ICERs improve, because the savings from preventing these diseases increase. 
This increase gets greater when the effectiveness of the smoking cessation intervention 
improves. The change in INMB for NRT versus unaided cessation because of a change in 
costs per patient with a smoking-related disease varies from -0.7% in Belgium to +9.2% 
in France. The change in INMB for bupropion versus NRT varies from -0.6% in Belgium to 
+7.6% in France. The change in INMB for varenicline versus bupropion varies from -0.6% 
in Belgium to +8.0% in France (figure 6.1).
F6: Resource use and F7: Unit costs of SCTs. When the intervention costs of a more 
effective SCT increase relatively more than the intervention costs of a less effective treat-
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ment, the INMB will go down and the cost-effectiveness will worsen. The change in INMB 
for NRT versus unaided cessation because of a change in the resource use component of 
the intervention costs varies from +1.7% in Sweden to +8.2% in Germany. The change in 
INMB for bupropion versus NRT varies from -8.2% in Sweden to +20.0% in the UK. The 
change in INMB for varenicline versus bupropion varies from -17.5% in the UK to +0.9% 
in Sweden. The change in INMB for NRT versus unaided cessation because of a change 
in the unit cost component of the intervention costs varies from -4.5% in France to +7.7% 
in the UK. The change in INMB for bupropion versus NRT varies from -17.1% in the UK 
to +16.3% in France. The change in INMB for varenicline versus bupropion varies from 
-5.6% in Belgium to +6.5% in the UK (figure 6.1).
F8: Utilities. In countries where the utility weights of the smoking-related diseases are 
higher than in the reference case, the QALY gains from preventing these diseases are lower. 
The reduction in QALY gain is greatest for the intervention with the highest effectiveness. 
Thus, higher disease-specific utility weights lead to lower INMBs and a worsening of the 
cost-effectiveness. This applies to all five countries in our analysis, because the reference 
case represents the only country that has changed the model’s default utility values. If 
the utility weights for the general, disease-free population of a country are lower than in 
the reference case, the QALY gains from preventing a smoking-related disease are lower. 
Again, the reduction in QALY gains is greater if the treatment is more effective because 
more people stay disease free and their live years are thus weighted with the lower utility 
weights. This causes the INMBs to go down and the ICERs to worsen. The change in 
INMB for NRT versus unaided cessation because of a change in utility weights varies from 
-18.1% in Germany, Sweden, the UK, and France, to -13.7% in Belgium. The change in 
INMB for bupropion versus NRT varies from -14.9% in Germany, Sweden, the UK and 
France, to -11.3% in Belgium. The change in INMB for varenicline versus bupropion varies 
from -15.8% in Germany, Sweden, the UK, and France, to -12.0% in Belgium (figure 6.1).
F9: Discount rates. In countries where the costs and outcomes are discounted more 
than in the reference case, the INMBs and the ICERs worsen because the cost savings and 
QALY gains of smoking cessation that occur far into the future are reduced. The change 
in INMB for NRT versus unaided cessation because of a change towards country-specific 
discount rates varies from -65.2% in Germany to +62.0% in Sweden. The change in INMB 
for bupropion versus NRT varies from -53.7% in Germany to +51.1% in Sweden. The 
change in INMB for varenicline versus bupropion varies from -56.9% in Germany to 
+54.1% in Sweden (figure 6.1).
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6.3.3 Ranking of impact on INMB
The ranking of factors according to their impact on the INMB of NRT versus unaided 
cessation is largely similar for the comparisons bupropion versus NRT and varenicline 
versus bupropion. Table 6.4 shows the rank order when averaged over all three pairwise 
treatment comparisons. The first row shows the rank orders after averaging the impact of 
each factor over all countries. When substituting the reference case input univariately by 
country-specific input, F9: discount rates had the biggest impact on the cost-effectiveness. 
This is followed by F4: epidemiology and F8: utility weights. The least important factor in 
Table 6.4: Univariate ranking of factors according to the percentage change in incremental net monetary 
benefit, averaged over the three pair-wise comparisons of smoking cessation therapies, using a threshold value 
€20,000 per quality adjusted life year and a lifetime horizon, unless otherwise stated.
F9 
Discount 
rates
F4 
Epidemi-
ology
F8 
Utility 
weights
F6 
Resource 
use
F7 
Unit 
costs
F2 
Smoking 
prevalence
F3 
All-
cause 
mortality
F5 
Costs of 
smoking-
related 
diseases
F1 
Demog-
raphy
Rank order 
averaged 
over all 
countries
1 2 3 4 5 6 7 8 9
Rank order for each country
Belgium 5 1 2 4 3 8 7 9 6
Germany 1 3 2 5 6 4 9 7 8
Sweden 2 1 3 6 7 5 4 8 9
United 
Kingdom 
1 5 2 3 4 6 8 7 9
France 1 2 3 8 5 6 7 4 9
Rank order averaged over all countries at different time 
horizons
2 years 7 4 5 2 1 6 9 3 8
10 years 5 3 4 1 2 7 9 6 8
Lifetime 1 2 3 4 5 6 7 8 9
Rank order averaged over all countries at different 
threshold values
€ 100 4 5 9 1 2 6 7 3 8
€ 500 4 5 7 1 2 6 8 3 9
€ 1,000 4 5 6 1 2 7 8 3 9
€ 5,000 1 2 5 3 4 7 8 6 9
€ 10,000 1 2 3 4 5 7 8 6 9
€ 20,000 1 2 3 4 5 6 7 8 9
€ 50,000 1 2 3 6 7 4 5 8 9
€ 100,000 1 2 3 7 6 5 4 9 8
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terms of its effect on the INMB is F1: demography, i.e., the age/gender distribution of the 
cohort of smokers making a quit attempt. 
6.3.4 Sensitivity analysis: impact of using a different time horizon
A shorter time horizon changes the importance of the various causes of variability in 
cost-effectiveness between countries. The importance of the three factors with the largest 
long-term mpact, i.e., F9: discount rates, F8: utility weights, and F3: all-cause mortality 
decreases. Using a time span of 2 or 10 years, the two most important factors become 
the two factors determining the costs of smoking cessation treatment: F6: resources used 
and F7: unit costs. These factors become so important because a time horizon of 2 and 10 
years is insufficient to capture the full gains in QALYs and savings in costs that result from 
the prevention of smoking-related diseases. In other words, time has been insufficient to 
fully get the returns on the investments in SCT.
6.3.5 Sensitivity analysis: impact of using a different threshold value
Using different threshold values to calculate the NMB also changes the rank order of 
the factors. When the threshold value increases, the factors with a large influence on 
the QALYs, i.e. all-cause mortality, smoking prevalence, and demography, become more 
important. When the threshold value decreases, factors with a large influence on costs be-
come more important. This includes resources used for the smoking cessation treatments, 
unit costs, and costs of smoking-related diseases. The discount rates remain important, 
irrespective of the threshold value. For threshold values of € 5,000 or higher, discount-
ing is the single most important factor. Using a threshold value of € 1,000 or lower, the 
discount rate becomes the fourth most important factor. For a threshold value of € 1,000 
or lower, the most important factor is the resources used to deliver SCT, followed by costs 
of smoking-related disease.
6.3.6 Multivariate analysis
In the multivariate analysis, we enter all country-specific input parameters at the same 
time. Table 6.5 shows how the INMB differs between countries when fully accounting for 
all known between-country differences. In Belgium, the decrease in INMB due to higher 
disease-specific utilities is offset by an increase in the INMB because of a higher incidence 
of all smoking-related diseases. As a result, the INMBs increase, except for varenicline 
versus buproprion because the difference in unit costs between the two SCTs is greater 
than in The Netherlands. 
In Germany, the INMBs of all three pair-wise comparisons decrease primarily because 
of the relatively high discount rate for costs and outcomes. Other causes are a lower 
incidence of COPD, higher disease-specific utility values and lower general population 
utility values.
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In Sweden, the INMB is also lower than in the reference case for all pair-wise com-
parisons, because of higher utility weights for the smoking-related diseases and because 
QALYs were discounted at 3.5% instead of 1.5%. This decrease offsets the increase in 
INMB caused by lower all-cause mortality rates and higher incidence rates for all smoking-
related diseases in most age/gender classes.
In the UK, the INMB of all three pair-wise comparisons is lower than in the reference 
case, primarily because of a higher discount rate (3%) for outcomes, higher utility weights 
for the smoking-related diseases and a lower incidence of COPD.
In France, lower smoking-related disease mortality, higher disease-specific utility val-
ues, and lower general population utility values cause the INMB of all three pair-wise 
comparisons to decrease. Nevertheless, the effect of no discounting (0%) on outcomes has 
such a large effect that the INMB is higher than in the reference case.
Figure 6.2 shows the differences between countries in terms of ICERs for NRT versus 
unaided cessation. Incremental costs per QALYs gained in the reference case were esti-
mated to be € 1,600, represented by the dotted line. This ICER improved for Belgium (BE), 
Sweden (SE), and the UK; it worsened for Germany (DE) and France (FR). Note that the 
ICER in Sweden and the UK improved whereas the INMB decreased. In France, the ICER 
worsened whereas the INMB improved. This is due to the valuation of the QALY gains with 
€ 20,000 per QALY, as a result of which a decrease in QALYs, as in the UK, has a much 
greater impact on the INMB than on the ICER.
Table 6.5: Incremental Net Monetary Benefit (INMB) per 1000 smokers undertaking a quit attempt, using a 
threshold of €20,000 per quality adjusted life year, for three pair-wise smoking cessation therapy comparisons, 
influenced by all nine identified factors.a
INMB (x€1 mln)
NRT versus 
unaided cessation
Bupropion versus 
NRT
Varenicline versus 
bupropion
The Netherlands 1.42 0.39 0.90
Belgium 1.46 0.45 0.86
Germany 0.39 0.17 0.32
Sweden 1.29 0.22 0.82
UK 0.95 0.25 0.54
France 1.47 0.64 1.01
a NRT, nicotine replacement therapy.
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6.4 DISCUSSION
Many factors should be taken into account when transferring cost-effectiveness results 
across countries and settings and there are many interactions between these factors. This 
stresses the importance of carefully considering whether foreign results can be applied 
and adapted to its own setting. In this paper, we systematically investigated the impact 
of nine groups of country-specific model input parameters (factors) on the cross-country 
variability in long-term cost-effectiveness of pharmacological smoking cessation inter-
ventions. An earlier article13 has already shown that outcomes from cost-effectiveness 
studies on SCTs differ considerably between countries, but causes were not unravelled. 
Among the factors that we have investigated, the choice of discount rate was the factor 
contributing the most to the between-country differences in cost-effectiveness, followed 
by the incidence and mortality of smoking-related diseases and the utility values used to 
calculate QALYs.
It is important to note that the importance of a factor in terms of its impact on the 
INMB depends on the WTP for a QALY. At a WTP of € 20,000 per QALY, the impact of 
between-country differences in the cost parameters is relatively low, because the changes 
in the INMB are largely driven by factors affecting the QALYs. At lower values of the WTP 
Figure 6.2: Cost effectiveness per 1,000 smokers with a quit attempt of nicotine replacement therapy versus un-
aided cessation influenced by all nine identified factors. Dotted line shows all points with the same ICER as NL 
(€ 1,637 / QALY). ICERs: BE = € 207 / QALY; GE = € 5,184 / QALY; SE = € 495 / QALY; UK = -/- € 6,566 / QALY; 
FR = € 2,125 / QALY.a
a ICER: Incremental cost-effectiveness ratio
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for a QALY, the costs of SCTs, in terms of both the unit costs and resource use, as well 
as the costs of smoking-related diseases, become much more important. Irrespective of 
the WTP for a QALY, the impact of differences between countries in demography and 
all-cause mortality in the INMBs is small, because the differences between the countries 
investigated were relatively small and do not greatly alter the cohort of smokers undertak-
ing a quit attempt.
Despite the differences between countries, all pair-wise treatment comparisons in our 
study showed that the more effective smoking cessation treatments were also cost-effec-
tive, and in some case even cost-saving. INMBs were positive and ICERs were consistently 
below € 5,300 per QALY gained. Hence, there are strong health economic arguments to 
support these treatments across all countries.
It is further relevant to note the differences between the changes in the ICERs and the 
changes in the INMBs compared with the reference case, which stresses the importance 
of the threshold value for a QALY in decision-making. Using the change in INMB instead 
of the change in ICER as a measure of the importance of a country-specific factor gives 
relatively greater weight to changes in QALYs. We have seen that the larger emphasis on 
QALYs in the INMB also affects the relative importance of a factor. For example, applying 
the Swedish discount rates (3% for costs and outcomes) causes both the incremental costs 
and QALYs gained to decrease. This leads to a change in ICER of -3% and thus a slight 
improvement of cost-effectiveness, whereas the INMB is a significant 32% lower.
In each country, we have used the same base-case estimates of the 12-month continuous 
abstinence rates.5 This is based on the assumption that the pure biological effect of a drug 
can be expected to be the same, irrespective of the country. Otherwise we have used as 
many country-specific estimates of model input parameters as available. Some of the input 
data were very difficult to compare across countries. For example, smoking prevalence 
data may differ, because countries use different definitions and methods to determine the 
number of current smokers, like including only daily smokers or also including irregular 
smokers. In The Netherlands for example, a smoker is defined as somebody that has 
smoked in the 7 days before being asked101, while in Belgium, people are asked whether 
they have smoked 100 cigarettes during their lives and whether they consider themselves 
a smoker or not.102 In addition, the epidemiological data on smoking-related diseases 
are difficult to compare across countries. Different countries also used different defini-
tions of the four diseases included in the model, especially with respect to COPD and 
CHD. For example, COPD was identified with ICD-10 code J40–44 in The Netherlands, 
but as J40-44 plus J47 in Sweden. Such a difference in definition could potentially be 
a source of the difference in reported epidemiology and its associated costs between 
countries. Furthermore, not all countries distinguish between the first-year costs of lung 
cancer, CHD and stroke and the costs of these diseases in later years, often because these 
data are not available. Such differences complicate the comparison of cost-effectiveness 
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between countries. Nevertheless, we have deliberately chosen to use the definitions of the 
smoking-related diseases and the associated cost that were actually applied at the time 
of writing the country-specific reimbursement dossiers for varenicline. By doing so, we 
highlight best the differences between countries and the influence of these differences on 
cost-effectiveness and cost-benefit estimates as they drive actual decision-making.
Despite its large influence on the outcomes, in only one of our six countries, The 
Netherlands, country-specific utility weights were available. This lack of country-specific 
utility data is probably due to the difficulty to collect these data and the assumption that 
utility values for a specific health state will probably not differ much between countries. 
Nevertheless, as this study shows, it is worthwhile to invest more time and resources 
in finding country-specific utility weights, because their impact on the INMB is large, 
especially at higher levels of the threshold value of a QALY.
6.5 CONCLUSION
The Transferability of Economic Data Task Force from ISPOR states on their webpage103 
that one of the most important questions to be answered with regard to transferability is 
“[w]hich elements of economic data vary most from setting to setting?” The results from 
this study suggest that it is not only important to see which factors vary, but also how 
much this variation in factors causes variation in cost-effectiveness. The factors that cause 
the most variation in cost-effectiveness do not necessarily have to be the same as the 
factors that vary most themselves. For example, the unit costs of the smoking cessation 
drugs differ considerably between countries, but the impact on the cost-effectiveness is 
limited when adopting a lifetime time horizon. We spent considerable time and effort on 
identifying data sources, adjusting input data to fit into the model and especially assessing 
the comparability of input parameters between countries. Based on this observation, we 
wholeheartedly agree with the concluding remark of the Task Force that “those developing 
national guidelines for economic evaluations should think carefully about the need for 
local data or methods, since this increases the burden on those undertaking studies in 
multiple jurisdictions.” The results of our study underline that, when studying the cost-
effectiveness of smoking cessation, there is a need for local data even for countries within 
a similar region of the world.
151
6
6.6 LITERATURE
 [1] Drummond M, Barbieri M, Cook JR, et al. Transferability of economic evaluations across 
jurisdictions, in International Society for Pharmacoeconomic and Outcomes Research 
(ISPOR)—13th International Meeting. 2008; Toronto, Ontario, Canada.
 [2] Weinstein M, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic 
modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Prac-
tices—Modeling Studies. Value Health 2003; 6: 9–17.
 [3] Weinstein M. Recent developments in decision-analytic modelling for economic evaluation. 
Pharmacoeconomics 2006; 24: 1043–53.
 [4] Howard P, Knight C, Boler A, Baker C. Cost-utility analysis of varenicline versus existing smok-
ing cessation strategies using the BENESCO Simulation model: application to a population of 
US adult smokers. Pharmacoeconomics 2008; 26: 497–511.
 [5] Hoogendoorn M,Welsing P, Rutten-van Mölken MPMH. Costeffectiveness of varenicline 
compared with bupropion, NRT and nortriptyline for smoking cessation in the Netherlands. 
Curr Med Res Opin 2008; 24: 51–61.
 [6] Bolin K, Mörk A, Willers S, Lindgren B. Varenicline as compared to bupropion in smokingces-
sation therapy—cost–utility results for Sweden. Respir Med 2008; 102: 699–710.
 [7] Rasch A, Greiner W. Gesundheitsökonomisches Modell der Raucherentwöhnung mit Vareni-
clin. Suchtmedizin in Forschung und Praxis. 2008; 11: 47–55.
 [8] Hind D, Tappenden P, Peters J, Kenjegalieva K. Varenicline for Smoking Cessation: A Single 
Technology Appraisal. Sheffield, UK: ScHARR, University of Sheffield, 2007.
 [9] Skoupá J, Doležal T, Hájek P, Kovárˇ P. Long term costeffectiveness and cost-utility analysis 
for smoking cessation in Czech Republic, in International Society for Pharmacoeconomic and 
Outcomes Research (ISPOR)—13th International Meeting. 2008; Toronto, Ontario, Canada.
 [10] Bae J, Song HJ, Joe KH, et al. A long term cost-effectiveness analysis model for smoking 
cessation in Korea, in International Society for Pharmacoeconomic and Outcomes Research 
(ISPOR)—13th International Meeting. 2008; Toronto, Ontario, Canada.
 [11] Igarashi A, Takuma H, Fukuda T, Tsutani K. Cost-utility analysis of varenicline, an oral smoking 
cessation drug, in Japan. Pharmacoeconomics 2009; 27: 247–61.
 [12] Poulsen P, Dollerup J, Keiding H. The cost-effectiveness of varenicline in smoking cessation in 
Denmark. 2008; ISPOR 11th Annual European Congress Athens.
 [13] Cornuz J, Gilbert A, Pinget C, et al. Cost-effectiveness of pharmacotherapies for nicotine de-
pendence in primary care settings: a multinational comparison. Tob Control 2006; 15: 152–9.
 [14] Rutten-van Mölken MPMH, Hoogendoorn M, Rasch A, Bolin K. Cost-effectiveness of vareni-
cline for smoking cessation in five European countries, in Meeting of the Society for Research 
on Nicotine and Tobacco. 2007; Madrid, Spain.
152
6
 [15] O’Regan C, Baker C, Marchant N. The cost-effectiveness of the novel presciption therapy 
varenicline in Scotland, in Meeting of the Society for Research on Nicotine and Tobacco. 
2006.
 [16] Orme M, Hogue SL, Kennedy LM, et al. Development of the health and economic conse-
quences of smoking interactive model. Tob Control 2001; 10: 55–61.
 [17] Thun M, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking-
attributable deaths: confounding in the courtroom. J Am Med Assoc 2000; 284: 706–12.
 [18] Feenstra T, van Genugten ML, Hoogenveen RT, et al. The impact of aging and smoking on the 
future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. 
Am J Respir Crit Care Med 2001; 164: 590–6.
 [19] Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst 
Rev 2007; (1): CD000031.
 [20] Jorenby D, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic ace-
tylcholine receptor partial agonist, vs placebo or sustained-released bupropion for smoking 
cessation: a randomized controlled trial. J Am Med Assoc 2006; 296: 56–63.
 [21] Statistics Netherlands (CBS). Available from: http: //www.cbs.nl [Accessed September 2, 2008].
 [22] Nationaal Instituut voor Statistiek. Available from: http: //statbel.fgov.be/ [Accessed November 
19, 2007].
 [23] Statistisches Bundesamt Deutschland. Leben in Deutschland—Mikrozensus 2005. 2006; 
Available from: http: //www.destatis.de/presse/deutsch/pk/2006/mikrozensus2005_tabellenan-
hang.pdf#search=%22%22durchschnittliches%20Alter%20des%20Rauchbeginns%22%22 
[Accessed August 14, 2007].
 [24] Statistics Sweden (SCB). Available from: http: //www.scb.se/default____2154.asp [Accessed 
August 31, 2007].
 [25] Office for National Statistics (ONS). Available from: http: //www.statistics.gov.uk/ [Accessed 
March 31, 2007].
 [26] Beaumel C, Daguet F, Richet-Mastain L, Vatan M. La situation démographique en 2004. 2006; 
Available from: http: //www.insee.fr/fr/ppp/ir/accueil.asp?page=SD2004/dd/sd2004_nais.htm 
[Accessed February 9, 2007].
 [27] Zeegers T, Segaar D, Willemsen M. Roken de Harde Feiten: Volwassen 2004. Den Haag: 
STIVORO-voor een rookvrije toekomst, 2004.
 [28] Demarest S, Drieskens S, Gisle L, et al. Health Interview Survey, Belgium. 2004; Available 
from: http: //www.iph.fgov.be/EPIDEMIO/hisia/index.htm [Accessed November 19, 2007]. 
Cost-Effectiveness of Smoking Cessation 239
 [29] Statistisches Bundesamt Deutschland. Gesundheitsberichterstattung des Bundes. 2006. Avail-
able from: http: //www.gbe.bund.de/ [Accessed August 14, 2007].
 [30] Auvray LDS, Le Fur P. L’état de Santé de la population en France en 2006. Indicateurs associé 
à la loi relative à la politique de santé publique, in Baromètre Santé 2005—premiers résultats. 
153
6
INPES, 2006. Available from: http: //www.sante.gouv.fr/drees/santepop2006/santepop2006.
htm [Accessed February 9, 2007].
 [31] Dumesnil S, Le Fur P, Auvray L. Santé, Soins et Protection sociale en 2000, in Série Résultats. 
Nancy: CREDES, 2001.
 [32] GAD. UK Interim Life Tables 2002–4. 2006. Available from: http: //www.gad.gov.uk/ [Accessed 
March 31, 2007].
 [33] Poos M. COPD: Prevalentie, Incidentie, Ziekenhuisopnamen en Sterfte naar Leeftijd en 
Geslacht, in Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid. 
Bilthoven: RIVM, 2006.
 [34] Swedish National Board of Health and Welfare. Available from: http: //www.socialstyrelsen.se/
en/ [Accessed August 31, 2007].
 [35] Lung and Asthma Information Agency. 2006. Available from: http: //www.laia.ac.uk/ [Accessed 
December 4, 2006].
 [36] Soriano J, Maier WC, Egger P, et al. Recent trends in physician diagnosed COPD in women 
and men in the UK. Thorax 2000; 55: 789–94.
 [37] Detournay B, Pribil C, Fournier M, et al. The SCOPE Study: healthcare consumption related to 
patients with COPD in France. Value Health 2004; 7: 168–74.
 [38] Benard E, Detournay B, Neukirch F, et al. Prévalence de la Bronchopneumopathie Chronique 
Obstructive (BPCO): estimation pour la France. La Lettre du Pneumologue 2005; 8: 158–63.
 [39] Pham Q, Gimenez M, Myre M, et al. Contribution à l’épidémiologie de la bronchite chronique 
chez les travailleurs du bâtiment. Bull Physio-patho Resp 1972; 8: 769–95.
 [40] Perdrizet S, Amphoux M, Liard R. Pathologie respiratoire en médecine du travail: évaluation 
de trois modes de recueil des données et recherche des facteurs de risque. Rev Mal Respir 
1984; 1: 99–103.
 [41] Neukirch F, Cooreman J, Liard R, et al. Occupational exposure to bad weather, dusts and 
chemical fumes and respiratory abnormalities in 404 men at work (abstract). Am Rev Respir 
Dis 1986; 133: A357.
 [42] Neukirch F, Perdrizet S. La bronchite chronique. Evolution, prévention. Rev Mal Respir 1988; 
5: 331–46.
 [43] Poos M. Longkanker naar Leeftijd en Geslacht, in Volksgezondheid Toekomst Verkenning, 
Nationaal Kompas Volksgezondheid. Bilthoven: RIVM, 2005.
 [44] Schmidtmann I, Husmann G, Krtschil A, Seebauer G. Krebs in Rheinland-Pfalz, Inzidenz und 
Mortalität im Jahr 2002. Mainz: Krebsregister Rheinland-Pfaltz, 2004.
 [45] Epidemiologisches Krebsregister Saarland. 2004. Available from: http: //www.krebsregister.
saarland.de/ [Accessed August 14, 2007].
 [46] Batzler WU, Giersiepen K, Hentschel S, et al. Krebs in Deutschland 2003–2004, Häufigkeiten 
und Trends. Berlin: Robert Koch Institut, 2008.
154
6
 [47] Robert Koch-Institut. Dachdokumentation Krebs. 2006. Available from: http: //www.rki.de 
[Accessed August 14, 2007].
 [48] Institut national de la santé et de la recherche médicale. Réseau français des registres du can-
cer. 2003; Available from: http: //www.invs.sante.fr/publications/2003/rapport_cancer_2003/
index.html [Accessed February 9, 2007].
 [49] Poos M. Coronaire Hartziekten: Prevalentie, Incidentie, Ziekenhuisopnamen en Sterfte Naar 
Leeftijd en Geslacht, in Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksge-
zondheid. Bilthoven: RIVM, 2006.
 [50] Kohler M, Ziese T. Telefonischer Gesundheitssurvey des Robert Koch-Instituts zu chronischen 
Krankheiten und ihren Bedingungen. Berlin: Robert Koch Institut, 2004.
 [51] British Heart Foundation. 2006. Available from: http: //www.bhf.org.uk/ [Accessed December 
4, 2006].
 [52] Fender M, Arveiller D, Facello A, et al. Vers une diminution de l’infarctus du myocarde dans 
le Bas Rhin. Ann Cardiol Angéiol 1994; 43: 373–79.
 [53] Volmink J, Newton JN, Hicks NR, et al. Coronary event and case fatality rates in an English 
population: results of the Oxford myocardial infarction incidence study. The Oxford Myocar-
dial Infarction Incidence Study Group. Heart 1998; 80: 40–4.
 [54] Poos M. Beroerte: Prevalentie, Incidentie, Ziekenhuisopnamen en Sterfte naar Leeftijd en 
Geslacht, in Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid 
2004. Bilthoven: RIVM, 2004.
 [55] Wolfe D, Giroud M, Kolominsky-Rabas P, et al. Variations in stroke incidence and survival in 
3 areas of Europe. Stroke 2000; 31: 2074–9.
 [56] Hoogendoorn M, Feenstra TL, Rutten-van Molken MP. [Projections of future resource use and 
the costs of asthma and COPD in the Netherlands] Dutch. Ned Tijdschr Geneeskd 2006; 150: 
1243–50.
 [57] Slobbe L, Kommer GJ, Smit JM, et al. Kosten van Ziekten in Nederland 2003. Bilthoven: RIVM, 
2006.
 [58] Suryapranata H, Ottervanger JP, Nibbering E, et al. Long term outcome and cost-effectiveness 
of stenting versus balloon angioplasty for acute myocardial infarction. Heart 2001; 85: 667–71.
 [59] Struijs J, van Genugten ML, Evers SM, et al. Future costs of stroke in the Netherlands: the 
impact of stroke services. Int J Technol Assess Health Care 2006; 22: 518–24.
 [60] Caekelbergh K, Annemans L, Spaepen E. Management of COPD in Belgium: A real life cost 
study. Value Health 2005; 8: 214.
 [61] Singh B, Golden R. The uninsured patient. Am J Med 2006; 119: 166.e1–5.
 [62] Muls E, van Ganse E, Closon MC. Cost-effectiveness of pravastatin in secondary prevention of 
coronary heart disease: comparison between Belgium and the United States of a projected risk 
model. Atherosclerosis 1998; 137(Suppl.): S111–16.
 [63] TCT. TCT database. Available from: https: //tct.fgov.be [Accessed November 19, 2007].
155
6
 [64] Nowak D, Dietrich ES, Oberender P, et al. [Cost-of-illness Study for the Treatment of COPD in 
Germany] German. Pneumologie 2004; 58: 837–44.
 [65] Läkemedelsstatistik AB, Medical Index Sweden. Stockholm: Läkemedelsstatistik AB, 2002.
 [66] Ghatnekar O, Persson U, Glader EI, et al. Cost of stroke in Sweden: an incidence estimate. Int 
J Technol Assess Health Care 2004; 20: 375–80.
 [67] Halpin D. Health economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 
2006; 3: 227–33.
 [68] Curtis L, Netten A. Unit Costs of Health and Social Care 2005. Kent, UK: PSSRU, University 
of Kent, 2005.
 [69] McMurray J, Hart W, Rhodes G. An evaluation of the cost of heart failure to the National 
Health Service in the UK. Br J Med Ec 1993; 6: 99–110.
 [70] Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the United Kingdom. 
Pharmacoeconomics 2003; 21(Suppl. 1): 43–50.
 [71] Fournier M, Tonnel A-B, Housset B, et al. Impact économique de la BPCO en France: Étude 
SCOPE (Economic impact of COPD in France: The SCOPE study). Rev Mal Respir 2005; 22: 
247–55.
 [72] Gonzalez D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic aceylcholine 
receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a 
randomized controlled trial. J Am Med Assoc 2006; 296: 47–55.
 [73] RIZIV/INAMI database. Available from: http: //www.riziv.be [Accessed November 19, 2007].
 [74] Geneesmiddelen Reportorium. Available from: http: //www.cbip.be [Accessed November 19, 
2007].
 [75] Kassenärztliche Bundesvereinigung. Einheitlicher Bewertungsmaßstab. 2006; Available from: 
http: //www.kbv.de/ebm2000plus/EBMGesamt.htm [Accessed August 14, 2007].
 [76] European Medicines Agency. Summary of Product Characteristics. London: EMEA, 2006.
 [77] Willers S. [Smoking cessation treatment-recommendations for Skåne, Sweden] (Swedish) in 
Bakgrundsmaterial till Skånelistans rekommendationer. Lund: Lund University, 2007.
 [78] NHS Clinical Knowledge Summaries (formerly PRODIGY). Available from: http: //cks.library.
nhs.uk/home [Accessed March 31, 2007].
 [79] Feenstra T, van Baal PH, Hoogenveen RT, et al. Cost-Effectiveness of Interventions to Reduce 
Tobacco Smoking in the Netherlands. An Application of the RIVM Chronic Disease Model. 
Bilthoven: RIVM, 2006.
 [80] CVZ. Medicijnkosten. 2006; Available from: http: //www.medicijnkosten.nl [Accessed Sep-
tember 2, 2008].
 [81] NHS Business Services Authority. Available from: http: //www.ppa.org.uk [Accessed March 31, 
2007].
 [82] van Baal P, Hoeymans N, Hoogenveen RT, et al. Disability weights for comorbidity and their 
influence on health-adjusted life expectancy. Popul Health Metr 2006; 4: 1.
156
6
 [83] Spencer M, Briggs AH, Grossman RF, Rance L. Development of an economic model to assess 
the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. 
Pharmacoeconomics 2005; 23: 619–37.
 [84] Mannino D, Buist AS, Petty TL, et al. Lung function and mortality in the United States: data 
from the First National Health and Nutrition Examination Survey follow up study. Thorax 
2003; 58: 388–93.
 [85] Trippoli S, Vaiani M, Lucioni C, Messori A. Quality of life and utility in patients with non-small 
cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. 
Pharmacoeconomics 2001; 19: 855–63.
 [86] Hay J, Sterling KL. Cost effectiveness of treating low HDLcholesterol in the primary prevention 
of coronary heart disease. Pharmacoeconomics 2005; 23: 133–41.
 [87] Duncan P, Lai SM, Keighley J. Defining post-stroke recovery: implications for design and 
interpretation of drug trials. Neuropharmacology 2000; 39: 835–41.
 [88] Tengs T, Lin TH. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics 
2003; 21: 191–200.
 [89] Szende A, Svensson K, Stahl E, et al. Psychometric and utilitybased measures of health status 
of asthmatic patients with different disease control level. Pharmacoeconomics 2004; 22: 
537–47.
 [90] Gage B, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic 
therapy for patients with nonvalvular atrial fibrillation. Stroke 1998; 29: 1083–91.
 [91] Stouthard M, Essink-Bot ML, Bonsel GJ, et al. Disability Weights for Diseases in the Nether-
lands. Rotterdam: Department of Public Health, Erasmus University Rotterdam, 1997.
 [92] Feenstra T, Hamberg-van Reenen HH, Hoogenveen RT, et al. Cost-effectiveness of face-to-face 
smoking cessation interventions: a dynamic modeling study. Value Health 2005; 8: 178–90.
 [93] McNamara R, Lima JA, Whelton PK, et al. Echocardiographic identification of cardiovasular 
sources of emboli to guide clinical management of stroke: a cost-effectiveness analysis. Ann 
Intern Med 1997; 127: 775–87.
 [94] Rodenburg–van Dieten HEM. Richtlijnen voor farmacoeconomisch onderzoek. Evaluatie en 
Actualisatie. Diemen: CVZ, 2008.
 [95] Cleemput I, van Wilder Ph, Vrijens F, Huybrechts M, Ramaekers D. Richtlijnen voor farma-
coeconomische evaluaties in België. Health Technology Assessment (HTA). Brussels: Federaal 
Kenniscentrum voor de Gezondheidszorg (KCE), 2008.
 [96] Hannoveraner Konsensus Gruppe. Deutsche Empfehlungen zur gesundheitsökonomischen 
Evaluation—Revidierte Fassung des Hannoveraner Konsens. Gesundheitsökonomie und 
Qualitätssicherung 1999; 4: A62–5.
 [97] Edling A, Stenberg AM. General Guidelines for Economic Evaluations from the Pharmaceuti-
cal Benefits Board (LFNAR 2003: 2). Solna: Pharmaceutical Benefits Board (LFN), 2003.
 [98] NICE. Guide to the Methods of Technology Appraisal. London: NICE, 2004.
157
6
 [99] Lévy É, De Pouvourville G. French Guidelines for the Economics Evaluation of Health Care 
Technologies. Paris: Collège des Économistes de la Santé, 2004.
 [100] OECD.stat. Available from: http: //www.oecd.org/statsportal/ [Accessed September 2, 2008].
 [101] STIVORO. Available from: http: //www.stivoro.nl [Accessed September 2, 2008].
 [102] Bayingana K, Demarest S, Gisle L, et al. Gezondheidsenquête België. Brussel: Wetenschap-
pelijk Instituut Volksgezondheid, 2004.
 [103] The Transferability of Economic Data Task Force. Available from: http: //www.ispor.org/coun-
cils/transferability.asp [Accessed September 2, 2008].

Chapter 7 
Largely ignored
The impact of the threshold value for a QALY 
on the importance of a transferability factor
P. Vemer, M.P.M.H. Rutten-van Mölken
Previously published in European Journal of Health Economics, 2011, 12:397–404
doi: 10.1007/s10198-010-0253-3
ABSTRACT
Recently, several checklists systematically assessed factors that affect the transferabil-
ity of cost-effectiveness (CE) studies between jurisdictions. The role of the threshold 
value for a QALY has been given little consideration in these checklists, even though 
the importance of a factor as a cause of between country differences in CE depends 
on this threshold.
In this paper, we study the impact of the willingness-to-pay (WTP) per QALY on the 
importance of transferability factors in the case of smoking cessation support (SCS). 
We investigated, for several values of the WTP, how differences between six countries 
affect the incremental net monetary benefit (INMB) of SCS. The investigated factors 
were demography, smoking prevalence, mortality, epidemiology and costs of smoking-
related diseases, resource use and unit costs of SCS, utility weights and discount rates.
We found that when the WTP decreased, factors that mainly affect health outcomes 
became less important and factors that mainly effect costs became more important. 
With a WTP below €1,000, the factors most responsible for between country differ-
ences in INMB were resource use and unit costs of SCS and the costs of smoking-re-
lated diseases. Utility values had little impact. At a threshold above €10,000, between 
country differences were primarily due to different discount rates, utility weights and 
epidemiology of smoking-related diseases. Costs of smoking-related diseases had 
little impact. At all thresholds, demography had little impact. 
We concluded that, when judging the transferability of a CE study, we should consider 
the between country differences in WTP threshold values.
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7.1 INTRODUCTION
Transferability has been defined as the degree to which the results of a cost-effectiveness 
study performed in one jurisdiction are representative for another jurisdiction, frequently 
another country. The term is also used to express the amount of adaptation that is neces-
sary to make the results applicable to another jurisdiction.1 A study that requires just a few 
simple adaptations, like a change in unit costs or discount rate, is more easily transferable 
than a study that requires many complicated adaptations, like a change in resource use 
pattern or a change in the case mix of the study population.
The question arises to what extent we can assess transferability. Recently, several check-
lists have been developed which systematically check the transferability of CE studies 
between jurisdictions [2–4]. Such checklists contain a list of issues which must be satisfied 
before a study is considered transferable. Examples of such issues are whether the per-
spective and comparators are relevant for the country of interest, whether the disease 
epidemiology is comparable in the country of interest and whether discount rates were 
specified. Some of the checklists generate a summary transferability score, assigning either 
equal importance to each issue2 or weighting the importance of each issue.3
The advantage of such checklists is that they force the user to systematically think about 
transferability. The disadvantage is that the transferability scores are difficult to interpret. 
What does a particular transferability score really say? Moreover, in all of these checklists, 
there is one aspect that has been given little consideration, namely the threshold value for 
a QALY. Although some checklists encourage the user to discuss the generalizability of the 
results in the light of country-specific decision criteria, the checklists ignore the fact that 
the importance of a transferability issue depends on the threshold value for a QALY. Issues 
that are important contributors to between country differences in CE at a low threshold 
need not be of equal importance at a higher threshold. For example, a difference in the 
incidence of an infectious disease between two countries, which causes the incremental 
cost-effectiveness ratio (ICER) of a vaccination program to double from € 12,000 in coun-
try A to € 24,000 in country B, is less important when the threshold value is € 50,000 per 
QALY but highly important when the threshold value is € 20,000.
As we will discuss later in this paper, no country has an explicit threshold value for 
a QALY. However, this does not mean that there is no threshold. Since no country has 
infinite resources available for health care, decisions have to be made which interventions 
to reimburse and which not. At the same time, although heavily criticized, the QALY is 
widely regarded as a relevant outcome for decision-makers. Assuming both the existence 
of a country-specific threshold and the acceptance of QALYs as an outcome measures that 
is relevant to the decision-makers in our countries of interest, country-specific INMBs can 
be calculated for all relevant countries.
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The aim of this paper is to assess whether the extent to which between country differ-
ences influence the country-specific INMB depends on the threshold value for a QALY. 
We ranked several possible causes (in this paper ‘‘transferability factors’’ or ‘‘factors’’) 
of between country differences in CE of smoking cessation support, according to their 
impact on the INMB. By doing this for different levels of the threshold value for a QALY, 
we studied how the importance of a transferability factor depends on this threshold value. 
In an earlier study, we found that at a threshold value of € 20,000, discount rates and 
the epidemiology of smoking-related diseases were important drivers of between country 
differences in INMB of smoking cessation interventions.5
7.2 METHODS
7.2.1 The BENESCO model
The economic evaluation of smoking cessation support was based on the Benefits of Smok-
ing Cessation on Outcomes (BENESCO) model, using a lifetime horizon and a healthcare 
sector’s perspective.6 The BENESCO model simulates the benefits of quitting smoking in 
terms of smoking-related morbidity, mortality and associated medical costs. Diseases 
included in the model are chronic obstructive pulmonary disorder (COPD), lung cancer, 
chronic heart disease (CHD) and stroke. The model is structured as a Markov model and 
follows a hypothetical cohort of current smokers making a single attempt to quit smoking 
at the beginning of the simulation. More information on the model can be found in the 
online appendix and several publications.7-9 
7.2.2 Smoking cessation support
If a person decides to quit smoking, (s)he can do this unaided, or using one of the available 
forms of smoking cessation strategies. In this paper, we compare three forms of pharma-
cological smoking cessation support: nicotine replacement therapy (NRT), bupropion and 
varenicline. NRT is the generic term for any form of smoking cessation aid which delivers 
a measured dose of nicotine to the person using it. Examples include the nicotine patch 
or nicotine gum. Bupropion is an antidepressant used to support smoking cessation.10 
Varenicline is designed to relieve symptoms of nicotine withdrawal including cigarette 
craving and block the reinforcing effects of continued nicotine use.11 The reference case 
to which the results of other countries in this analysis are compared is an economic 
evaluation performed from the Dutch health care perspective. In this study, NRT has been 
shown to be costeffective compared to unaided cessation, bupropion was dominant over 
NRT and varenicline was dominant over bupropion.7
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7.2.3 Cost-benefit
The primary outcome of the economic evaluation was the INMB. The INMB was chosen 
because it explicitly incorporates the threshold value for the willingness-to-pay (WTP), or 
the societal value for a QALY (k). Hence, we could study the extent to which the impor-
tance of the transferability factors depends on the λ (see paragraph below). The INMB was 
calculated for different values of λ ranging from € 0 to € 50,000. Comparing two smoking 
cessation interventions, A and B, the INMB was calculated as:
[QALY(A) – QALY(B)] x λ – [Costs(A) – Costs(B)].
A positive INMB indicates that the net benefits of intervention A are higher than the net 
benefits of intervention B. A negative INMB indicates that the net benefits of intervention 
A are lower than the net benefits of intervention B.
7.2.4 Factors affecting transferability
Within the BENESCO model, all variables except the risk ratio of getting a smoking-related 
illness were changed to calculate country-specific cost-effectiveness. These variables can 
intuitively be grouped in a total of nine transferability factors, which could potentially 
cause differences in the cost-benefit of smoking cessation support between countries. We 
investigated each of these factors. Each transferability factor consisted of a group of coun-
try-specific input parameters which were varied simultaneously. Demography included 
the total number of people older than 18 years of age in six age/gender classes. Smoking 
prevalence refers to the percentage of smokers, non-smokers and former smokers in each 
age/gender class. All-cause mortality was the percentage of the total number of people in 
each age/gender class that dies during a single year. The epidemiology of smoking-related 
diseases consisted of three elements: the incidence rates, prevalence rates and annual 
cause-specific mortality rates by age/gender class. The costs of smoking-related diseases 
were separated into first year costs and costs in subsequent years, except for COPD. The 
amount of resource use (i.e., medication and counselling) associated with the SCS and 
the unit costs of these resources were the two elements defining the intervention costs. 
The utility weights were defined both for the general population and for patients with a 
smoking-related disease. The discount rates for both costs and outcomes were set equal to 
the values recommended in 2007 in the national guidelines for economic evaluations. For 
each country, we adopted a health care perspective. Information on the main input factors 
can be found in appendix A7.
7.2.5 The importance of each transferability factor
Based on the hierarchy of effectiveness of the smoking cessation interventions, we calcu-
lated the INMB of NRT versus unaided cessation, bupropion versus NRT and varenicline 
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versus bupropion in The Netherlands.7 These results were used as the reference values. 
We then changed the Dutch input values of each of the nine factors individually to the 
country-specific values for Germany, Sweden, the UK, Belgium and France.5, 8, 12, 13 This 
changes the INMB. The percentage of change in the INMB was then averaged over the 
three treatment comparisons. Each factor is then rank ordered from highest (1) to lowest 
(9) percentage of change in INMB. We compare these rankings for different threshold 
values, ranging from € 0 to € 50,000 per QALY, for each country separately.
7.3 RESULTS
The INMB of NRT versus unaided cessation in The Netherlands at a WTP threshold of 
€ 20,000 per QALY was € 1.42 million. The INMB of bupropion versus NRT was € 0.39 
million, and the INMB of varenicline versus bupropion was € 0.90 million. Table 7.1 shows 
the ranking of factors at different threshold values for a QALY, after replacing the Dutch 
reference values with the German country-specific values. It is clear from this table that 
the threshold value has a considerable impact on the importance of each factor.
This can be seen most clearly for the cost of smoking-related diseases, resource use, unit 
costs and utility weights. The INMB is calculated as the difference in QALYs multiplied 
by λ minus the difference in costs. Hence, the QALY gains are weighted with the λ before 
subtracting the additional costs. When λ decreases, the transferability factors that mainly 
affect the health outcomes are given less weight and become less important, whereas 
the transferability factors which mainly affect the costs become more important. Among 
the latter are the costs of smoking cessation support, which are driven by the resources 
Table 7.1: Univariate ranking of factors after changing to the German values, at different threshold values for 
the WTP for a QALY.a
Threshold 
value for 
WTP
Demog-
raphy
All-cause 
mortality
Smoking 
prevalence
Epidemiol-
ogy
Costs of 
smoking-
related 
diseases
Resource 
use
Unit 
costs
Utility 
weights
Discount 
rates
€ 0 7 8 6 5 3 1 2 9 4
€ 100 7 8 6 5 4 1 2 9 3
€ 500 8 9 6 5 4 1 3 7 2
€ 1,000 8 9 7 5 3 1 4 6 2
€ 5,000 8 9 7 4 6 2 5 3 1
€ 10,000 8 9 6 3 7 4 5 2 1
€ 20,000 8 9 4 3 7 5 6 2 1
€ 50,000 7 9 4 3 8 5 6 2 1
a WTP: Willingness-to-pay; Ranked according to the percentage change in INMB compared to the reference 
country, averaged over three pair-wise comparisons of smoking cessation strategies.
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used and the unit costs of these resources, and the costs of smoking-related diseases. 
When λ increases, the transferability factors with a large impact on the QALYs are given a 
higher weigh, increasing their importance as a cause of between country differences in net 
benefit. As a consequence, utility weights, epidemiology (mainly incidence and mortality) 
of smoking-related diseases and smoking prevalence become more important. 
When replacing Dutch by German input values, the discount rate, which changed from 
4% for costs and 1.5% for effects in The Netherlands to 5% for both costs and effects 
in Germany, led to the highest percentage of change in INMB at thresholds of € 5,000 
or higher. At lower thresholds, the relative importance of the discount rate decreases, 
with the resource use taking over as the most important factor. All-cause mortality and 
demography are relatively unimportant at all threshold values.
Similar tables result for the other countries. They are shown in appendix A7. For the 
other four countries, the same general overview can be seen, although there are individual 
differences. Tables on the outcomes of other countries can be found in appendix A7. In 
all countries, unit costs and/or resource use are amongst the two most important causes 
of between country differences in cost benefit at low thresholds. At high thresholds, utility 
weights, discount rates and the epidemiology of smoking-related diseases are the three 
most important factors for all countries, except for Belgium which had almost the same 
discount rates as in The Netherlands.
Figure 7.1 shows the percentage of change in the INMB of NRT versus unaided cessa-
tion, when substituting the reference case input values to the German values, at various 
levels of λ. The results were comparable for the other pair-wise comparisons of smoking 
cessation interventions (not shown, available on request). At a λ of € 0, substituting Dutch 
resource use by German resource use led to the greatest change in INMB, a decrease of 
92%. The second most important transferability factor was the costs of smoking-related 
diseases, decreasing the INMB with 29%. At a λ of € 500, Germany-specific resource 
use still caused the INMB to change most, but now followed by the discount rates. At a 
λ of € 5,000 or above, the discount rates had the highest impact on the INMB, causing a 
decrease in INMB of 99%, followed by the utility weights, causing a decrease in INMB 
of 25%.
The closer the threshold value of a QALY was to the original ICER in the reference 
country—in this case € 1,637 per QALY—the more the INMB was affected by a change to 
country-specific input data. This was true for every transferability factor, since the INMB 
of the base case comparison is close to zero with a λ close to the ICER. For most transfer-
ability factors, the sign of the impact on the INMB at a threshold of € 1,000 or lower 
switched from positive to negative or vice versa at a threshold of € 5,000 or higher. Only 
the factor discount rates for Sweden and the UK and the factor epidemiology for Belgium 
and Sweden show a slightly different pattern. The reason is that the INMB of the base case 
comparison is always positive with a λ above the value of the ICER, but negative with a λ 
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below the ICER. A similar change in INMB due to a new country-specific variable value 
will therefore have a directly opposite effect. 
Figure 7.2 shows, for various levels of λ, the change in INMB of NRT versus unaided 
cessation, when all reference case input values are simultaneously replaced by country-
specific values. This change to the country-specific INMB is shown for each country 
separately. At lower levels of λ, the INMB changes most when adapting the Dutch input 
data to the UK input data. This is because the resource use and costs of NRT in the UK 
Figure 7.1: Percentage of change in the INMB of NRT versus unaided cessation, when replacing Dutch input 
values for each factor by the German input values, at different threshold values for the WTP for a QALY. F1: 
demography, F2: smoking prevalence, F3: mortality, F4: epidemiology, F5: costs of smoking-related diseases, 
F6: resource use, F7: unit costs, F8: utility weights, F9: discount rates.
a WTP: Willingness-to-pay
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differ most from that in The Netherlands, i.e., NRT is considerably less expensive in the 
UK than in The Netherlands. At higher levels of λ, the INMB changes most when adapting 
the Dutch input data to the German input data. This is because of the great difference in 
discount rates.
Figure 7.2: Percentage of change in the INMB of NRT versus unaided cessation, when simultaneously replac-
ing Dutch input values for all transferability factors by the country-specific input values at different threshold 
values for the WTP for a QALY. 
a WTP: Willingness-to-pay
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7.4 DISCUSSION
This paper has clearly shown that, when we transfer a foreign economic evaluation to 
the country of interest, the factor which should most carefully be adapted is driven by 
the threshold value for a QALY. We feel that this aspect has been given too little attention 
in the transferability debate until now. When discussing the transferability of smoking 
cessation evaluations in countries with low threshold values, we should pay most at-
tention to the country-adaptation of the cost drivers, i.e., the costs of the interventions 
and the disease that are studied. In countries with high threshold values, we should pay 
most attention to the country-adaptation of the factors that affect the health outcomes. 
These include disease epidemiology and utility values. Although the results are specific 
for smoking cessation interventions, and indeed for the BENESCO model, we feel this con-
clusion is applicable to similar interventions of a preventative nature that require initial 
investments which by far precede the returns on these investments in terms of improved 
health outcomes and savings in the costs of health care utilization. In addition, we feel 
that based on this paper, the threshold value for a QALY should be an integral part of the 
investigation of transferability for all economic evaluations.
The approach taken in this paper assumes the acceptance of the QALY as a relevant 
decision-making outcome and the existence of threshold values, either explicit or implicit. 
The reason that the role of the threshold value has been largely ignored in the transfer-
ability discussion may be related to the fact that we are far from reaching a consensus 
on the maximum willingness to pay for a QALY. There is not a single jurisdiction where 
the threshold value is really fixed. With respect to the countries in our current study, 
NICE (National Institute for Health and Clinical Excellence) in the UK mentions the most 
explicit threshold value, but they too reject the use of a single, absolute threshold, instead 
preferring to make decisions on a case-by-case basis. NICE is unlikely to reject a technol-
ogy with a ratio in the range of £ 5,000 – £ 15,000 per QALY solely on the grounds of 
cost ineffectiveness but would need special reasons for accepting technologies with ratios 
over £ 25,000 – £ 35,000 per QALY as cost effective.14 In The Netherlands, a threshold of 
€ 20,000 per QALY is often cited. However, this threshold was obtained from economic 
evaluations of preventive interventions and is certainly not used consistently.15 Currently, 
there is discussion in The Netherlands on increasing the threshold value depending on 
the burden of the disease of interest, with a maximum threshold of up to € 80,000 for 
very severe diseases.16,17 In Germany, IQWiG (Institut für Qualität und Wirtschaftlichkeit 
im Gesundheitswesen) has prepared guidelines for economic evaluation as part of the 
evaluation of the value of pharmaceuticals18, but coverage does not depend on any ex-
ternally set maximum standard. In 2008, the Belgian KCE (Federal Knowledge Centre 
for Health Care) started to produce methodological reports in order to help standardize 
the methodology used for health technology assessment.19 One such report mentions 
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that CE is now only rarely used as an argument for reimbursement. The budget impact is 
considered more important. This report was intended as a starting point for a discussion 
on the role of threshold values in Belgium.20 In Sweden, no guidance has been given as 
to acceptable cost-effectiveness ratios, defined in terms of cost per QALY or otherwise, 
although cost-effectiveness is considered a crucial aspect in the Swedish reimbursement 
system.21 Rather than apply a single threshold, there may be different (implicit) thresholds 
depending on the severity of the disease or an assessment of patient need.22 In France, no 
threshold value is used when making health care decisions.23
In a cost-utility analysis, an intervention is found to be cost-effective if the cost per 
QALY falls below the WTP for a QALY. This value is used as an external threshold value 
against which the ICER is compared. In the cost benefit analysis, the societal value of a 
QALY is directly incorporated into the analysis. For an intervention to be cost-effective, 
the INMB (calculated as [QALY(A) – QALY(B)] x λ – [Costs(A) – Costs(B)]) needs to be 
positive. In the net benefit approach, it is apparent that the impact of a country-specific 
model parameter on the decision to adopt an intervention depends on the threshold value 
of the QALY. Though not immediately visible in the cost-utility analysis itself, the impact 
of a parameter on the probability that the ICER falls below the threshold value equally 
depends on the level of this threshold value. Whether or not the threshold value is ex-
plicitly incorporated into the analysis does to affect the importance of a country-specific 
parameter in the transferability discussion. The consequence of our findings may be that 
we have to adjust the available transferability check lists to encourage checking whether 
there might be differences in the willingness to pay between the countries, next to check-
ing how well a foreign study represents the circumstances in the country of interest and 
how much effort is required to adapt particular data inputs to the country of interest. For 
example, NRT, bupropion and varenicline are currently not covered by the basic health 
care insurance in The Netherlands, although the health insurance board CVZ has recently 
advised the Ministry of Health to reimburse them as part of an integrated smoking ces-
sation program.24 This implies a current willingness to pay of € 0. Consequently, when 
future foreign CE studies of new smoking cessation interventions (e.g., a vaccine) become 
available, the transferability of the cost of this intervention to The Netherlands will be 
driving the reimbursement discussion. In contrast, in the UK, where NRT, bupropion and 
varenicline are already paid by the NHS, the discussion on the transferability of foreign 
cost-effectiveness studies of such a drug might focus more on the representativeness of 
the epidemiology of smoking-related diseases for the UK and the utility values of patients 
having a smoking-related disease.
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7.5 CONCLUSION
When judging the transferability of a CE study from one jurisdiction to another, it is rel-
evant to consider the between country differences in threshold values per QALY. Between 
country, differences in cost-effectiveness are determined by between country differences 
in unit costs, disease epidemiology, discount rates etc., but the importance of each of 
these is influenced by the threshold value for a QALY. Between country differences that 
are important at a low threshold value might be less important at a high threshold value 
and vice versa.
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A7 APPENDIX
A7.1 Background information BENESCO model and additional results
The projections of the effects of smoking cessation were based on the BENESCO (Benefits 
of Smoking Cessation on Outcomes) model.1 The BENESCO model simulates the conse-
quences of smoking and the benefits of quitting in terms of smoking-related morbidity, 
mortality and associated medical costs in a population. The model is structured as a 
Markov model (cycle length 1 year) and follows a hypothetical cohort of current smokers 
making a single attempt to quit smoking at the beginning of the simulation. The cohort 
is followed from the time of their quit attempt until all members of the cohort have died. 
Individuals are classified into one of three smoking states, i.e., smoker, recent quitter (ab-
stinent 1–5 years after successful quit attempt) or long-term quitter. Transition probabilities 
between smoking states in the first year depend on cessation rates of the interventions, 
while the probabilities after 1 year depend on relapse rates, which in turn depend on time 
since quitting. The model simulates the age, gender and smoking status-specific incidence 
and mortality of four major diseases for which smoking is a well-established risk factor: 
chronic obstructive pulmonary disease (COPD), lung cancer, coronary heart disease and 
stroke. Smoking state-specific incidence and mortality rates were calculated using relative 
risks.2, 3 The incidence and mortality rates for recent quitters were calculated using the 
relative risks of former smokers versus never smokers, while the rates for long-term quitters 
were assumed to be the same as those of never smokers. Because COPD and lung cancer 
are chronic progressive conditions, these diseases were given hierarchical prominence 
over the other conditions with acute recurrent events. This means that individuals with 
COPD or lung cancer remain in this state until they die and cannot move to a CHD or 
stroke state, whereas individuals with CHD or stroke can move to the COPD or lung 
cancer state. A patient cannot have two diseases at the same time. The model calculates 
the total number of smokers and quitters that have one of the smoking-related diseases 
as well as the number of deaths (due to one of the smoking-related diseases and overall) 
over the time horizon of the simulation. Based on these numbers, the total health care 
costs associated with the different disease states and the total number of (quality adjusted) 
life years are calculated. The model uses three age bands: 18–34 years, 35–64 years and 
65 years and older. Subjects alive in the model at age 99 years are all assumed to die in 
the next cycle. It is assumed that there is no smoking-related morbidity or mortality in the 
18–34 years age class. 
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ABSTRACT
Background National regulatory agencies often have to use cost-effectiveness (CE) 
data from multinational randomized controlled trials (RCTs) for national decision 
making on reimbursement of new drugs. We need to make the best use of these 
patient-level data to obtain estimates of country-specific CE. Several methods, ranging 
from simple to statistically complex, have existed for years. We investigated which 
of these methods are used to estimate CE ratios in economic evaluations performed 
alongside recent, multinational RCTs that enrolled at least 500 patients.
Methods In this systematic literature review, studies were classified based on whether 
resource use, unit costs, health outcomes and utility value sets were obtained from 
all countries, a subset of countries or one country. We recorded if the study presented 
trial-wide and country-specific CE results and reported the statistical analyses that 
were used to estimate them.
Results We included 21 studies, of which the majority used measurements of health 
care utilization and health outcomes from all countries to estimate CE. Thirteen stud-
ies used a one-country valuation of health care utilization; six used a multi-country 
valuation. Despite the availability of country-specific utility value sets, none of the 
studies that presented quality-adjusted life-years (QALYs) used multi-country valua-
tion. Valuation of health care utilization and health outcomes was not always consis-
tent within a study: three studies combined a multi-country valuation of health care 
utilization, with a one-country valuation of health outcomes. Most studies calculated 
trial-wide CE estimates, while 11 studies calculated country or region-specific esti-
mates. Thirteen studies used relatively simple methods, which do not take the possible 
interaction between the country and treatment effect on health care utilization and 
health outcomes into account. Eight studies used more advanced statistical methods. 
Three of them used a fixed-effects modeling approach. Five studies explicitly took 
the hierarchical structure of the data into account, which leads to more appropriate 
estimates of population average results and associated standard errors. In this way, 
they help improve transferability of the published results.
Conclusion Based on this systematic review, we concluded that the uptake of more 
advanced statistical methods has been relatively slow, while simpler naïve methods 
are still routinely employed.
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8.1 INTRODUCTION 
Once regulatory approval has been obtained, pharmaceutical companies have to file 
for reimbursement of a drug in many different countries, each with their own specific 
regulations. In many countries, decision makers are in principle prepared to consider 
cost-effectiveness (CE) evidence from an international origin, provided that the data are 
adapted to their own country and setting. Such adaptations are often done with decision 
analytic models that are filled with country-specific epidemiological and economic data. 
Sometimes, the country of interest has participated in a CE study that was linked to a 
multinational clinical trial. In that case, there are patient-level data on cost-effectiveness. 
The challenge is to make the best use of this data to obtain a CE estimate that represents 
the country of interest best. This is the topic of this paper. 
Three simple methods are frequently used to calculate CE estimates from multinational 
randomized controlled trials (RCTs). The first simple method is to use only data from 
the country of interest. This method disregards all data collected in other countries.1 For 
example, in a trial with both Dutch and UK data, only the data from Dutch patients 
is included. The second method is to combine measurements of health care utilization 
and health outcomes from all  or a subset of  countries included in the RCT, which are 
then valued with weights (unit costs, utility values) from a single country (one-country 
valuation, see table 8.1). In our example, we count the number of hospital bed days in 
both countries, which are then multiplied with the Dutch costs for each bed day. In effect, 
all patients in the trial are treated as if they come from the country where the valuation 
comes from.2,3 The final simple method that is frequently used, combines measurements 
of resource utilization and health outcomes with country-specific values that only apply 
to that specific country (multi-country valuation). In our example, the hospital bed days 
used by Dutch patients are multiplied by the Dutch unit costs, and the bed days from UK 
patients are multiplied by the UK unit costs. These three methods do not take into account 
the interaction between country and treatment effect on health care utilization and health 
outcomes, an interaction that may be due to differences in for example epidemiology, 
practice patterns, payment systems and unit costs. In this sense, they might be called 
naïve.
More advanced statistical techniques have been developed, which do take this inter-
action into account. The first such method was introduced in 1998 by Willke and col-
leagues4, who proposed the use of two separate patient-level regression models, modeling 
both the direct effect of a treatment on costs and the indirect effect of treatment on costs 
through a change in health outcomes. They were soon followed by other studies proposing 
different fixed effect models with country-level covariates, for example Koopmanschap 
and colleagues and more recently Clarke and colleagues.5,6
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Health economic data from multinational RCTs naturally fall into the hierarchical struc-
ture of multiple micro units (patients) within macro units (countries). To take this structure 
into account, multilevel modeling (MLM) has been used.7-10 MLM uses a random intercept 
for each macro unit to model the hierarchical structure, but can be expanded to include a 
random slope or country-level (fixed) covariates. Hierarchical models lower the variability 
of country-specific CE results by borrowing strength from the other countries, and lead 
to more appropriate estimates and associated standard errors.11-14 In a recent review of 
available methods, Manca et al. conclude that these hierarchical models are the most 
appropriate tool to analyze CE alongside a multinational trial.15
In 2005, Barbieri and colleagues showed that one of the most frequently used methods 
of calculating CE was to combine country-specific measurements of health care utilization 
and weights from a single country.2 Because more advanced methods have been avail-
able for several years and their use has been recommended by the ISPOR Task Force on 
Transferability16, we aimed to review the experience with these methods. We examined 
recent multinational cost-effectiveness analyses (CEAs) that were conducted alongside 
large RCTs and described and summarized how these studies dealt with transferability 
aspects. In more detail, we aimed to answer the following questions:
- In what way have the researchers looked for evidence of heterogeneity between 
countries and (how) have heterogeneity issues been addressed?
- How have the researchers calculated trial-wide CE estimates?
- How have the researchers calculated country-specific CE estimates?
Table 8.1: Terminology used in classifying transferability issues of multinational trials.
Measurement
One-country (1C) Measurements from a single country are included
Subset Measurements from a subset of countries are included
All countries (All) Measurements from all countries in the RCT are included
Measurements in
 health care utilization E.g.: number of days in a hospital, number of pills taken 
 health outcomes E.g.: survival, number of exacerbations, number of events
Valuation
One-country valuation (1C) The weights used, come from a single country
Multi-country valuation (MC) Each country has their own weights
Unweighted (UW) No weights are used
Measurements in
 health care utilization Unit costs
 health outcomes Quality of life weights
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At all points in the texts where we say country, it could also be read as any other 
jurisdiction.
8.2 METHODS
8.2.1 Search strategy
A systematic electronic literature search was performed for CEAs alongside multinational 
RCTs, published in 2005 or after, written in English, Dutch or German. Because the more 
advanced statistical techniques can only be applied to large numbers of patient, the RCT 
in question needed to be conducted on at least 500 individual patients from at least 2 dif-
ferent countries. The CEA needed to be performed on individual patient-level data (IPD). 
We searched both PubMed and EMBase with combinations of the following key words 
(one from each category): 
- “multinational”, “international”, “multiple countries”, “multi-country” and/or “re-
gional”;
- “cost-effectiveness”; “cost-utility”; “costs”; “ICER” (incremental cost-effectiveness 
ratio) and/or “QALY” (quality adjusted life year);
- “trial” and/or “RCT”.
Additional studies were sought by hand searching the reference list of original research 
papers and review papers on transferability that were found in the initial literature search. 
As we only wanted to include CEAs, we excluded studies that did not measure both 
health care utilization and health outcomes. We excluded all (systematic) reviews, meta-
analyses, evaluations or overviews of treatments and programs, guidelines and recom-
mendations for performing an RCT. Decision analytic models, like Markov models, were 
also excluded. Studies where the primary source of data was not a randomized controlled 
trial (i.e. registries, cohort studies, longitudinal studies or non-randomized studies) and 
published abstracts were excluded.
8.2.2 Data extraction
For all the papers included in the study, we first looked for the name of the RCT, disease 
area, interventions, number of patients and number of countries. Next, we classified the 
studies based on whether the measurement of health care utilization and health outcomes 
was based on patients in just one country, a subset of countries or all countries. See 
table 8.1 for an overview of the terminology used. In addition, studies were classified by 
the source of the valuation for the health care utilization and the health outcomes: unit 
costs and utility values (quality of life weights). In a one-country valuation, an analyst ap-
plies the weights from one country to measurements from all countries. In a multi-country 
valuation, an analyst applies weights from each individual country to the quantities from 
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that same country. If the health outcomes reported are other than QALYs, no value sets 
are used for health outcomes and the valuation is classified as unweighted. Studies may 
be classified differently for the valuation of health care utilization and health outcomes.
We recorded if the study described trial-wide and country-specific CE results, how these 
were calculated and how heterogeneity between countries was measured. Finally, we 
classified the studies based on the statistical methods used to analyze the data. The studies 
were classified as a “simple method”, a “fixed effects regression model” or a “hierarchical 
regression model”.
8.3 RESULTS
8.3.1 Literature search
The literature search was performed on Jul 12th, 2013. We identified 821 potentially 
eligible papers, with 318 titles from PubMed and 716 from EMBase. Based on the title 
of the paper, we excluded 391 titles. Reasons for exclusion are listed in figure 8.1. Upon 
 
Figure 8.1: In- and exclusion of papers at various stages.
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Table 8.2: Papers included in study.
RCT on which study is based
First author and year Diseasea Name Interventions and 
number of patientsb
Number of 
countries
Lindgren 2005 17 Hypertension ASCOT-LLA Atorvastatin (n = 5,168)
Placebo (n = 5,137)
7
Lofdahl 2005 18 COPD - Budesonide (n = 257) 
Formoterol (n = 255) 
BFC (n = 254)
Placebo (n = 256)
15
Peeters 2005 19 Psoriasis vulgaris - Calipotriol / betamethasone 
dipropionate followed by 
calcipotriol alone (n = 249)
Tacalcitol (n = 252)
4
Pinto 2005 13 Acute MI ASSENT-3 N = 6,095
Heparin
Enoxaparin
Abciximab
26
Radeva 2005 20 Severe side 
effects after heart 
transplantation
- Everolimus 1.5 mg/day (n = 
209)
Everolimus 3.0 mg/day (n = 
211)
Azathioprine (n = 214)
14
Reed 2005 21 Acute MI VALIANT Valsartan (n = 4,909) 
Captopril (n = 4,909) 
Both (n = 4,855)
24
Weintraub 2005a 22 ACS CURE N = 12,562
Clopidogrel
Placebo
28
Weintraub 2005b 23 Acute MI EPHESUS N = 6,632
Eplerenone
Placebo
37
Briggs 2006 24 Asthma GOAL N = 3,416
FP alone 
SFC
44
Tonkin 2006 25 ACS LIPID Pravastatin (n = 4,470)
Placebo (n = 4,544)
2
Willan 2006 26 Parkinson’s 
Dementia 
Disease 
EXPRESS Rivastigmine (n = 362)
Placebo (n = 179)
12
Bachert 2007 27 ARC - (idem 
Canonica)
Grazax (n = 316)
Placebo (n = 318)
8
Canonica 2007 28 ARC - (idem 
Bachert)
Grazax (n = 316)
Placebo (n = 318)
8
Manca 2007 29 CHF ATLAS Low dose lisinopril (n = 1,596)
High dose lisinopril (n = 1,568)
19
Rutten-van Mölken 
2007 30
COPD - Roflumilast (n = 761)
Placebo (n = 753)
14
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reading the abstract, a further 351 titles were excluded for various reasons. Hand search-
ing resulted in six more studies. A total of 21 papers were included after reading in full 
(table 8.2).13,17-36
8.3.2 Characteristics of studies
The studies come from a variety of disease areas, with eight papers on cardiovascular 
diseases, four on lung diseases and three on allergies. The other studies investigated inter-
ventions in Parkinson’s disease, colon cancer, anesthesia, psoriasis vulgaris and hyperten-
sion. Three studies only used the trial data as a convenient data sample for exploring a 
new method of analysis.13,29,31 Because they used a particular clinical trial to demonstrate 
how CEAs can be performed alongside RCTs in order to obtain country-specific estimates 
of CE, they were included in the review. One of these papers did not reveal the original 
RCT nor disease area, “so as not to conflict with previous publications”.31 The minimum 
number of countries in an RCT was two in the LIPID trial in patients with a history of acute 
coronary syndromes25; the maximum was 48 in the ExTRACT TIMI 25 study in patient with 
a myocardial infarction.32 This last study also had the highest number of patients, namely 
20,506. The lowest number of patients was 501 in the trial discussed by Peeters et al. in 
psoriasis vulgaris.19
Table 8.2: Papers included in study. (Continued)
RCT on which study is based
First author and year Diseasea Name Interventions and 
number of patientsb
Number of 
countries
Willan 2008 31 ? ? “T” (n = 680)
“S” (n = 676)
14
Marcoff 2009 32 ST-segment 
elevation MI 
ExTRACT–
TIMI 25
N = 20,506
Enoxaparin
Unfractionated heparin
48
Briggs 2010 33 COPD TORCH Salmeterol (n = 1,521)
FP (n = 1,534)
SFC (n = 1,533)
Placebo (n = 1,524).
42
Gomes 2010 34 Anaesthesia for 
carotid surgery
GALA General Anaesthetic (n = 1,753)
Local infiltration and cervical 
plexus nerve block (n = 1,773)
24
Lorgelly 2010 35 CHF CORONA Rosuvastatin (n = 2,514)
Placebo (n = 2,497)
21
Rogkakou 2011 36 Persistent rhinitis XPERT Levocetirizine (n = 278)
Placebo (n = 237)
5
a MI = Myocardial infarction, ARC = Allergic rhinoconjunctivitis, ACS = Acute Coronary Syndromes, CHF = 
Chronic heart failure, COPD = Chronic obstructive pulmonary disease.
b Number of patients per arm when available (“n”) or total number of patients in the trial (“N”). 5fu/lv = 
5-fluorouracil/leucovorin, BFC = Combination of budesonide / formoterol, FP = Fluticasone propionate, SFC = 
Combination of Salmeterol / Fluticasone propionate. 
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8.3.3 Classification of studies
Measurement: resource use and health outcomes
Table 8.3 classifies the studies according to the sample of countries from which data on 
resource use and health outcomes were obtained. Most studies based both health care 
utilization and health outcomes on information from all countries. None of the studies 
was based on data from only one country, but three based their analysis on a subset of 
countries.[27,29,33[ Bachert et al. only used data from the five North European countries, out 
of eight countries included in the RCT.27 The study by Manca and colleagues excluded two 
unnamed countries with a very low number of patients and/or an extremely unequal al-
location of patients between the two treatment groups in the trial.29 Briggs and colleagues 
based their results on 21 of the 42 participating countries for which validated translations 
of the EuroQol-5D (EQ-5D) instrument were available. The CE analysis was therefore 
limited to 70% of the trial participants.33 Weintraub et al. used all patients for their health 
outcomes, but only measures utility weights in patients from English speaking countries. 
For other patients, the average utility by treatment arm from the English speaking countries 
was used to estimate utility.23 Although theoretically possible, none of the studies based 
the health care utilization on a different selection of countries than the health outcomes. 
Valuation: unit costs and utility value sets
Table 8.3 also reports the valuation of health care utilization (unit costs) and health 
outcomes (utility value sets) for each of the studies. Twelve studies used a one-country 
valuation for health care utilization13,17-19,22,23,25,26,30,32,34,35, six a multi-country valua-
tion.20,21,24,27,28,33 In 3 studies this was unclear.29,31,36 In two studies this was because their 
focus was more on the analytical methodology, than on how data was gathered and the 
resulting CEA.29,31 In the study by Rogkakou et al. it was not stated if every country has 
their own unit cost vector or if only one unit cost vector is used.36
In twelve of the studies, health outcomes were unweighted. The health outcomes in 
these papers were, for example, the number of avoided exacerbations18,30, major car-
diovascular events35, patient-level survival32 and event-free-days.34 None of the studies 
used a multi-country valuation to obtain utilities, while four studies used a one-country 
valuation. All four of these studies used the recommended tariffs for the EQ 5D for the 
United Kingdom (UK)37,38, although only two studies calculated country-specific CE results 
for the UK. Bachert et al. used these UK tariffs for calculating country-specific results for 
the UK, Germany, The Netherlands, Sweden, Denmark, Norway and Finland.27 Willan and 
colleagues applied the UK tariffs on data from all countries to calculate the CE results for 
the UK, and, in a separate calculation, applied the Canadian tariffs when calculating CE 
results for Canada.26 Canonica and colleagues used the UK tariffs to calculate CE results 
for Spain, France, Italy and Austria.28 The study by Briggs and colleagues used the UK 
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weights to calculate CE results for four groups of countries called regions, of which one, 
Western Europe, included the UK.33 In five studies, the valuation of health outcomes was 
not apparent from the text. In three studies this was because of their methodological fo-
cus.13,29,31 In the study by Briggs et al., the authors applied a mapping algorithm to mat the 
IPD on the Asthma Quality of Life Questionnaire to the EQ-5D in order to obtain a utility 
estimate.24 Since no further information about this algorithm was given and no reference 
could be found, it is unknown whether it is transferable across countries. In the study by 
Weintraub et al. the source of the utility valuation was not mentioned in the text.23 
The valuation of the health care utilization and health outcomes was not consistent 
in three studies. They used a one-country valuation for health outcomes, the UK EQ-5D 
tariffs discussed above, and a multi-country valuation for health care utilization: unit costs 
from each individual country.27,28,33
8.3.4 Trial-wide and country-specific CE estimates
Thirteen studies calculated a trial-wide CE estimate, of which three also calculated coun-
try-specific CE estimates (table 8.3).29,31,34 Briggs and colleagues calculated both trial-wide 
CE results, and CE results for four regions.33 The remaining eight studies calculated only 
country-specific CE estimates. Two studies extrapolated the results beyond the countries 
included in the original trial.27,28 They did this by applying country-specific unit costs 
of countries not participating in the trial to trial-wide resource use. However, as was 
mentioned before, these studies calculated QALYs by using the same utility value set (UK) 
for all countries.27,28 Both Lindgren and colleagues and Willan and colleagues combined 
all available data and applied one-country valuation for health care utilization and health 
outcomes.[17,26[ By performing the procedure twice, once using unit costs from one country 
and once from the other country, they could calculate country-specific results for two 
countries The study by Marcoff and colleagues mentioned estimates of country-specific CE 
in an online appendix, but these estimates could not be found in the appendix.32
Differences between country-specific CE results
When the same study publishes results for more than one country, it is informative to 
compare these results. Five studies calculated CE results for more than one country25-29 
and one for four regions.33 
Willan and colleagues found that the incremental costs were positive in the Cana-
dian setting and negative in the UK setting (intervention was dominant).26 However, the 
confidence intervals were very wide and both symmetrically straddle the origin. They 
therefore concluded that there is very little evidence of a difference in costs between the 
two countries. 
The studies by Bachert et al. and Canonica et al. are based on the same RCT about 
allergic rhinoconjunctivitis. Bachert and colleagues concluded that the ICER was similar 
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in every country, ranging between € 13,000 and € 18,000 per QALY gained.27 Possible 
reasons for the differences in CE results given by the authors were differences in discount 
rates, unit costs and treatment costs. Canonica and colleagues calculated ICERs ranging 
from € 14,000 to € 22,000. They did not list potential reasons for these differences.28 Nei-
ther of the two studies commented on the difference in ICERs between the two studies, nor 
on the difference in intervention costs, which was € 1,200 for all countries in Canonica et 
al. versus € 1,500 for all countries in Bachert et al.27,28
In the study by Manca and colleagues there are large differences in outcomes between 
the 17 countries.29 Incremental costs ranged from approximately -UK£ 200 to +UK£ 400 
and mean incremental survival ranged from approximately -100 days to +100 days. The 
size of the confidence intervals also differed significantly between the countries, as did the 
shape of the scatter plot in the CE planes and the CE acceptability curves. 
Briggs and colleagues calculated regional ICERs for two treatment comparisons in 
COPD.33 In the first comparison, the region-specific ICERs ranged from US$ 21,500 to 
US$ 77,100, with a trial-wide estimate of US$ 43,600. The second comparison showed a 
range of region-specific ICERs from US$ 13,200 to US$ 46,300, with a trial-wide estimate 
of US$ 26,500. In both comparisons, the ICER in the USA was by far the highest estimate. 
The authors mentioned in their discussion that this reflects the higher unit costs in the 
USA, although it was also clear from the results that the incremental QALYs were also 
lowest in the USA, which would also have contributed. 
8.3.5 Heterogeneity
Differences in CE results between countries can be partly explained by heterogeneity 
between the countries, which is the part of the variation, in addition to that accounted 
for by chance, that can be explained by local characteristics, such as average age or 
cost levels.39 Only one of the studies formally tested for heterogeneity before calculating 
CE results: Briggs and colleagues used joint tests of significance for treatment-by-region 
interactions.33,40 The only evidence of heterogeneity they found was in the costs of study 
medication. They made a post-hoc comparison of the combined estimate with region-
specific estimates based on dividing the dataset in region-specific subsets. They could not 
reject homogeneity across regions, but the authors acknowledge that such an approach 
suffers from a lack of power, making negative test results difficult to interpret. 
Six studies did not discuss the possibility of heterogeneity between countries at 
all.19,20,25,28,35,36 Two studies addressed heterogeneity by performing subgroup analyses. 
Löfdahl and colleagues conducted a subgroup-analysis to investigate differences between 
European and non-European countries.18 They assumed that healthcare delivery and uti-
lization is somewhat more homogenous within Europe, compared with other continents. 
Gomes and colleagues performed a similar subgroup-analysis. They analyzed patients 
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from the UK and patients not from the UK, separately.34 This did not change the CE results 
significantly.
Lindgren and colleagues expected no problems with averaging resource use across 
patients unless resource consumption differed markedly between countries. They did not 
detect such problems and concluded that combining countries is not likely to have biased 
their analyses. Reed and colleagues recognized that there are differences in practice pat-
terns and unit costs between countries, but argued that the randomized design of the 
RCT would not bias the findings in either direction.21 Weintraub and colleagues (a) stated 
that their costing approach, combining country-specific measurements of resource use 
with one-country valuation, does not fully account for possible differences in treatment 
practices and resource use between countries or health care systems.22 However, they felt 
their method yielded unbiased results and should even reduce “unwanted variability”. 
Weintraub and colleagues (b) stated that it is not possible to adequately account for varia-
tion in costs across countries, but using country-specific costs should have little effect 
on their results. Bachert and colleagues justified not checking for heterogeneity due to 
(assumed) “similarities in costs and healthcare systems” for North European countries.27 
Rutten-van Mölken and colleagues assumed that the relative treatment effect on outcome, 
the prevention of COPD exacerbations, is generalizable across countries although no 
test was done.30 They acknowledged that this approach does not account for many of the 
differences between countries that may affect CE, since differences between countries 
in relative prices of resources may lead to a different mix of resource use. For example, 
in countries where specialist contacts are relatively expensive compared to GP contact, 
patients may be referred to specialists less often. Applying a single set of unit costs to 
multiple countries ignores the presence of such substitution effects. Briggs and colleagues 
used an indicator variable for the country of interest, the UK, in two of the estimated 
regression models. The coefficient showed that the resource use needed for the treatment 
of an asthma exacerbation was relatively low in the UK.24
Finally, there were five studies explicitly taking differences between countries into ac-
count in the analysis, as explained in the next section.1,13,29,31,32 However, no formal test of 
heterogeneity was performed beforehand.
8.3.6 Statistical methods
Thirteen studies used relatively simple methods to calculate trial- and country-specific CE 
results; while eight studies used more advanced statistical methods. Of these, three studies 
used a fixed effects modeling approach and the remaining five studies explicitly took the 
hierarchical structure of the data into account.
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Simple methods
Thirteen studies calculated a simple country-specific patient-level average of the resource 
use and health outcomes. The resource use was then multiplied by either the same unit 
costs for all countries (one-country valuation), or by country-specific unit costs (multi-
country valuation). If applicable, the health outcomes were multiplied by the utility value 
sets, which could also be the same for all countries, or country-specific. Dividing the 
resulting mean country-specific costs per patient by the mean country-specific health 
outcomes per patient led to country-specific CE estimates. Eight studies used a one-
country valuation17,18,20,22,23,25,30,35, two a multi-country valuation19,21 and two combined a 
multi-country valuation for health care utilization with a one-country valuation for health 
outcomes.27,28 The method used by Rogkakou and colleagues is unknown, as the method 
of valuation of health care utilization is unknown.36
Fixed effects models
Briggs and colleagues used a series of statistical regression models for costs and health- 
related quality of life weights in their 2006 study, including an adjustment to the country 
of interest via an indicator variable.24 In their 2010 study, Briggs and colleagues used a 
Weibull survival model and multivariate patient-level regression models for costs and EQ-
5D preference data.33 Explanatory variables included patient-level data and dummies for 
each region. Both studies estimated the models for costs and health outcomes separately. 
These models were then used to calculate incremental costs, incremental health outcomes 
and CE results. Gomes and colleagues explicitly modeled the correlation between costs 
and health outcomes, by estimating a system of regressions and assuming a correlation 
between the error terms. This is called SUR modeling, or Seemingly Unrelated Regres-
sion.34 No specific adjustment for country was made.
Hierarchical models
Five studies took the hierarchical structure of health care data explicitly into ac-
count.13,26,29,31,32 Despite the use of many different names –multilevel modeling with ran-
dom intercepts, empirical Bayesian shrinkage estimation, bivariate hierarchical models- all 
these methods are variations of multilevel modelling (MLM).7 All models were analyzed 
using Bayesian methods, although MLM can be estimated using Frequentist methods.8,9,11
The studies by Pinto and colleagues and Willan and colleagues calculated trial-wide 
CE results by including a random intercept for each country.13,26 They used two normal 
distributions for both costs and effects. Marcoff and colleagues extended this method by 
also including a random slope for each country. They analyzed the incremental net health 
and monetary benefits.32 
There was no correlation modeled between costs and effects in any of these three stud-
ies. In contrast, both Manca and colleagues and Willan and colleagues extended the 
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hierarchical model by explicitly linking costs and effects. They both used flexible specifi-
cations which treat the trial-wide mean costs and effects as fixed effects, but differ in the 
specification of the assumed country-specific random effects. The model of Manca et al. 
was based on O’Hagan et al.29,41 and assumed a bivariate normal (BVN) distribution to 
model the interaction. Willan et al. extended the model by Nixon and Thompson10, which 
does not necessarily assume a normal distribution, but may accommodate for example 
skewed distributions when necessary.31 Costs and effects do not need to have the same 
distribution. In both methods, costs and effects are correlated across equations in the same 
way. Both models allow extension of the hierarchical structure by including explanatory 
variables at the country level, on top of patient level covariates.
8.4 DISCUSSION
In this paper, we looked at CEAs that were based on recent, large multinational RCTs. We 
categorized the studies by the methods used to calculate trial-wide and country-specific 
cost-effectiveness. What we found was that simple, naïve methods were still frequently 
used. Within these studies one-country valuation of the healthcare utilization of patients 
from multiple countries was the most applied method. Each of the simple methods has its 
own advantages and disadvantages. An analysis that only uses the data from the country of 
interest, provides an unbiased country-specific estimator, but ignores all the information 
we have about the other countries. In addition, it requires enough patients within the coun-
try of interest to counter the risk of low statistical power. This defeats the purpose of doing 
a multinational RCT. A one-country valuation that uses one set of unit costs multiplied 
with trial-wide health care utilization has the advantage of keeping the statistical power. 
When different sets of unit costs from different countries are repeatedly combined with 
trial-wide resource use, we get insight in the influence of different absolute and relative 
prices on CE. However, differences in treatment patterns between countries are ignored 
and applying the unit costs from one country to trial-wide resource use could confound 
‘price effects’ with ‘country effects’.14 A multi-country valuation accounts for differences 
between countries in both unit costs (or utility value sets) and treatment patterns. When 
averaging over all countries, the resulting point estimate is an accurate representation of 
the average in the trial, but it is difficult to interpret and generalize, as it is not representa-
tive for any of the countries.
Regardless of whether the investigator is interested in trial-wide or country-specific 
results, not taking the interaction between country and treatment effect on health care 
utilization and health outcomes into account may lead to wrong conclusions. Several 
models have been proposed that take this interaction into account. They can be grouped 
into fixed effects models and hierarchical models. The key advantage is that they improve 
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statistical efficiency by ‘borrowing’ information from all available data in the estimation of 
the difference between treatments for an individual country.
The effect of the interaction between country and treatment on costs, due to the differ-
ences in for example epidemiology, practice patterns and prices, is widely recognized.42-44 
At the same time, most models assume that the clinical effectiveness does not differ greatly 
between countries. However, many factors could potentially affect the between-location 
variability of health outcomes, such as the availability of health care services, local treat-
ment guidelines, and differences in quality of health care.29 Because of this, the between-
country variability in differential health outcomes can be even greater than the variability 
in differential costs.13 Allowing for variation across countries in both costs and health 
outcomes is, in our view, a preferred strategy.
In fixed effects models, applied by 3 studies in this review, country-level covariates are 
used to model the country-specific differences. These covariates may just be a series of 
simple country-dummies, but can also measure differences more explicitly with variables 
that measure differences in epidemiology, medical practice and economic factors. The 
precise formulation of the model can differ widely, ranging in this review from simple 
ordinary least squares regression and survival analysis to SUR modeling. Fixed effects 
models are typically included to ”control for” differences across countries. Because of 
this, Drummond et al. argue that they might not be adequate to produce country-specific 
results.16
Hierarchical modeling, applied by 5 studies included in this review, lowers the vari-
ability of the country-specific CE results, by borrowing strength from other countries. 
Compared to the observed difference in country means, Pinto et al. achieved a 21–59 
per cent reduction in average standard error of the difference. For one of the included 
countries, achieving this gain in precision using only country-specific data would have 
required more than twice as many patients.13 Hierarchical models also lead to more ap-
propriate estimates of population average results and associated standard errors compared 
to other methods.11,12,14 For example, Grieve et al. modeled both length of stay and total 
costs of stroke admissions, in an observational study across 11 countries. They compared 
MLM with simple OLS and showed that the OLS analysis severely overestimated the preci-
sion of centre-level associations and made incorrect inferences.11 In particular, the OLS 
analyses found that centre-level variables were associated with resource use, whereas the 
MLM analysis showed that, once the hierarchical nature of the data was recognized, none 
of these variables predicted resource use.
Manca et al. have recently compared advanced statistical methods for CE estimation, 
alongside multinational trials.15 They conclude that Bayesian hierarchical models, using 
both patient- and country-level information, are the most appropriate tool to analyze 
CE alongside a multinational trial. This recommendation is based on the flexibility in 
facilitating the inclusion of patient- and cluster-level explanatory variables, and the ability 
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to accommodate distributions when costs and/or effects are not normally distributed. The 
Bayesian methodology allows direct interpretation of the country-specific (posterior) mean 
estimates and it provides probability statements regarding the CE in any given country.
In MLM, the country-specific estimates are latent variables, which must be quantified 
rather than estimated. This is achieved using shrinkage estimation, which is a weighted 
sum of the country-specific observed difference (one-country analysis) and the estimates 
provided by the MLM trial-wide estimate. It implements the idea that although different, 
country-specific data might share some degree of similarity and therefore contain informa-
tion that is usable for all countries. The term ‘shrinkage’ reflects that the country-specific 
estimate for all countries will be closer (‘shrunken’) to the combined estimate, than the 
observed difference is. The degree of shrinkage depends on the between- and within-
country variance, with more shrinkage occurring when the within-country variability is 
greater relative to the between-country variability.
In addition to the statistical advantages, Grieve and colleagues propose that hierarchi-
cal models may be used to assist in the design of multinational RCTs, which often only 
measure costs for a subsample of centers.11 The choice of centers to collect costs is usually 
based on pragmatic grounds, but the factors identified as being associated with total costs 
from hierarchical models could be used to choose where best to measure costs. As an 
example, if the level of health care spending as a percentage of GDP is associated with 
total or incremental costs, centers could be selected which were broadly representative of 
countries with high, medium or low levels of spending on health care.11 
A limitation to MLM is that it is assumed that countries are “exchangeable”. This means 
that there are no a priori reasons to assume that one country has higher or lower health 
outcomes or costs, and can be represented by the same variance across all countries. 
Since MLM are often used to explore these differences, making this a priori assumption 
may be unreasonable.16 Adding fixed effects on country-level may solve this.45
Despite the availability of these fixed effects and hierarchical models and demonstrated 
increased precision of the estimates11-15, these newer methods have not yet been applied 
on a wide scale amongst researchers, nor have they replaced the simpler, naïve methods. 
Studies that did use more advanced methods were often studies with a theoretical, statisti-
cal point of view focused on the (illustration of) methods.One of the reasons for not using 
the advanced models might be found in the relative complexity. The resulting lack of 
transparency may limit their use in decision making.46 Especially the hierarchical models 
require an advanced knowledge of (Bayesian) statistics and programming. Moreover, if 
these models demonstrate a difference in effectiveness of a treatment between countries, 
it may be very problematic to include this in a reimbursement dossier, especially for the 
country in which results differ from the drug’s label claim.
Another drawback of the more advanced methods is the need of a large number of 
patients per country. Because one of our inclusion criteria was a minimum number of 500 
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patients, all studies in this review could have applied the more advanced methods. This 
is illustrated by the study of Willan et al.26, which had a total of 541 patients and applied 
hierarchical models. The smallest study in the sample, the one by Tonkin25, applied a 
simple method, but still had more patients in each arm than Willan in the placebo arm 
(179).26 On the other hand, one of the largest studies, the study by Reed et al. with more 
than 14,500 patients in three arms, was analyzed by a simple method.21 It is unclear why 
this dataset was not analyzed by a more advanced method and whether it would have 
changed the results. In any case it would have increase the precision of the estimates. 
Unfamiliarity with the methods may be a reason why more advanced methods are not 
used. Although the ISPOR Good Research Practices Task Force on transferability recom-
mends the advanced methods16, guidance on the analysis of IPD from multinational trials, 
and the calculation of country-specific CE estimates, in national guidelines is scarce.47 The 
Canadian pharmacoeconomic (PE) guidelines mention the advanced methods discussed 
in this paper as a possible option to analyze IPD from multinational trials, but do not 
explicitly recommend them.48 The other PE guidelines and recommendations found on the 
ISPOR website do not suggest way to calculate country-specific CE estimates from multi-
national RCTs.47 Multilevel models may not be necessary when only a few countries are 
included in a trial. Drummond et al. suggest 4 or 5 as a lower bound, suggesting that all 
RCTs in this review but one25 could have been be analyzed by more advanced methods.16 
Heterogeneity between countries can be tested formally, which was done in only one 
study, based on the method proposed by Cook and colleagues.33,40 Fixed effects models 
typically contain several interaction terms to investigate whether the treatments differ 
between countries. If these interaction terms are statistically significant, there is hetero-
geneity between the countries. On the other hand, if they are not statistically significant, 
and there is sufficient statistical power, one may conclude that the effect of the treatment 
is not different between countries. In this case, the treatment effect may best be estimated 
for all countries together.40 Unfortunately, low power within a single country is a common 
problem in multinational trials. One way of handling this problem is using a higher level 
of significance, or combining several countries with similar characteristics.53
Another formal test, based on the likelihood ratio, was proposed by Gail and Simon.54 
They distinguish between qualitative interaction, which occurs when the treatment effect 
is positive for the patients in some countries and negative for those in other countries, 
and quantitative interaction, which occurs when the magnitude but not the direction of 
treatment effects varies. Other examples of formal tests for qualitative interactions include 
the range test proposed by Piantadosi and Gail, and a simple test based on simultaneous 
confidence intervals proposed by Pan and Wolfe.55,56 
When policy makers are judging the results of a study in one country for applicability 
in their own country, one of the first things they compare is the characteristics of the study 
population. This information makes it easier to interpret CE results and to determine to 
195
8 
what extent the results are valid for the target population in their country. However, only 
ten of the 21 papers produced a table showing demographic characteristics of patients 
in the original trial.20,22,23,25,27,28,30,32,33,35 Even if this information is included in the clini-
cal paper on the same study, it is relevant for policy makers to repeat this information 
in the cost-effectiveness paper.57 Other important information for policy makers is the 
valuation of health care utilization. Only eight papers specified the unit costs used in the 
study.17,18,22,26-28,30,34 Some studies did not list total health care utilization and/or health out-
comes by treatment arm, which is considered to be basic information for a CEA.18,21,26-28,31
Calculating country-specific CE results for many countries may lead to challenges in 
presentation. This is apparent in the study by Manca and colleagues, which shows results 
for 17 countries.29 They improved the readability of the results by choosing to show 95% 
confidence ellipses and CE acceptability curves, for a selection of countries. They also 
refrained from presenting point estimates. However, if point estimates and results for all 
countries are of primary importance, these may not be viable solutions and other ways of 
improving readability need to be explored.
8.5 CONCLUSION
Several advanced statistical techniques are available to calculate country-specific CE 
results from multinational trials. These methods take the interaction between country and 
treatment effect on health and health care utilization into account. Hierarchical models 
also lower variability of the country-specific CE results and lead to more appropriate 
estimates of population average results and associated standard errors. However, they 
have not been used on a wide scale yet, while simpler, naïve methods are still routinely 
employed. This should change in future.
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9.1 INTRODUCTION
After introducing the (simple) concept of health technology assessment (HTA) in chapter 1, 
chapter 2 showed a practical application of health economic (HE) modelling, by calculat-
ing the cost-effectiveness (CE) of the reimbursement of aids in smoking-cessation. The 
following chapters explored several types of differences, and how these differences may 
be handled. Chapter 3 discussed differences between patients, which can be attributed to 
patient characteristics, called patient heterogeneity. Chapters 4 and 5 discussed different 
data sources, and how they can be combined using meta-analysis. Chapters 6, 7 and 8 ex-
plored issues that occur in decision making, when dealing with several different countries. 
These issues fall within the field of health-economics called transferability, which tries to 
tackle these differences and provide useful information for the decision maker. 
9.2 PRACTICAL APPLICATION: SMOKING CESSATION
Chapter 2 explored the long term societal effects of reimbursement of smoking cessation 
support (SCS). We found that reimbursement led to more successful quitters and a gain in 
life years and QALYs. Accounting for overhead, administration costs and the costs of SCS, 
these health gains could be obtained at relatively low cost, even when including costs in 
life years gained. Hence, reimbursement of SCS seems to be cost-effective in the long term 
from a health care perspective.
The discussion on the reimbursement of smoking cessation has known many stages in 
The Netherlands. At the moment the study was performed, during the summer of 2008, 
SCS was only partly reimbursed and pharmacological SCS was not reimbursed at all. To-
bacco control policy in The Netherlands at that time aimed to reduce smoking prevalence 
to 20% in 2010.1 Smoking prevalence was declining, but additional efforts were required 
to reach the goal. In 2007 28% of the Dutch population still smoked.2 The health insur-
ance board (CVZ) had advised the Dutch Ministry of Health to reimburse an integrated 
smoking cessation programme, consisting of a combination of behavioural counselling 
and pharmacotherapy.3 
A randomized controlled trial (RCT) was performed to investigate the effects of such 
a reimbursement policy in the Dutch region of Friesland in May 2002.4,5 This study was 
funded by the Dutch Ministry of Health and the then Minister of Health, Mrs. Borst, 
expressed a willingness to start reimbursement, once effectiveness was shown. The trial 
found that the number of participants using SCS was higher in the intervention group than 
in the control group.4 It also showed that the intervention would be cost-effective, in the 
short term. Unfortunately, when the results were presented, the new Minister of Health, 
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Mr. Hoogervorst, had to reduce costs in the basic insured package. He decided not to 
reimburse SCS in 2003.
A pilot study investigated the feasibility of large-scale implementation of reimbursement 
in The Netherlands in 2008. This so-called Agis Study, performed in the Dutch province 
of Utrecht, looked in particular to the availability and accessibility of care, and attain-
ability of the program.6 At the end of the test period, a third of respondents said they had 
stopped smoking. Based on insurance declarations, the estimated costs of nation-wide 
SCS reimbursement are between € 14.0 en € 22.7 million. Expanding on this study, Over 
et al. concluded that reimbursement of SCS produced overall health gains, but did not 
reduce health disparities between different socioeconomic groups.7
The goal to reduce smoking prevalence to 20% in 2010 was not met. In 2011, SCS 
programs were reimbursed leading to a much higher use of SCS than in the years before 
and an unprecedented drop in smokers from 27.2% to 24.7%. As a recent population 
study concluded, full health insurance coverage for smoking cessation treatment in The 
Netherlands was accompanied by a significant increase in the number of (dispensed) 
prescriptions of stop-smoking medication and a decrease in smoking prevalence.8 In 
2012, this was changed again, with a stop of the reimbursement of nicotine replacement 
therapies (NRTs) and pharmacotherapy. Behavioural counselling was still reimbursed. 
This immediately led to a drop in the use of effective SCS, a drop in the number of SCS 
prescriptions of 21.6 per 1,000 smokers, a rise in smoking prevalence by 1.2% and pres-
sure on political actors by GPs and medical specialists to reinstate reimbursement.8-11 As 
of 2013, NRTs and pharmacotherapies are now reimbursed for a maximum of one attempt 
per calendar year, provided they are accompanied by behavioural counselling. 
Public health, personal health and health-economic arguments all point in the direction 
that SCS should be reimbursed. This includes the results in chapters 2 and 6. In chapter 
2, the long-term incremental CE ratio of the reimbursement for NRT, bupropion and 
behavioural counselling, compared to no reimbursement, is below € 16,000 per QALY 
gained. In chapter 6, varenicline to aid in smoking cessation dominates buproprion in The 
Netherlands. However, these arguments do not seem to be enough to keep reimbursement 
of SCS in place.
The choice whether SCS are reimbursed in The Netherlands seems to be more a political 
debate on “life style” medications. This also includes contraceptives, erectile dysfunction 
medication and cholesterol lowering medication, for which reimbursement also changes 
from year to year. This discussion centers on the amount of responsibility that can be 
laid at the feet of Dutch citizens for their own life style and its consequences. Another 
issue working against the health(-economic) arguments, seems to be the influence of the 
tobacco industry lobby in both The Netherlands12-14 and wider Europe.15,16
A separate methodological issue that is addressed in chapter 2 is the inclusion of costs 
in life-years gained. In the extra life years gained by successful quitters, additional costs 
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are generated for diseases unrelated to smoking, such as dementia or hip fractures in 
old age.17 This makes CE estimates both more conservative and more accurate. In most 
CE-studies published these costs are not taken into account (for example chapter 3), even 
though the inclusion of these costs is now facilitated by an online tool called Practical 
Application to Include Disease costs (PAID).18
9.3 DIFFERENT PATIENTS
Chapter 3 discussed the difference between patient heterogeneity and parameter uncer-
tainty. We compared four ways of dealing with heterogeneity and showed that they led to 
widely different results in CE. Three of the methods can all be viable options, depending 
on the decision makers’ information need. When little or no heterogeneity is expected, 
or when it is not expected to influence the CE results, disregarding heterogeneity may be 
correct. Subgroup analyses may inform policy decisions on each subgroup, as long as they 
are well defined and the characteristics of the cohort that define a subgroup truly represent 
the patients within that subgroup. Despite the necessary calculation time, the Double 
Loop PSA is a viable alternative which leads to better results and better policy decisions, 
when accounting for heterogeneity in a Markov model.
The final method draws from all available distributions at the same time: probabil-
ity distributions that reflect parameter uncertainty and frequency distributions of patient 
characteristics. The expected outcome of this analysis reflects parameter uncertainty and 
patient heterogeneity in a heterogeneous population, but ignores the fundamental differ-
ence between the two. We have shown that this Single Loop PSA should not be used in CE 
research. It disregards the fundamental differences between heterogeneity and sampling 
uncertainty and overestimates uncertainty as a result.
9.4 DIFFERENT DATA SOURCES
In chapters 4 and 5, we discussed the combining of different sources of information using 
meta-analysis. In chapter 4 we compared four methods of direct meta-analysis and found 
that three of these methods lead to comparable HE outcomes, while the Bayesian random 
effects methods tends to overestimate uncertainty. Based on this study, we recommended 
using the frequentist random effects method proposed by DerSimonian and Laird as the 
preferred method of meta-analysis.19 It automatically reduces to a fixed effects model in 
the absence of heterogeneity. Compared to the Bayesian methods it is easier to implement 
and more easily understood by physicians and policy makers who will be using the results. 
In chapter 5 we compared four methods of network meta-analysis. The method proposed 
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by Puhan and the Bayesian fixed effects generalized fixed effects model are preferred.20-22 
The method proposed by Song has slightly less preferable characteristics, while the Bayes-
ian random effects generalized model overestimated uncertainty and had shown large 
biases and absolute deviations.
One of the major issues in meta-analysis is how different sources of evidence can be 
combined. This is a particular issue with a program like ‘expensive drugs’, where only 
little evidence is available at the start of conditional reimbursement, and usually the only 
additional evidence available after the conditional reimbursement period is evidence from 
use in real world observational studies. Since the decision to continue reimbursement 
can have a major impact, both in a financial and medical sense, it should be based on all 
available evidence.
For many researchers, the randomized controlled trial (RCT) is the gold standard, 
because of its rigorous evaluation design. This would indicate that CE results should 
be based on RCTs alone. However, the strict protocols in RCTs do not generally reflect 
clinical practice. Because of this, other researchers may prefer observational evidence 
alone. However, due the lack of a rigorous design, there is a possibility that the efficacy 
outcomes cannot be directly interpreted, and might be biased. In either situation, valuable 
information may be left unused.
If it is decided that both sources of evidence can be combined, a weight needs to be 
defined to combine all sources of evidence. Either one of the sources may get a relatively 
higher weight than other evidence. In the hierarchy of evidence framework, an RCT pro-
duces stronger evidence than an observational study.23 If the weighing of the evidence in 
a meta-analysis would be based on this hierarchy, the strength of evidence from observa-
tional studies would be graded relatively low compared to RCTs. However, the results of 
well-designed observational studies do not necessarily contain bias in the magnitude of 
the effects of treatment.24 This would argue for the same weights for observational stud-
ies and RCTs, provided the observational studies are well-designed. In some instances, 
observational studies may provide better evidence, for example in the case of rare events. 
Moreover, the result of an RCT may not be applicable at all, for example if the patients 
are highly selected or motivated relative to the population of interest.25 In these cases, one 
might argue for giving observational studies a higher weight than RCTs.
Even if the results of the real life outcomes study would be treated the same as the 
results of an RCT, a meta-analysis of the evidence is still likely to be driven by trial results, 
since the uncertainty around the trial-based estimates of the treatment effect is likely to be 
smaller due to the generally homogeneous nature of included patients. Moreover multiple 
RCTs are often available, compared to one, perhaps relatively small, real life outcomes 
study. In order to take other issues than study design into account, the GRADE Working 
Group proposed a systematic and explicit method of making judgments on the quality of 
evidence under consideration.25 Next to study design, the other three key elements they 
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named in reviewing available evidence are study quality, consistency and directness. On 
each of these elements, each source of evidence is graded High, Moderate, Low or Very 
Low. Using this grading system, different sources may be combined qualitatively, ranking 
the trade-offs between health benefits and harms before considering costs. This methodol-
ogy can provide insight in the way different types of evidence can be weighted.
Once an appropriate weight has been determined, this weight will have to be incorpo-
rated into the meta-analysis. As most of the frequentist methods are based on the Inverse-
Variance (IV) approach, where studies with a low standard error get a larger weight, it 
is logical to apply the weights directly to the standard error of the weights. This also 
works for the Bayesian methods, which use standard errors as a proxy for the strength of 
evidence, except when the link function is discrete (binomial, multinomial, Dirichlet). In 
this case, the weights can be applied directly to both the number of patients in the trial 
and the number of “successes” (transitions, events, etc). 
The question remains how big a certain weight should be. Since every choice of weight 
would be arbitrary, it is recommended to perform the same analysis several times, for 
different types of weights and comparing the results.26 In addition, it is recommended not 
using higher weights for sources of evidence with high quality, but using lower weights 
for sources of evidence with low quality instead.26 Artificially giving a trial a higher weight 
would imply a larger number of patients than are really available. In essence, this means 
“inventing patients” and artificially “adding certainty” about the newly synthesized pa-
rameter. On the other hand, giving a trial a lower weight as is recommended would imply 
fewer patients than were really there, thus reflecting the extra uncertainty due to the 
quality of evidence. 
This issue of combining different sources of evidence is still being discussed. In open 
debates at HTA conferences, for example during the ISPOR 16th Annual European Meet-
ing (2-6 Nov 2013, Dublin), it is now being suggested that these two types of data should 
not be combined at all. The reasoning is that both forms of evidence provide information 
for two different policy questions: the RCT on whether the new intervention is at all better 
than what it is compared with (efficacy), and the real life data whether this better efficacy 
translates to better results in the real world. Combining these two forms of information is 
deemed unlikely to answer either question.
9.5 DIFFERENT STATISTICAL PARADIGMS
In chapters 4 and 5, a simulation study is described, which compares several methods 
of meta-analysis. In these chapters, the two existing statistical paradigms, the frequentist 
and the Bayesian approaches, meet. These two paradigms differ in the way they approach 
inference. If one wants to estimate the value of an unknown parameter, a likelihood func-
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tion can be defined based on the data. This likelihood function is used in both approaches, 
albeit in different ways. The frequentist approach is to maximise the likelihood function 
over all possible parameter values to obtain the maximum likelihood estimate (mle). As-
ymptotically, as the information available increases (usually sample size) the distribution 
of the mle tends towards a normal distribution. Population means, standard errors and 
confidence intervals can then be estimated. The Bayesian approach is to define a prior 
distribution, which is a summary of the knowledge the statistician has before starting 
the analysis. This prior knowledge can be non-existent (“any value is equally likely”), 
somewhat informative (“it is centered around 0”; “the probability must lie between 0 
and 1”) or very informative (“previous research indicates a point estimate of 4.55, with 
a 95% credibility interval between 4.50 and 4.62”). These (subjective) prior probabilities 
are then combined with the (observed) frequency probabilities, which are summarized in 
the likelihood function. This forms a posterior distribution, with a population mean and 
credibility interval.
Normally, statisticians are proponents of one or the other paradigm, which directs the 
kind of analysis they perform. As Crowder puts it: “Some of the more vocal proponents 
of the different approaches to inference have been shouting at each other for years from 
their respective hilltops.”27 Therefore, a study comparing frequentist and Bayesian methods 
is not found very often, even if both methods have their own merits and drawbacks. For 
example, the estimated outcomes of a frequentist exercise are always (implicitly) normally 
distributed, while Bayesian outcomes may have every possible shape. The frequentist 
approach says the parameter we want to estimate is unknown, but fixed. The Bayesian 
approach treats the unknown parameter as a random variable, even if we know it’s a fixed 
number, for example the distance Groningen-Rotterdam (although this distance seems to 
be shorter than the distance Rotterdam-Groningen).
The biggest criticism of the frequentist approach is often about the p-value. It is in-
terpreted as the probability that the hypothesis is correct, given the data. However, the 
p-value derives from the likelihood of the data given the hypothesis, and can therefore 
strictly speaking not be interpreted as such. A 95% Bayesian credible interval is that region 
in which we believe the parameter to lie with probability 95%. This is how many prac-
titioners actually interpret a frequentist confidence interval, but the “95%” refers to the 
long-term frequency with which 95% intervals of multiple trials contain the true value.28 
Within the Bayesian framework one can also calculate the probability that the outcome 
has a particular range of values, which cannot be done in the classical framework.28
The biggest drawback of the Bayesian approach is the introduction of subjective knowl-
edge, via the prior distribution. The frequentist therefore says this method is inappropriate 
for objective scientific decision making and should only be used for individual decisions. 
The Bayesian in return says that there is no such thing as objectivity, since inference is 
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always done via an interpreter, whose background influences the inference. In addition, 
given enough data, the data can speak for themselves.
Bayesian statistics at its heart is ideally suited for meta-analysis, since the premise of 
both are the same: you have prior information available and it is updated with new data.29 
However, during the performance of the underlying study, Bayesian statistics was found 
not to be ideally suited for a simulation study such as we have done. When perform-
ing Bayesian statistics, the available data has to be the starting point. Ideally, the data is 
examined in detail, which will drive the modelling decisions around all aspects: priors, 
link function, initial values, etc. Additionally, the outcomes of a Bayesian model are 
meaningless when the model itself does not converge. Checking for convergence requires 
the visual examination of plots, and careful examination of other outcome measures. 
However, all these aspects are impossible to do in a simulation study, where many data 
sets are fitted one after the other.
9.6 DIFFERENT COUNTRIES
In chapters 6, 7 and 8 we discussed several aspects of transferability. Chapter 6 showed 
how differences in parameters between countries, also influenced the health economic 
outcomes. In our case study, these differences were primarily related to the epidemiology 
of diseases and the choice of discount rate. The least important factor was demography, i.e. 
the age/gender distribution of the cohort of smokers making a quit attempt. Unfortunately, 
this happens to be the easiest available set of parameters for new countries, whereas less 
easily available parameters were not specified country by country. Only one out of the six 
included countries had completely country-specific data.
In the case of quality of life, this was partly due to the lack of availability of country-
specific utility values. In chapter 6, the country-specific results for the Belgian model used 
the Dutch value set.30 Four out of the six countries referred back to the recommended 
tariffs for the EQ-5D for the UK.31,32 Three papers in chapter 8 also used this value set, even 
when the study is not trying to calculate country-specific CE results in the UK. The UK 
tariffs are often used as it was the first validated value-set available. This may have been 
done to improve comparability between outcomes, but can also be due to unfamiliarity 
of researchers with the availability of other value sets for other countries. Apart from 
a Dutch value set which has been available since 2006, validated value sets for other 
countries have also been published, for example for Spain in 200133 and Germany in 
200434, and many other countries. (See http://www.euroqol.org/ for other value sets). Dif-
ferences between country-specific value sets of the EQ-5D are considerable, and some of 
the variation is due to cultural dissimilarities between countries. Using value sets from one 
country for another without any form of adjustment is therefore not advisable.35
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In order to make good policy decisions, decision makers need to have all information 
available. In chapter 8, we have seen that a large percentage of papers is missing crucial 
information. Less than half of the included studies produced a table showing the demo-
graphic characteristics of patients in the original, underlying trial. Furthermore, less than 
a third of the papers specified the unit costs used in the study and almost a quarter of the 
papers did not list total health care utilization and/or health outcomes by treatment arm. 
All of this is considered basic information for a CEA. It is clear that a stricter adherence to 
for example the CHEERS guidelines, is necessary.36
9.7 DIFFERENT THRESHOLD VALUES
Several different outcome measures that are used in HTA are presented within the thesis. 
Chapters 2 to 5 perform a CE analysis (CEA), where the HE outcomes are shown as an 
incremental CE ratio (ICER). The ICER is the ratio of the difference in costs between two 
treatment options, and the difference in health outcomes. As explained in chapter 1, 
the ICER is compared to an (implicit or explicit) threshold. Policy makers can deem the 
intervention to be cost-effective compared to the comparator when the ICER is below this 
threshold. 
In chapters 6 and 7, the outcomes are presented as the incremental net monetary 
benefits (INMB). The ICER was not used, due to several well-known problems with ratio 
statistics37, combined with the fact that we wanted to calculate percentile changes in CE 
outcomes. The INMB is the difference in health outcomes, valued in monetary terms, 
minus the monetary costs. If the INMB is positive, the new intervention has more value to 
society than costs, and can thus be considered cost-effective compared to the comparator. 
If the INMB is negative, the new intervention will cost more than the societal benefits, 
and the intervention cannot be considered cost-effective compared to the comparator. In 
order to value the health outcomes in monetary terms, a “price” is needed for each unit of 
health. In chapter 6, the price, or “Willingness-to-pay” (WTP), is set at € 20,000 per QALY 
gained. In that chapter, this was called “relatively low”. 
The price which can be deemed acceptable to pay for a unit of health, whether it is the 
threshold value to compare the ICER with, or the WTP to calculate the INMB, should be 
set by public discussion. Within CE studies, as was done in for example chapters 2 and 3, 
the outcomes can be presented for different threshold values, which allows the reader to 
make their own conclusion of CE. Another presentation tool is the CE acceptability curve, 
which shows the uncertainty around the outcomes for a whole range of threshold values. 
In order to avoid interfering directly with the public debate of the “price for health”, the 
INMB may not be ideally suited to present results of CE studies, as it assumes a threshold 
value. However, academic research can be used to inform this public debate, by study-
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ing what threshold value is deemed acceptable by the general public, or what implicit 
thresholds have been applied in past decisions.38-43
In 1998, a Dutch publication mentioned a threshold value of fl 40,000,- (€ 18,000), 
which was used for the first time in a clinical guideline.44 In 1999, a threshold ICER of 
€ 20,000 per QALY gained has been proposed by the CVZ.41 More recently, the Dutch 
Council for Public Health and Health Care (RVZ) suggested a maximum value of € 80,000 
per QALY for illnesses associated with a considerable burden.45,46 This value corresponded 
to the implicit £ 50,000 per QALY gained from NICE at that time, and it reflected the ap-
plication of the World Health Organization (WHO) threshold ICER to The Netherlands.41 
The WHO Commission on Macroeconomics and Health suggested that health technolo-
gies costing less than three times the gross domestic product (GDP) per capita for each 
disability adjusted life year (DALY) averted, represents good value.47
However, CVZ is reluctant to explicitly name a maximum threshold value for a number 
of reasons.46 Firstly, there will always be other arguments that may influence a decision. 
Secondly, naming an explicit threshold value may elicit strategic pricing behaviour 
from pharmaceutical companies. Finally, it was found to be extremely difficult to elicit 
“societal” preferences from the general population. Other regulatory agencies around 
the world seem to have the same concerns. The UK regulatory organization NICE has 
publically discussed an “acceptable” threshold value. As a guideline rule, NICE accepts as 
cost-effective those interventions with an ICER of less than £ 20,000 per QALY gained and 
that there should be increasingly strong reasons for accepting as cost effective interven-
tions with an ICER above a threshold of £ 30,000 per QALY gained.48 
9.8 FOURTH HURDLE OR FOURTH FLOOR?
In considering how a new (pharmaceutical) product comes to market, CE is often described 
as the “fourth hurdle” in drug development.49-51 In this terminology, the demonstration of 
quality, safety and efficacy are the first three hurdles. They can be considered hurdles, 
as they must all be overcome to secure a successful market registration. But being on 
a market does not guarantee successful commercialization in that market. This can be 
illustrated by for example the 13-valent pneumococcal conjugate vaccine (PCV13, Pre-
venar13, Pfizer). This vaccine is available for use in the Dutch infant population, but the 
10-valent competitor PCV10 (Synflorix, GSK) won a tender for inclusion in the national 
vaccination program.52 As such, PCV10 is free for parents, but PCV13 is not. CE was 
a crucial criterion in this policy decision. Another illustration is roflumilast, which was 
discussed in chapter 2. European market access has been gained in 2010, but it is still not 
reimbursed in The Netherlands at the end of 201353, despite pressure from patient groups 
and medical experts.54 This is largely due to a lack of direct evidence of effectiveness 
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compared with inhaled corticosteroids.54 The available indirect evidence, used in chapter 
2, was not accepted due to a possible difference in patient population between the two 
combined trials. Once a product gains market access, the critical fourth hurdle to success-
ful commercialization is thus to gain product reimbursement.
However, CE can also be judged in a different way: as the top floor of a metaphori-
cal building, representing the evidence about a certain intervention. The ground floor of 
this building (or first floor, if we follow the US numbering) is evidence on the quality of 
medicines, encompassing for example such aspects as manufacturing, packaging, stability 
and impurities.55 The next floor would be made from evidence that the intervention can 
be considered to be safe for use, followed by evidence that the intervention is effective in 
the indication for which it is to be used.55 Having reached this floor, the researchers may 
gain market access and move up to the top floor, which offers a view towards successful 
commercialization.
Evidently, the stronger each of the lower floors are, the more solid the building. How-
ever, researchers in HTA usually only work on the top floor, and can often not personally 
check the source of evidence for every parameter. Instead, as in chapters 5 and 6, most if 
not all of the parameters come from sources in the published literature. These publications 
are read for any anomalies and differences in case definitions, but are otherwise taken at 
face value. In some cases, researchers in HTA can’t even work with published or properly 
peer reviewed material. For example, the efficacy of roflumilast in the group of severe 
COPD patients used in chapter 2 were obtained from a subgroup analysis of patients in 
two RCTs. The efficacy for this “LABA subgroup” does not have an official publication, and 
thus a peer-reviewed evidence base. The references used in this chapter lead to the trial 
publication, where outcomes from the subgroups are not mentioned.56 The numbers used 
in the chapter come from an internal publication, which cannot be cited from. Others 
have also brought to light problems with the evidence on lower floors, pointing at possible 
missing or shaky evidence on safety, efficacy and effectiveness of drugs (e.g.57-59) 
These are potentially severe issues for the lower floors of the evidence building, making 
building on top of them a potentially hazardous business. However, in addition, the fourth 
floor has its own methodological problems. In chapters 4 and 5, we discussed methods 
of meta-analysis, which bring together evidence from several sources in order to inform a 
CE model. However, many CE studies are based on evidence from a single source, either 
because only one source of evidence existed at that time, or because of pragmatic choices 
made by the modeller. This leads to less confidence in the outcomes of the CE study. 
Chapter 7 was a review of CE studies, all based on a single trial. Additionally, since this 
one source of data is often a RCT, these data are collected on ideal patients, often younger, 
with less co-morbidities and more homogeneous than “real-life” patients.
Another important current issue with CE research is structural uncertainty, which rep-
resents a lack of knowledge of the underlying true system. Just as parameter uncertainty 
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which arises from uncertainty around the population average, heterogeneity which arises 
from measurable differences in patient characteristics, and statistical uncertainty which is 
representative of unknowns that differ each time we run the same experiment, structural 
uncertainty is an integral part of HTA.60 For example, the choice to model the difference 
between two interventions as a risk difference or a risk ratio is often a pragmatic one, 
not based on empirical knowledge of the ‘true’ difference between interventions, even if 
it is possible that such a ‘truth’ can be found. Unlike the other three important forms of 
uncertainty in HTA, structural uncertainty cannot be measured easily, and is often ignored 
in practice. 
In conclusion, there are many possibilities of structural problems in the lower floors, in 
addition to many methodological issues that need to be solved on our own floor. Because 
of this, the fourth floor can be a rather shaky place to be. But with good research practice, 
and a continuous eye open for the potential pit falls, it is a worthwhile one.
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10.1 SUMMARY
At its heart, health technology assessment (HTA) is very simple. It compares two or more 
alternative courses of action, often pharmaceutical interventions, in terms of both their 
costs and health outcomes. Better health outcomes usually come at extra costs, often in 
the way of a higher price for the intervention. HTA makes this exchange between costs 
and effects explicit. However, HTA is facing many methodological challenges, calling for 
more complexity in the analyses.
In chapter 2, we gave an example of a health-economic (HE) decision model as is 
commonly used to tackle the analysis complexity. The model was used to show the long 
term HE effects of the reimbursement of smoking cessation treatments. The study showed 
that reimbursement of smoking cessation support via the obligatory health care insurance 
in The Netherlands would result in fewer smokers and more quality-adjusted life years 
(QALYs). It is a cost-effective way to contribute to a reduction in the percentage of smokers. 
One of the complexities discussed in this thesis was the heterogeneous nature of pa-
tients. In chapter 3, we showed that there are several ways of dealing with heterogeneity 
and that the outcomes, and thus the policy decision, may change when heterogeneity is 
handled differently. Three of these methods discussed can be useful in cost-effectiveness 
(CE) research, each in different circumstances. When little or no heterogeneity is expected, 
or when it is not expected to influence the CE results, disregarding heterogeneity may be 
correct. Subgroup analyses may inform policy decisions on each subgroup, as long as they 
are well defined and the characteristics of the cohort that define a subgroup truly represent 
the patients within that subgroup. Despite the necessary calculation time, the Double 
Loop Probabilistic Sensitivity Analysis (PSA) is a viable alternative, which leads to better 
results and better policy decisions, when accounting for heterogeneity in a Markov model. 
The Single Loop PSA can only be used to calculate the point estimate of the expected 
outcome. It disregards the fundamental differences between heterogeneity and sampling 
uncertainty, and overestimates overall uncertainty as a result. 
The second complexity discussed in this thesis was the difference between data 
sources that have to be combined. In chapters 4 and 5, we compared several methods of 
meta-analysis. Using a simulation study we could compare the HE outcomes to a golden 
standard, and each other. In chapter 4, which compared methods of direct meta-analysis, 
frequentist fixed effects (FFE), frequentist random effects (FRE) and Bayesian fixed effects 
(BFE) led to comparable HE outcomes, even in scenarios where we built in heterogeneity. 
Bayesian random effects (BRE) tends to overestimate uncertainty reflected in the shape of 
the CE acceptability curve.
In chapter 5 we compared several methods of indirect meta-analysis. Puhan’s method 
and the Generalized Linear Model Fixed Effects (GLMFE) showed similar results, with 
GLMFE having the tendency to overestimate uncertainty, but also having lower average 
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bias and mean absolute deviation (MAD). Generalized Linear Model Random Effects 
(GLMRE) showed large bias and MAD, and overestimated uncertainty even more. Based 
on this study, where we had to combine nine trials in a network that includes evidence 
for all treatment combinations, we would recommend Puhan’s method or GLMFE as the 
preferred method of indirect meta-analysis.
The final complexity discussed in this thesis, were differences between countries. 
Many factors should be taken into account when transferring cost-effectiveness results 
across countries and settings and there are many interactions between these factors. This 
stresses the importance of carefully considering whether foreign results can be applied 
and adapted to a different setting. We’ve shown in chapter 6 that it is not only important to 
see which factors vary, but also how much this variation in factors causes variation in CE. 
The factors that cause the most variation in cost-effectiveness do not necessarily have to be 
the same as the factors that vary most themselves. Chapter 7 showed that the importance 
of each of the factors is also influenced by the local threshold value for a QALY. When 
studying the CE of smoking cessation, there is a need for local data even for countries 
within a similar region of the world.
Chapter 8 discussed CE analyses that were based on recent, large multinational random-
ized controlled trials. Several advanced statistical techniques are available to calculate 
country-specific CE results from multinational trials. These methods take the interaction 
between country and treatment effect on health and health care utilization into account. 
Hierarchical models also lower variability of the country-specific CE results and lead to 
more appropriate population estimates. However, they have not been used on a wide 
scale yet, while simpler, naïve methods are still routinely employed.
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10.2 NEDERLANDSTALIGE SAMENVATTING
Het principe van evaluatieonderzoek in de gezondheidszorg (health technology assess-
ment, HTA) is simpel. Twee of meer alternatieve behandelingen, vaak farmaceutische 
interventies, worden vergeleken in termen van kosten en effecten. Betere gezondheidsuit-
komsten gaan meestal gepaard met hogere kosten, vaak door een hogere prijs voor de 
interventie. HTA maakt deze vergelijking expliciet. Echter, diverse methodologische 
problemen binnen de HTA vragen om steeds complexere analyses.
In hoofdstuk 2 werd een voorbeeld van een gezondheidseconomisch (GE) beslismodel 
gegeven, zoals deze gebruikt worden voor dergelijke complexe analyses. Het model werd 
gebruikt om de lange termijn kosteneffectiviteit (KE) te berekenen voor het vergoeden van 
stoppen-met-roken behandelingen. De studie toonde aan dat een dergelijke vergoeding 
vanuit de verplichte ziektekostenverzekering in Nederland zal leiden tot minder rokers en 
meer voor kwaliteit van leven gewogen levensjaren (quality-adjusted life years, QALYs). 
Het is een kosteneffectieve manier om het percentage rokers in Nederland naar beneden 
te brengen. 
Eén van de complexiteiten die in dit proefschrift zijn besproken, is de heterogeniteit 
in groepen patiënten. In hoofdstuk 3 lieten we zien dat er diverse manieren zijn om met 
heterogeniteit om te gaan en dat de KE uitkomsten, en dus de beleidsbeslissing, anders 
kunnen zijn als een andere methode wordt gekozen. Drie van de genoemde methodes 
kunnen van nut zijn in HTA, elk in andere omstandigheden. Met weinig of geen hetero-
geniteit, of wanneer het wordt verwacht dat dit de KE uitkomsten niet zal beïnvloeden, 
kan heterogeniteit worden genegeerd. Subgroepen kunnen beleidsbeslissingen voor 
elke subgroep apart ondersteunen, zolang deze subgroepen goed zijn afgekaderd en de 
karakteristieken van het cohort binnen elke subgroep ook daadwerkelijk alle patiënten 
binnen de subgroep vertegenwoordigen. Ondanks de benodigde rekentijd, is de Double 
Loop probabilistische gevoeligheidsanalyse (Probabilistic Sensitivity Analysis, PSA) een 
goed alternatief dat leidt tot betere resultaten en beleidsbeslissingen. De Single Loop PSA, 
waarin heterogeniteit en parameteronzekerheid tegelijk worden geanalyseerd, negeert het 
fundamentele verschil tusen beide en zal daardoor de onzekerheid overschatten.
De tweede complexiteit die in dit proefschrift werd beschreven, is het verschil tussen 
databronnen die samengevoegd moeten worden. In hoofdstukken 4 en 5 werden diverse 
methoden van datasynthese vergeleken. Met een simulatiestudie was het mogelijk om de 
GE uitkomsten te vergelijken met een Gouden Standaard en met elkaar. In hoofdstuk 4, 
waarin vier methoden van directe datasynthese werden vergeleken, bleken de frequentist 
fixed effects (FFE), frequentist random effects (FRE) en Bayesian fixed effects (BFE) tot 
vergelijkbare GE resultaten te leiden, zelfs in scenarios waarin heterogeniteit was inge-
bouwd. Bayesian random effects (BRE) neigde naar een overschatting van de onzekerheid.
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In hoofdstuk 5 werden diverse methodes van indirecte datasynthese vergeleken. Pu-
han’s methode en Generalized Linear Model Fixed Effects (GLMFE) leidde tot vergelijkbare 
resultaten, waarin GLMFE de neiging vertoonde om de onzekerheid te overschatten, maar 
ook een lagere systematische fout en absolute afwijking had. Generalized Linear Model 
Random Effects (GLMRE) liet een grote bias en absolute afwijking zien, en overschatte 
de onzekerheid nog meer. Gebaseerd op deze studie, met negen studies in een netwerk 
waarin bewijs is voor alle mogelijke interventiecombinaties, zouden wij Puhan’s methode 
of GLMFE prefereren voor het doen van indirecte datasynthese.
De laatste complexiteit in dit proefschrift besproken, is het verschil tussen landen. Een 
grote hoeveelheid factoren moet in acht worden genomen wanneer KE resultaten worden 
vertaald tussen landen, en er diverse interacties tussen deze factoren zijn. Dit benadrukt 
het belang om goed na te gaan of resultaten uit een andere land kunnen worden toe- en 
aangepast in de eigen omgeving. In hoofdstuk 6 hebben we laten zien dat het niet alleen 
van belang is om goed te kijken welke factoren veranderen, maar ook hoeveel de variatie 
in deze factoren, de variatie in KE veroorzaakt. Factoren die de meeste variatie in KE 
veroorzaken tussen landen, zijn niet noodzakelijk factoren die zelf veel variëren tussen 
landen. Hoofdstuk 7 toonde aan dat het belang van elke factor ook kan veranderen als de 
maatschappelijke bereidheid om te betalen voor een QALY verandert. Wanneer de KE van 
stoppen-met-roken middelen wordt onderzocht, is er een duidelijke noodzaak voor lokale 
data, zelfs voor landen in vergelijkbare regio’s.
Hoofdstuk 8 besprak KE studies die zijn gebaseerd op recente, grote multinationale 
studies. Diverse geavanceerde statistische technieken zijn beschikbaar om landspecifieke 
KE resultaten te berekenen. Deze methodes houden rekening met de interactie tussen 
het land en het behandeleffect. Hiërarchische modellen verlagen ook de variabiliteit in 
landspecifieke resultaten en leiden tot betere schattingen. Echter, deze methodes worden 
niet op grote schaal gebruikt, terwijl simpelere, naïeve methodes nog regelmatig worden 
toegepast.
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